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Abstract
Individuals with abdominal obesity are at higher risk for developing type 2 diabetes,
predisposing cardiovascular events and insulin resistance. Low glycemic index (GI) diets may
be beneficial in the management of insulin resistance. Insulin resistance is associated with
increased intramyocellular lipid (IMCL) content as measured by proton nuclear magnetic
resonance spectroscopy (1H-MRS). The primary objective of this thesis was to determine
whether a low GI diet can improve insulin sensitivity by reducing IMCL of skeletal muscle. One
hundred and twenty-one male and female participants aged 30 to 70 years (mean+SD, 53+10))
with abdominal obesity, entered a 4 to 6 week weight-maintaining, low-fat dietary advice run-in
phase. Of the 121 eligible participants, 95 completed the run-in phase and were randomly
assigned to either a low-GI (LGID, n=48) or high-GI diet (HGID, n=47) for 24 weeks.
Participants underwent a 75g oral glucose tolerance test (OGTT) and had soleus-muscle IMCL
measured by 1H-MRS at the beginning and end of the intervention period. Insulin sensitivity
was assessed by the homeostatic model assessment index (HOMA) and the insulinogenic index
(ISI) was calculated for insulin secretion. At the end of the run-in phase, there were significant
reductions in serum total-, LDL-, and HDL-cholesterol (all, p<0.0001) and an increase in fasting
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plasma glucose (p<0.05). In 57 participants who wore a continuous glucose monitoring system
for 24 hours during the run-in period, a total of 30% (p<0.001) of the variation in the incremental
area under the blood glucose curve after self-selected breakfast meals was explained by GI.
After 24 weeks, diet GI was significantly lower in the LGID than HGID group (55.5+3.1 vs
63.9+3.1, p<0.0001). Plasma glucose 60 minutes after the OGTT was significantly lower on the
LGID than at baseline (p<0.05) and there was a non-significant trend towards an increase in ISI
(p=0.07). On the HGID, ISI increased significantly from baseline (p<0.01). It is concluded that
the LGID reduced 60 minute plasma glucose but did not significantly affect IMCL or insulin
sensitivity in individuals with abdominal obesity.
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CHAPTER 1
INTRODUCTION
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1. Introduction
Abdominal obesity, characterized by the accumulation of visceral adipose tissue, is now
recognized as an independent risk factor for the development of cardiovascular disease (CVD),
type 2 diabetes, metabolic syndrome and insulin resistance (1, 2, 3, 4, 5). Insulin resistance,
defined as an impairment of insulin action on glucose metabolism is a complex, multi-organ
dysfunction that is brought about by a multitude of genetic and environmental factors, such as a
sedentary lifestyle and high fat diets leading to excess energy intake (6). Although not fully
understood, it has been suggested that individuals with abdominal obesity cannot store lipids
effectively in subcutaneous fat, which in turn leads to an increased delivery of fats to organs
other than adipose tissue such as the liver, pancreas and skeletal muscle, causing insulin
resistance in these tissues (7, 8).
Skeletal muscle facilitates insulin-stimulated glucose uptake and is the main contributor to
glucose homeostasis in the body (6, 9). Research has shown that the accumulation of
triglyceride in muscle is correlated with insulin resistance independently of visceral fat (10).
Muscle triglyceride content is categorized as extramyocellular lipids (EMCL, lipids stored
between muscle fibres) and intramyocellular lipids (IMCL, lipids stored within the muscle cell)
(11). Muscle triglyceride content can be assessed by examination from proton nuclear magnetic
resonance spectroscopy (1H-MRS), a non-invasive quantification of muscle fat content in human
muscle that can identify the relative contributions of IMCL (11). Research has shown a positive
relationship between the accumulation of IMCL content and insulin resistance when measured
by 1H-MRS demonstrating that IMCL is an indicator of whole body insulin sensitivity (12, 13,
14, 15).
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Evidence supports the role of carbohydrates in influencing insulin sensitivity by improving
insulin-stimulated glucose uptake by adipocytes when following a low glycemic index diet (16,
17, 18). The glycemic index (GI) was developed as a classification of the blood glucose-raising
potential of carbohydrate containing foods (19). The GI is defined as the incremental area under
the blood glucose response curve (iAUC) after consumption of a 50g available-CHO portion of a
test food expressed as a percentage of that after ingestion of 50g oral glucose (20). Low GI
carbohydrates are slowly digested and release glucose gradually into the blood stream and
therefore may suppress hepatic glucose production and non-esterified fatty acid (NEFA) release
from adipocytes, creating a more insulin-sensitive condition (21, 22). This in turn, may reduce
IMCL storage by promoting skeletal muscle glucose uptake (23). It still remains unclear whether
a low GI diet can reduce IMCL stores in the muscles of individuals with abdominal obesity, a
population at risk for developing insulin resistance and type 2 diabetes.
The primary objective of the research outlined in this dissertation was to determine
whether a low GI diet would reduce IMCL stores thereby improving insulin sensitivity in
individuals with abdominal obesity. A secondary objective of this research was to determine
whether a low GI diet would improve insulin sensitivity and glucose tolerance in individuals
with abdominal obesity.
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CHAPTER 2
LITERATURE REVIEW

7

2. Literature Review
2.1

Obesity

2.1.1 Obesity Definition
Obesity is a complex disease characterized by an excessive accumulation of fat in adipose
tissue (1). It is estimated that 23.1% (CI 21.7 to 24.6) of adult Canadians are obese (2), with
consistent trends in different parts of the world (3). Obesity is the result of a positive energy
balance where food intake is greater than the body’s ability to utilize the food as energy (1). The
excess energy, in the form of triglycerides, is stored in adipocytes which increase in size and
weight (hypertrophic obesity) and number (hyperplasic obesity) (4). The excessive accumulation
of adipose tissue leads to an undesirable weight gain to the extent that health may be adversely
affected (1). Health risk factors and comorbidities associated with obesity include
cardiovascular disease (CVD) (5, 9), stroke (6, 7, 9), hypertension (5, 8), type 2 diabetes (10, 11,
12, 13), sleep disordered breathing (14), kidney disease (15) certain cancers such as colon (16),
ovarian (17), breast (18), and endometrial cancers (19), gallbladder disease (20), and
musculoskeletal conditions (21).
The World Health Organization (WHO) developed a standard classification for obesity
based on body mass index (BMI) (defined as weight in kilograms divided by height in metres
squared (kg/m2) and the risks associated with each classification of BMI and mortality, including
type 2 diabetes and cardiovascular disease are shown on Table 1-1 (1). The WHO states that
obesity is present when BMI is 30 or greater, however it does not differentiate between weight
associated with fat mass and weight associated with lean body weight (muscle mass) (1).
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Table 1-1. WHO Classification of Obesity for Adults According to BMIa
____________________________________________________________________________
BMI
Classification
(kg/m2)
Risk of Comorbidities
____________________________________________________________________________
Underweight
< 18.50
Low (but risk of other clinical
problems increased)
Normal range
Overweight:

18.50 – 24.99

Average

> 25.00

Preobese

25.00 – 29.99

Increased

Obese class I

30.00 – 34.99

Moderate

Obese class II

35.00 – 39.99

Severe

Obese class III
> 40.00
Very Severe
____________________________________________________________________________
a
These BMI values are age-independent and the same for both sexes. However, BMI may not
correspond to the same degree of fatness in different populations due, in part, to differences in
body proportions. The table shows a simplistic relationship between BMI and the risk of
comorbidity (disease), which can be affected by a range of factors, including the nature of the
diet, ethnic group and activity level. The risks associated with increasing BMI are continuous
and graded and begin at a BMI above 25. The interpretation of BMI gradings in relation to risk
may differ for different populations. Both BMI and a measure of fat distribution (waist
circumference or waist:hip ratio (WHR)) are important in calculating the risk of obesity
comorbidities.

Two large population studies, the National Health and Nutrition Examination Surveys
(NHANES) and the Study to Help Improve early evaluation and management of risk factors
Leading to Diabetes (SHIELD) have shown a strong relationship between BMI and diabetes,
hypertension and dyslipidemia (p<0.001) (23, 24). The NHANES also showed an association
with obesity (BMI>30) and increased mortality (111,909 excess deaths; 95% CI, 53,754 –
170,064), and of the excess deaths associated with obesity, the majority of deaths occurred in
individuals with a BMI of 35 or greater (82,066 deaths; 95% CI, 44,843 – 119,289) (23).
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Other population studies have also shown that obesity was related to an increase in the
development of cardiovascular disease. The Framingham Heart Study (5) showed the ageadjusted relative risk (RR), 95% CI for cardiovascular disease was increased in obese individuals
(BMI > 30) (men: 1.46 [1.20 – 1.77]; women: 1.64 [1.37 – 1.98]). Further, the Framingham
Offspring Study (9) demonstrated that obesity (BMI>30) was predictive of the occurrence of first
events in both coronary heart disease (p=0.05) and cerebrovascular disease (p=0.03).
2.1.2

Obesity and Body Fat Distribution

2.1.2.1 Abdominal Obesity
Abdominal obesity, characterized by the accumulation of visceral or intra-abdominal
adipose tissue, is now recognized as an independent risk factor for the development of
cardiovascular disease (CVD), type 2 diabetes, and metabolic syndrome (10, 11, 13, 25, 26, 27,
28, 30, 31, 32). The metabolic syndrome consists of metabolic disturbances such as insulin
resistance, dysglycemia, dyslipidemia, and hypertension (25, 26, 27). Metabolic syndrome is
strongly associated with abdominal obesity and is also recognized as a risk factor for developing
CVD and type 2 diabetes (22, 25, 26, 28, 29, 31).
The National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III)
acknowledges the WHO’s definition of obesity according to BMI but also identifies obesity
according to body fat distribution, specifically around the abdominal area (22). The NCEP ATP
III states that abdominal obesity is more highly correlated with insulin resistance and metabolic
syndrome than measures of BMI (22). The NCEP, ATP III identifies a waist circumference of
greater than 102 cm in men, or greater than 88 cm in women as an indicator of abdominal
obesity (22).
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The NCEP, ATP III (22) defines the metabolic syndrome as having 3 out of 5 criteria on
which clinicians can diagnose the syndrome, including a high waist circumference, high serum
triglycerides, low high density lipoprotein cholesterol (HDL-C), high blood pressure, and high
fasting glucose (Table 1-2).

Table 1-2. NCEP-ATP III Clinical Identification of the Metabolic Syndrome
Risk Factor

Defining Level

Abdominal Obesity*

Waist Circumference†

Men

>102 cm (40 inches)

Women
>88 cm (35 inches)
Triglycerides

>1.7 mmol/L (150 mg/dL)

HDL Cholesterol
Men

<1.0 mmol/L (<40 mg/dL)

Women

<1.3 mmol/L (<50 mg/dL)
>130 / >85 mmHg

Blood Pressure
Fasting Glucose

>6.1 mmol/L (110 mg/dL)

* Overweight and obesity are associated with insulin resistance and metabolic syndrome.
However, the presence of abdominal obesity is more highly correlated with the metabolic risk
factors than is elevated body mass index (BMI). Therefore, the simple measure of waist
circumference is recommended to identify the body weight component of the metabolic
syndrome.
†Some male patients can develop multiple metabolic risk factors when the waist circumference
is only marginally increased, eg. 94-102 cm (37-39 in). Such patients may have a strong genetic
contribution to insulin resistance. They should benefit from changes in life habits, similarly to
men with categorical increases in waist circumference.
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2.1.3 Obesity and Insulin Resistance
Insulin resistance, a key feature of the metabolic syndrome, is a complex, multi-organ
dysfunction that is defined as an impairment of insulin action on glucose metabolism (33) or the
inability of the cell to respond to the action of insulin. Insulin sensitivity on the other hand, is
the degree to which a rise in plasma insulin can reduce postprandial blood glucose by stimulating
glucose uptake in the peripheral tissues (skeletal muscle and adipose tissue) and suppress its
production in the liver (33).
Insulin resistance rises with increases in body weight and body fat (26, 34). Most obese
individuals (BMI>30) tend to have hyperinsulinemia and low insulin sensitivity (34), however it
has been established that not all obese individuals are insulin resistant (34, 36). Imaging studies
assessing abdominal adipose tissue (magnetic resonance imaging (MRI) and computed
tomography (CT)) have shown that visceral adiposity is a strong predictor of insulin resistance in
abdominally obese men (37), premenopausal women (38), and postmenopausal women (39)
independent of subcutaneous abdominal and non-abdominal adipose tissue.
2.1.3.1 Mechanisms Linking Obesity and Insulin Resistance
Mechanisms have been proposed for the development of insulin resistance in those
individuals with visceral adiposity. One proposed mechanism is that a combination of a
sedentary lifestyle, high fat diet, and excess energy intake can result in a positive energy balance
leading to adipocyte hypertrophy and an increase in visceral adipose tissue (36, 42, 43). This
excess of energy intake results in an increase in circulating triglycerides (via portal circulation)
and an increase in lipolysis, with a subsequent release of glycerol and free fatty acids (FFA) into
circulation (40, 41). Within the adipose tissue, insulin promotes fatty acid re-esterification into
triglyceride and inhibits lipolysis, therefore impairment of insulin action results in excess
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circulating FFA (33). When the liver is exposed to elevated concentrations of FFA, it may lead
to hyperinsulinemia (due to a decrease in insulin clearance), hyperglycemia (glucose intolerance
due to an increase in hepatic glucose production), and dyslipidemia (low HDL-C, increased
levels of low density lipoprotein cholesterol (LDL-C), high triglycerides, and an increase in very
low density lipoprotein (VLDL) apolipoprotein B secretion) (40, 42).
A second proposed mechanism is that adipose tissue, especially visceral adiposity, is now
recognized as an endocrine organ that secretes adipokines (cytokine-like molecules in adipose
tissue including leptin, resistin, and adiponectin), inflammatory cytokines (such as interleukin-6
(IL-6) and tumor necrosis factor-α (TNF-α)) and free fatty acids (FFA), which contribute to
insulin resistance and the proinflammatory, prothrombotic, and hypertensive state (26, 40, 41,
42).
A third proposed mechanism is that individuals with abdominal obesity cannot store
circulating lipids effectively in the subcutaneous adipose tissue (35, 36, 40). If this tissue is
subjected to excessive amounts of lipids, there will be an increased delivery and redistribution of
fats to organs other than adipose tissue such as the liver, pancreas, heart, and skeletal muscle (33,
35, 36, 40, 43). This notion has been referred to as lipotoxicity (35, 44) and suggests that
increased lipids stored in these organs appear to inhibit insulin signaling, leading to a reduction
in insulin-stimulated glucose uptake causing insulin resistance in these tissues (33, 35, 36, 40).
This thesis will focus on the potential role of skeletal muscle lipid accumulation in insulin
resistance.
2.2 Skeletal Muscle and Insulin Resistance
Skeletal muscle facilitates insulin-stimulated glucose uptake and is the main contributor to
glucose homeostasis in the body (33, 45). In obese individuals, elevated free fatty acids (FFA)
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and excess fat located in the muscle cell appear to reduce insulin-stimulated glucose uptake and
suppress muscle glycogen synthesis and glycolysis (33, 46) contributing to the development of
skeletal muscle insulin resistance (41).
Fat stored in the muscle cell is categorized as either extramyocellular lipid (EMCL, lipids
stored between muscle fibres) or intramyocellular lipid (IMCL, lipids stored within the muscle
cell) (47). IMCL provides a readily available source of energy within the muscle exceeding that
of glycogen stores (48, 49). However, abnormally high IMCL content tends to reduce the
muscles sensitivity to insulin and therefore have become a focus of interest in the development
of insulin resistance (48, 49, 50).
The impact of the accumulation of muscle triglyceride and the association with insulin
resistance has been examined in muscle biopsies. In 1985, Falholt et al (51) first proposed the
potential relationship between elevated muscle triglycerides and insulin resistance by reporting
an increase in muscle triglycerides in normoglycemic, hyperinsulinemic dogs with low plasma
triglycerides (171.4+46.6 vs 41.2+7.7µmol/g, p<0.001). In 1988, Falhot et al (52) then
addressed the relationship between elevated muscle triglyceride in the development of insulin
resistance in humans with type 2 diabetes. The diabetic patients showed an elevation of
triglyceride in the muscle biopsies compared to the non-diabetic controls (290+52 vs
48+6µmol/g, p<0.001)). Further proof linking elevated muscle triglycerides with insulin
resistance came from later research demonstrating that muscle triglycerides are increased in
healthy, normoglycemic women, varying in adiposity (50), young, healthy, overweight Pima
Indians (54), and type I diabetics (53).
Computed tomography (CT) is a non-invasive approach to assess the distribution of
adipose and lean tissue volume and density based on muscle attenuation values (Hounsfield
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units), with lower attenuation values indicating a greater fat content within muscle (55).
Simoneau et al (56) were first to report that muscle with reduced attenuation on CT scans
(indicating elevated lipids in muscle) was strongly related to obesity and insulin resistance in
healthy women. Later, Goodpaster et al observed a relationship between elevated muscle lipids
(reduced muscle attenuation on CT) and insulin resistance in healthy sedentary, obese men and
women (57) and in obese individuals with and without type 2 diabetics (58).
2.2.1 Proton-Nuclear Magnetic Resonance (1H-NMR) Spectroscopy
In the determination of skeletal muscle triglycerides, both muscle biopsies and CT
techniques are unable to differentiate between IMCL and EMCL (47). Since research has shown
that only IMCL is related to insulin resistance (59), it is necessary to quantify the
intramyocellular triglyceride in order to establish the metabolic role of lipids within the muscle
cell.
Proton-nuclear magnetic resonance (1H-NMR) spectroscopy is a non-invasive imaging
method that is able to distinguish between IMCL and EMCL muscle triglyceride content due to
the different geometrical arrangement of the lipid compartments (47). IMCL are spherical
droplets located within the cytoplasm of muscle cells close to the mitochondria, whereas EMCL
are elongated droplets located between the muscle fibres (47). Chemical shift differences in
IMCL and EMCL produce separate resonance frequencies which makes it possible to identify
peaks in the spectral patterns that correspond to the methylene signals (CH2 resonances) of these
two types of muscle lipids (47) (Figure 2-1 (63)). When the muscle fibre orientation is aligned
with the axis of the magnet tube (Magnetic Resonance Imaging (MRI)), separation of the
spectral patterns between the IMCL and EMCL is approximately 0.2 parts per million (ppm)
(IMCL 1.28 ppm and EMCL 1.5 ppm on the spectrum, however there is slight variation for
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IMCL (ppm) and EMCL (ppm) between studies) (60, 61). Spectral intensities of IMCL and
EMCL are referenced to either water or the methyl signal of Cr (Cr3, total creatine) (47, 60, 62).

Figure 2.1. 1H-NMR Spectra of the Human Soleus Muscle
Methylene signals of IMCL and EMCL are indicated at 1.25 ppm and 1.4 ppm respectively (63).

Generally, the soleus or tibialis anterior calf muscle are the two most common muscles
chosen in to identify IMCL using 1H-NMR spectroscopy (Figure 2-2 (59)). The soleus muscle is
highly oxidative due to the large amounts of slow twitch (Type I) muscle fibres, whereas the
tibialis anterior muscle contains more fast twitch (Type II) glycolytic fibres and contain less
IMCL than the soleus muscle (60). Both muscle groups have been used in 1H-NMR
spectroscopy to determine whether IMCL is a predictor of insulin resistance (59, 63, 64, 65, 66,
67, 68, 69).
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Figure 2.2. Magnetic Resonance Image of the Human Calf Muscle
1 indicates the tibialis anterior muscle and 2 indicates the soleus muscle (59).

2.2.1.1 Intramyocellular lipid (IMCL) and Insulin Resistance/Insulin Sensitivity
Studies using 1H-NMR spectroscopy in lean adults have shown a relationship between
elevated IMCL and insulin resistance. Jacob et al (59) found that IMCL was 57% higher in the
tibialis anterior muscle (3.26+0.36 vs 2.08+0.3 arbitrary units, p<0.017) and 84% higher in the
soleus muscle (11.8+1.6 vs 6.4+0.59 arbitrary units, p=0.008) in lean insulin-resistant offspring
adults of type 2 diabetic patients compared to matched insulin-sensitive offspring of type 2
diabetic patients. Jacob et al (59) also found a negative relationship between insulin sensitivity
and the IMCL of the tibialis anterior muscle (r=-0.53, p<0.01) and the soleus muscle (r=-0.35,
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but not significant p=0.1), demonstrating that insulin resistance was correlated with IMCL.
Perseghin et al (64) found similar results where offspring adults of type 2 diabetic parents were
characterized with insulin resistance (p=0.04) and increased IMCL content in the soleus muscle
(p<0.01). Perseghin et al (64) also found that IMCL of the soleus muscle was the main predictor
of whole body insulin sensitivity (R2=0.29, p<0.01). Krssak et al (63) also found an inverse
correlation between IMCL and whole-body insulin sensitivity in a group of normal weight nondiabetic adults (r=-0.69, p=0.0017) using 1H-NMR spectroscopy of the soleus muscle.
Studies using 1H-NMR spectroscopy have also shown a relationship between elevated
IMCL and insulin resistance in overweight and obese individuals. Sinha et al (65) found both
the IMCL and EMCL content of the soleus muscle was significantly greater in obese adolescents
compared to the lean, control adolescents (p<0.01). Further, the results from Sinha et al (65)
showed an inverse correlation between IMCL and insulin sensitivity (r=-0.59, p<0.02) and that
this relationship was independent of percent total body fat and subcutaneous abdominal fat
(r=-0.73, p<0.01) but not of visceral fat (r=-0.54, p<0.08). Moro et al (69) studied a group of
sedentary obese non-diabetic and diabetic adults treated with sulfonylurea and metformin. In
Moro’s study (69), IMCL was inversely related to insulin sensitivity in both the soleus muscle
(r=-0.48, p=0.02) and tibialis anterior muscle (r=-0.18, but not significant p=0.06). Further, body
fat was the main determinant of IMCL in the tibialis anterior muscle (r2=0.30, p=0.0054) (69).
In contrast to these studies, Perseghin et al (66) showed no significant differences in IMCL
content in the soleus muscle (p=0.22) or the tibialis anterior muscle (p=0.67) in moderately
overweight vs normal weight subjects. The lack of significance in IMCL in Perseghin’s study
(66) may be due to the small variation and definition of overweight according to BMI
(overweight 23.5+0.8 vs normal weight 21.2+0.6 kg/m2). Perseghin (66) did find that insulin
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sensitivity was inversely related to the IMCL content of the soleus muscle (R2=0.38, p<0.01) and
the tibialis anterior muscle (R2=0.36, p<0.02).
2.3 Effect of Diet on IMCL and Insulin Sensitivity
2.3.1 High fat diets, IMCL and Insulin Sensitivity
In animal studies, high fat feeding in rats increased muscle lipids and reported links
between the accumulation of intramyocellular lipids and insulin resistance, characterized by
reduced insulin-stimulated skeletal muscle glucose uptake and disposal (70, 71, 72, 73). In
human studies using 1H-NMR spectroscopy to determine IMCL content, high fat diets have also
been shown to increase IMCL in healthy individuals. Studies using a lipid infusion protocol to
increase plasma FFA (74) or circulating non-esterified fatty acids (75) found increases in IMCL
and corresponding changes in insulin sensitivity. Short term high fat diets of 3 days (75) and 7
days (76) consisting of approximately 60% total energy from dietary fat found that IMCL
increased with high fat feeding as well as a decrease in insulin sensitivity (75). A longer
crossover design study (25 days) consisting of a diet which was either low fat (30.8%), high fat
(37.9%), or high in total fat (36.3%) and polyunsaturated fat (9.7%) in healthy adults with mildly
elevated LDL-cholesterol found that IMCL was higher in the high fat diet but was not changed
by type of dietary fat (77). St-Onge et al (77) did not find any correlations between IMCL and
glucose or insulin concentrations.
2.3.2 Carbohydrate, IMCL and Insulin Sensitivity
2.3.2.1 Carbohydrate
The majority of dietary carbohydrate consists of monosaccharides (glucose, fructose,
galactose), disaccharides (sucrose, lactose, maltose), and polysaccharides (starch (amylose,
amylopectin)), and fibre (soluble, insoluble)) (111, 112). Ingestion of dietary carbohydrate
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increases postprandial blood glucose. This in turn results in the release of insulin by the
pancreas to stimulate the uptake of glucose into the skeletal muscle and adipose tissue, as well as
decreasing the production of glucose by the liver by reducing glycogenolysis and
gluconeogenesis (111, 112). Postprandial blood glucose response is dependent on the type of
dietary carbohydrate consumed. Foods with carbohydrate high in glucose are easily digested,
absorbed rapidly, and have an immediate effect on postprandial blood glucose, whereas soluble
fibre decreases the rate of glucose absorption and reduces the glycemic response (113).
Specifically, soluble fibres high in viscosity (gel forming) slow carbohydrate absorption and
decrease postprandial blood glucose responses (112). Plant starch occurs mainly as amylose and
amylopectin however amylopectin breaks down more easily and digests more rapidly (112).
Research has shown that consumption of high-amylose carbohydrates decreases the glucose and
insulin responses in normal individuals (112, 114). Some starches are partially broken down and
very slowly digested, or do not get digested at all in the human small intestine because humans
lack the enzymes to break them down (115). These starches are termed partially resistant starch
and resistant starch, and reduce the glycemic responses compared to readily digestible starch
(115). Further, research has demonstrated the role of dietary fibre in reducing the risk for
diseases including diabetes (116, 117) and cardiovascular disease (118). The interest in the
glycemic effects of carbohydrate and the mechanisms by which dietary fibre improves blood
glucose and insulin responses led to the development of the glycemic index (GI).
2.3.2.2 Glycemic Index
The glycemic index (GI) was developed in 1981 by Jenkins et al (78) as a classification of
the blood glucose-raising potential of the available carbohydrate in foods. The GI is defined as
the 2 hour incremental area under the blood glucose response curve (iAUC, defined as the area
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under the curve that is above fasting values only) after consuming a 50 gram availablecarbohydrate (total carbohydrate minus fibre) portion of a test food expressed as a percentage of
the response after consuming 50 grams of oral anhydrous glucose by the same subject (79, 80).
The term glycemic load (GL) was also developed to account for the amount of carbohydrate in
food and is calculated by multiplying the glycemic index of the food by the food’s available
carbohydrate (g) (81). Research has demonstrated that both the source and amount of
carbohydrate in foods influence postprandial blood glucose and insulin (82, 83). Foods
containing carbohydrate that are classified as low GI are digested and absorbed more slowly than
high GI foods and would therefore have a lower postprandial blood glucose and insulin response
due to the reduced rate of glucose absorption (81). Examples of carbohydrate foods with a low
GI include barley, cooked pasta (al-dente), parboiled rice, beans, lentils, and oatmeal (noninstant), whereas white bread, cooked potatoes, and breakfast cereals (low in fibre) are a few
examples of high GI foods (84). Since the GI is a classification of the degree to which
carbohydrate containing foods increase blood glucose, foods containing solely protein and/or fat
would not have a GI value (85). Further, differences in the amounts of fat and protein in normal
meals have been shown to have little effect on the postprandial glucose and insulin responses
(86).
Since its development, many studies with varying populations have shown that low GI
diets improve fasting blood lipids (87, 88, 89, 90, 91, 92, 93, 94, 95, 96) and glycemic control
(88, 92, 93, 94, 95, 96, 97, 98, 99), as well as decreasing the risk of developing cardiovascular
disease (100), type 2 diabetes (101, 102, 103, 104), metabolic syndrome and insulin resistance,
(105) and obesity (106), suggesting a possible role in the treatment and prevention of disease.
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2.3.2.2.1

Glycemic Index and Insulin Sensitivity

Research has demonstrated that low glycemic index carbohydrates can influence insulin
sensitivity by improving glucose and insulin responses during the day as well as improving
insulin-stimulated glucose uptake by adipocytes (93, 98, 99). Frost et al (98) studied the effects
of a 4 week low-vs-high GI diet on glucose and insulin responses in patients with coronary heart
disease as well as the relationship between insulin-stimulated glucose uptake in adipocytes (fat
biopsy) and insulin sensitivity (hyperinsulinemic glucose clamp technique). A significant
positive linear relationship was found between glucose uptake in adipocytes and the
hyperinsulinemic glucose-clamp technique (r=0.72, p<0.02). Subjects on the low GI diet had a
significant decrease in insulin iAUC (p<0.03) and a significant increase in insulin-stimulated
glucose uptake (p<0.05). In a second study, Frost et al (99) studied the effects of a 3 week lowvs-high GI diet on in-vivo whole-body insulin sensitivity (measured by the short insulin tolerance
test) and in vitro adipocyte insulin sensitivity (fat biopsy) in premenopausal women with a
parental history of coronary heart disease. The low GI diet increased the in vitro adipocyte
insulin sensitivity (p<0.05) and the in vivo insulin sensitivity (p<0.01). Although these two
studies by Frost et al (98, 99) have demonstrated that low GI diets can improve insulin
sensitivity, they have been criticized because the ‘gold standard’ euglycaemic, hyperinsulinaemic
clamp technique was not used.
In a randomized, crossover study of either a low-vs-high glycemic index diet for 24 days in
20 type 2 diabetic subjects, Jarvi et al (93) evaluated insulin sensitivity using the euglycemichyperinsulinemic clamp technique. Subjects peripheral insulin sensitivity increased significantly
on both the low GI diet (p<0.01) and the high GI diet (p<0.05), however it was more pronounced
on the low GI diet compared to the high GI diet (30% vs 21% change respectively). The iAUC
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was also 31% lower (p<0.05) for blood glucose and 27% lower (p<0.01) for plasma insulin
following the low GI diet.
Rizkall et al (92) also performed a randomized crossover design study of a 4 week low and
high glycemic index diet in 12 type 2 diabetic subjects using the euglycemic-hyperinsulinemic
clamp technique to measure insulin sensitivity. Whole body glucose disposal was significantly
higher following the low-vs-high GI diet (7.0+1.3 vs 4.8+0.9mg glucose/kg/min, respectively,
p<0.001). The iAUCs were also lower for plasma glucose after the low GI meals compared with
the high GI meals during the 8 hour metabolic profiles at baseline (32%, p<0.05) and at 4 weeks
following the diet (47%, p<0.05) and 23% lower for plasma insulin (p<0.05) after the low GI
diet compared to the high GI diet during the 8 hour metabolic profile at the beginning of the two
dietary periods.
2.3.2.2.2

Glycemic Index and IMCL

Since low GI carbohydrates are slowly absorbed and release glucose gradually into the
blood stream, they may suppress hepatic glucose production and non-esterified fatty acid
(NEFA) release from adipocytes (107, 108). Reducing plasma fatty acids may decrease IMCL
storage and promote insulin-stimulated glucose transport by muscle (109) creating a more insulin
sensitive condition. Goff et al (110) investigated the effects of a 4 week low GI diet on insulin
sensitivity (oral glucose tolerance test) and IMCL storage (magnetic resonance spectroscopy) in
healthy adults. Results showed a significant improvement in the insulin sensitivity index
(baseline 7.8+1.1 (SEM) vs post-intervention 9.7+1.1, p<0.02) and a significant decrease in the
insulin iAUC (baseline 30.8+4.2 vs post-intervention 23.7+3.3 mmol/min/L, p<0.01). There
were also significant decreases in fasting LDL cholesterol (p=0.01), plasma triglycerides
(p=0.01), but no significant changes in NEFA concentrations (p=0.63) post-intervention. IMCL
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concentrations did not significantly change post-intervention, and no significant correlations
were found between IMCL and insulin sensitivity suggesting that insulin sensitivity is
independent of IMCL in healthy individuals. It must be noted however, that the reduction in GI
was only 15% for four weeks, which may not have been enough of a reduction in GI or a long
enough intervention to affect IMCL concentrations.
It still remains unclear whether a low GI diet can reduce IMCL stores in the muscles of
individuals with abdominal obesity, a population at risk for developing insulin resistance and
type 2 diabetes. The primary purpose of this thesis was to determine if a low GI diet would
reduce IMCL stores thereby improving insulin sensitivity in individuals with abdominal obesity.
2.4

Continuous Glucose Monitoring System (CGMS)

2.4.1 Overview of the CGMS
Both fasting and postprandial blood glucose monitoring are used for the diagnosis and
treatment of diabetes, as well as improving glycemic control and reducing the risk of
complications arising from diabetes (119, 120). Self-monitoring blood glucose (SMBG) is an
important practice for those individuals with diabetes (121), and may also help with glycemic
control in non-diabetic individuals who are at risk for developing diabetes (e.g. obese
individuals), however, there are limitations to this practice. Since blood glucose is influenced by
changing variables throughout the day (e.g. stress, physical activity, diet, rate of nutrient
absorption) (122)), SMBG would need to be performed several times throughout the day which
may not be practical for most individuals. Continuous glucose monitoring systems were
originally developed for diabetics to accurately identify blood glucose levels throughout the day
(123). The MiniMed Continuous Glucose Monitoring System (CGMS; MiniMed Inc.,
Northridge, CA) (Figure 2.3) was the first to develop a continuous sensor that could monitor
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Figure 2.3. Continuous Glucose Monitoring System (MiniMed Inc, Northridge, CA)
A: CGMS Monitor and Sensor; B: CGMS Com-Station (123)

glucose profiles for 72 hours (123) and is the monitor used in this research (refer to Chapter 6).
This model is a Holter-style sensor system consisting of the following components: a glucose
monitor that stores the electrical signals from the glucose sensor; a sensor inserter (senserter)
which is used to insert the sensor; a sterile, subcutaneous glucose sensor that continuously
detects electrical signals (measured in namoamperes (nA)) every 10 seconds by the reaction of
glucose in the interstitial fluid with glucose oxidase, and averages 30 electrical signals every 5
minutes from the sensor for a total of 288 measurements per day; a connecting cable; and a
communication device (Com-Station) which enables glucose data stored in the monitor to be
downloaded to a computer to be analyzed (123). Once the sensor is inserted, typically in the
abdominal area, the individual must enter at least four blood glucose values obtained from a
portable finger-stick glucose meter to calibrate the monitor (123). Since the original
development of the CGMS, MiniMed Inc. and other manufacturers have updated the design of
the monitors to give the individual real-time access to their blood glucose values, as well as
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providing alarms when blood glucose values reach hypoglycemic and hyperglycemic ranges
(124, 125). Research has shown that CGMS is beneficial for glycemic control in patients with
diabetes and is an important clinical tool to help health care providers make recommendations to
patients for reducing complications arising from diabetes (124, 126, 127, 128).
2.4.2 CGMS and Glycemic Index
Research has examined the effects of glycemic index on glycemic control using the CGMS
in type 2 diabetics (129), type 1 diabetics (130), healthy adults (131), and healthy adults at risk
for heart disease (132). Brynes et al (129) investigated the effects of a 7 day low GI diet (LGID)
on glycemic profiles in free-living type 2 diabetics using the CGMS for two 24 hour periods.
Significant reductions were found in fasting glucose (p<0.01), 24 hour area under the curve
(AUC) for glucose (p<0.04), and overnight 8 hour AUC glucose (p<0.05), suggesting that
glycemic control can be improved following a short term LGID (129). Byrnes et al (131)
performed another study in free-living healthy young adults, and used the CGMS to investigate
changes in blood glucose profiles after following a 7 day LGID. A significant reduction was
found in fasting blood glucose (p<0.001), mean blood glucose over the 24 hour period
(p=0.004), area under the 24 hour glucose curve (p=0.004), and overnight 8 hour glucose curve
(p=0.01), suggesting that a LGID can have a significant effect on glucose profiles by improving
hepatic insulin sensitivity and decreasing hepatic glucose output (131). Nansel et al (130) used
the CGMS to examine changes in glycemic profiles in type 1 diabetic youths, following a one
day high vs low GI diet in a controlled setting, cross-over study. Participants demonstrated
lower daytime mean blood glucose and lower blood glucose area under the curve (p<0.001)
following the low GI diet, suggesting that a low GI diet may reduce glucose excursions and
improve glycemic control (130). Philippou et al (132) studied the effects of a 12 week LGID on
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24 hour glycemic responses using the CGMS in free-living adults at risk for developing heart
disease. Results showed a significantly lower 24 hour area under the curve (AUC) for glucose
(p=0.045) and overnight AUC (p=0.006) for the LGID compared to the high GI diet but no
significant changes in blood lipids (p>0.05) (132). Further, Philippou et al (132) found that both
groups significantly reduced their energy intake (p<0.05) but only the LGID group lost weight,
concluding that a LGID in addition to weight loss may reduce cardiovascular risk These studies
(129, 130, 131, 132) showed that the GI can reduce fasting and postprandial blood glucose
responses in individuals who are given specific foods to consume, however, the question about
whether the GI can predict individual glycemic responses to self-selected meals remains unclear.
Fabricatore et al (133) addressed this issue by examining the relationship of the GI and other
dietary variables to glycemic responses, assessed by a CGMS, when meals were consumed in
self-selected amounts by free-living overweight and obese type 2 diabetics. Results showed that
GI was positively related to CGMS AUC glucose (p=0.01), mean glucose (p=0.01), and time
spent in a hyperglycemic range of greater than 10 mmol/L (p=0.02), and a multiple regression
analysis showed that the dietary GI was the strongest predictor of glycemic variability
accounting for 10% to 18% of the variance in each glycemic variable, independent of energy and
carbohydrate intake (133). Fabricatore et al (133) concluded that the results of their study
support the validity of the GI and that consumption of a LGID is beneficial for controlling blood
glucose in type 2 diabetics. A purpose of this thesis was to determine whether GI is a significant
determinant of individual glycemic responses elicited by self-selected breakfast meals in healthy,
abdominally obese adults, a population at risk for diabetes.
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CHAPTER 3
RATIONALE, HYPOTHESES, AND OBJECTIVES
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3. Rationale, Hypotheses, and Objectives
Research has shown that insulin sensitivity may in part be determined by the increased
storage of lipids in organs other than adipose tissue such as muscle. It has been hypothesized
that increased lipid storage in muscle reduces sensitivity to insulin, thereby reducing insulinmediated glucose uptake in muscle. This would lead to elevated insulin and glucose levels
which in turn may lead to insulin resistance. Although research has shown a relationship
between insulin sensitivity and IMCL, it still remains unclear whether IMCL stores are a cause
or an effect of insulin resistance.
Although controversial, the role of the glycemic index (GI) in influencing insulin
sensitivity has been documented. It has been hypothesized that low GI diets may improve
insulin sensitivity by suppressing non-esterified fatty acid release. This in turn may reduce
IMCL storage by promoting skeletal muscle glucose uptake.
It has been suggested that individuals with abdominal obesity have elevated levels of
IMCL. Documenting a positive effect of a low glycemic index diet on IMCL content and
insulin sensitivity may have important implications in the treatment for individuals with
abdominal obesity, as well as potentially help in the prevention of metabolic and cardiovascular
complications in these individuals. Further, demonstrating that a low GI diet as an
intervention can reduce IMCL content and improve insulin sensitivity would be considered a
major step forward in the understanding of insulin resistance.
This dissertation will be divided into three research chapters to address the information
discussed above, each with their hypotheses and objectives. All three chapters are from one
long-term study. The first chapter is the low-fat dietary advice run-in phase of the main study,
the second chapter is the main study, and the third chapter is a sub-study from the run-in phase.
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3.1 Effects of an ad-libitum low fat diet on metabolic profiles in adults with abdominal
obesity
Hypothesis:
Following dietary advice on lowering overall fat and saturated fat intake will improve
metabolic profiles in adults with abdominal obesity.
Objective:
The primary purpose of designing a 4 to 6 week low fat dietary advice run-in phase prior to
the main study was to eliminate potential effects of variations in dietary fat intake which may
influence IMCL content.
A secondary purpose was to determine whether dietary advice on consuming low fat foods
will improve metabolic profiles in adults with abdominal obesity.
A third purpose was to determine whether there is a relationship between the glycemic
index and metabolic profiles after following a low fat dietary advice phase for 4 to 6 weeks.
3.2 Effects of a eucaloric low glycemic index diet on insulin sensitivity and
intramyocellular lipid content in adults with abdominal obesity
Hypothesis:
A low glycemic index diet will reduce intramyocellular lipid stores, thereby improving
insulin sensitivity in adults with abdominal obesity.
Objective:
The primary objective was to determine if a 24 week low glycemic index diet will reduce
intramyocellular lipid stores, thereby improving insulin sensitivity in individuals with
abdominal obesity compared to a high glycemic index diet.
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3.3 Glycemic index predicts individual glucose responses after self-selected breakfasts in
free-living, abdominally obese adults
Hypothesis:
The glycemic index is a significant determinant of individual glycemic responses elicited
by self-selected breakfast meals in free-living, abdominally obese adults.
Objective:
The primary objective was to determine if the glycemic index is a significant determinant
of individual glycemic responses elicited by self-selected breakfast meals in free-living
abdominally obese adults.

49

CHAPTER 4
EFFECTS OF AN AD-LIBITUM LOW FAT DIET ON METABOLIC PROFILES IN
ADULTS WITH ABDOMINAL OBESITY

50

4. Effects of an ad-libitum low fat diet on metabolic profiles in adults with abdominal
obesity
4.1 Introductory Statement
In both animal and human studies, high fat diets have been shown to increase IMCL
storage. In order to examine the role of the glycemic index and IMCL in the primary study, a
weight maintaining, ad-libitum low fat dietary advice run-in phase was designed to eliminate
potential effects of variations in fat intake on IMCL content.
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4.2 Abstract
Background: Individuals with abdominal obesity are at higher risk for developing
cardiovascular disease, type 2 diabetes, and insulin resistance. High fat diets have been shown to
increase intramyocellular lipids (IMCL) causing insulin resistance in these individuals. Low fat
and low glycemic index (GI) diets may be beneficial in the management of insulin resistance.
Objectives: The primary purpose of this low fat, dietary advice study was to eliminate potential
effects of variations in dietary fat intake which may influence IMCL content and insulin
sensitivity in a primary study.
Design: Ninety-five men and non-pregnant, non-lactating women with abdominal obesity, ages
30 to 70 years (mean+SD 53.3+9.5) completed a 4-to-6 week weight maintaining, low fat dietary
advice run-in study. The participants completed a 3-day food diary at the start and end of the
study. At 4 to 6 weeks, participants underwent a 75g oral glucose test (OGTT) and soleusmuscle IMCL, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were
measured by proton nuclear magnetic resonance spectroscopy (1H-MRS).
Results: Participants significantly reduced their serum total-, LDL-, and HDL-cholesterol (all,
p<0.0001), and fasting plasma glucose significantly increased (p<0.05). The GI was positively
correlated with the insulinogenic index and fasting insulin (both, p<0.05). IMCL was positively
correlated with waist circumference (p<0.01) and BMI, hip circumference, VAT, and total grams
of dietary fat (all, p<0.05).
Conclusions: This study demonstrated that individuals with abdominal obesity can significantly
reduce blood lipids by following a weight maintaining, low fat diet.
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4.3 Introduction
Obesity is a complex disease characterized by an abnormal deposition of fat in adipose
tissue and is mainly the result of a positive energy balance where food intake is greater than the
body’s ability to utilize the food as energy (1). Individuals who have excessive accumulation of
adipose tissue, especially in the abdominal region, are at higher risk for developing
cardiovascular disease (2, 9), type 2 diabetes (3, 4, 5, 6, 9) and metabolic syndrome and insulin
resistance (7, 8). Dietary interventions for these individuals include lowering the overall fat,
saturated fat, and cholesterol in the diet (1). One purpose of this study was to determine whether
dietary advice on consuming low fat foods will improve metabolic profiles in adults with
abdominal obesity.
It has been suggested that individuals with abdominal obesity cannot store lipids
effectively in the subcutaneous adipose tissue which in turn leads to an increase in intracellular
storage of lipids in organs other than adipose tissue such as the liver, pancreas and skeletal
muscle causing insulin resistance in these tissues (10, 11). In animal (12, 13, 14, 15) and human
studies (16, 17, 18), high fat diets have been shown to increase skeletal muscle fat, specifically
intramyocellular fat (IMCL) and decrease insulin sensitivity. The primary purpose of designing a
low fat dietary advice run-in phase prior to the main study was to eliminate potential effects of
variations in dietary fat intake which may influence IMCL content and insulin sensitivity.
Low glycemic index carbohydrate foods have also been extensively researched as a
possible dietary intervention in the prevention of diseases. The glycemic index (GI) was
developed as a classification of the blood glucose-raising potential of the available carbohydrate
in foods (19) and is defined as the incremental area under the blood glucose response curve after
consuming a 50 gram available-carbohydrate portion of a test food expressed as a percentage of
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the response after consuming 50 grams of oral anhydrous glucose or white bread by the same
subject (20, 21). Low glycemic index carbohydrate foods have been shown to improve
metabolic profiles related to obesity, diabetes and cardiovascular disease among free-living
individuals (22). A third purpose of this study was to determine whether there is a relationship
between the glycemic index and metabolic profiles after following a low fat dietary advice phase
for 4 to 6 weeks.
4.4 Subjects and Methods
This study was carried out on an outpatient basis at the Hamilton General Hospital,
Centre for Cardiovascular Obesity Research and Management, McMaster University, Faculty of
Health Sciences. The study protocol was approved by the Hamilton Health Sciences, McMaster
University human research ethics board and carried out in accordance with the Declaration of
Helsinki as revised in 2000. All participants were given a participant information sheet and gave
informed consent to participate in the study (Appendix 8.1). The trial is publicly registered with
ClinicalTrials.gov, number NCT00147264.
4.4.1 Protocol
This thesis chapter describes the results of a 4-to-6 week weight maintaining low-fat
dietary advice run-in period of a randomized 2x2 factorial design clinical trial which determined
the effects of a low GI diet and telmisartan on intramyocellular lipids (TRIM trial (TelmistartanInduced Reduction in Intra-Myocellular Lipids)). An initial screening visit occurred two weeks
prior to the study to determine whether the participant met the inclusion criteria. The dietary
intervention phase of the TRIM trial is discussed in Chapter 5 of this thesis. The results of the
telmisartan trial are not reported in this thesis.
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4.4.2 Study Sample
A total of 2433 participants from the general population responded through advertisement
in local media and underwent a telephone screening process. Of the 171 participants who were
invited for an initial screening visit to assess eligibility, 32 participants did not meet the inclusion
criteria and 18 refused to participate. Of the 121 enrolled participants, 95 completed the study
resulting in a 21% drop out rate. Seven of the subjects dropped out because they wanted to lose
weight, 6 left due to personal reasons, 5 participants had time commitment issues, 5 had adverse
events and 3 dropped out for other unknown reasons. Men and non-pregnant, non-lactating
women aged 30 to 70 years with abdominal obesity, with or without additional features of the
metabolic syndrome, were eligible to participate. Abdominal obesity was defined as a waist
circumference of >102 cm for males and >88 cm for females (Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III) (ATP III)) (23). Inclusion
criteria included abdominal obesity, ability to provide written informed consent, between 30 and
70 years of age, and the ability and willingness to complete dietary and activity diaries and
questionnaires. Exclusion criteria included diabetes or use of any anti-diabetic drug,
uncontrolled hypertension, serum triglycerides >10 mmol/L, active malignancy, chronic
inflammatory disorders, endocrine, renal or hepatic dysfunction, use of angiotensin converting
enzyme inhibitors or angiotensin receptor blockers in the last 3 months, use of a lipid lowering
medication-the dose of which had not been stable for at least 3 months, body mass index of >45,
intent to lose weight or use weight loss medications during the study, contraindications to
magnetic resonance imaging (MRI) such as claustrophobia or metal prostheses, and any dietary
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restrictions that would prevent the participants from following the study protocol during the
randomization phase of the study (to be discussed in Chapter 5).
4.4.3 Ad-Libitum Low Fat Diet
The run-in phase consisted of dietary advice on following a standardized low fat diet as
outlined by the American Heart Association (24) consisting of 55% energy from carbohydrate,
30% from fat, less than 7% from saturated fat and 15% from protein. Daily energy requirements
were estimated according to the Lipid Research Clinic Requirement formula (25) with an
additional 300 kcal per day added on for exercise and daily energy expenditure (Appendix 8.2).
Diets were prescribed on an ad libitum basis. The aim of the diet was to be weight maintaining
and to eliminate potential effects of variations in fat intake on IMCL content. Participants were
given an information sheet (Appendix 8.3) to provide dietary advice on following a low fat diet.
The participants completed three MEDFICTS dietary assessment questionnaires to assess dietary
fat intake (Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III) (ATP III)) (26) and completed a 3-day food diary at the start and end of the study to
assess fat intake and to provide dietary advice (Appendix 8.5). Micronutrients, macronutrients,
and GI of test foods were calculated using the Food Processor SQL Nutrition Analysis & Fitness
software package version 9.5 (ESHA Research, Salem, OR, USA) with missing values for GI
added using the NutriPro diet analysis program (Glycemic Index Laboratories Inc., University of
Toronto). The GI was expressed with the GI of glucose = 100. Participants were instructed to
maintain their habitual level of physical activity throughout the study. The Baecke habitual
physical activity questionnaire was administered at the start and end of the study to determine
activity levels (Appendix 8.6) (27).
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4.4.4 Anthropometric Measurements, Blood Pressure and Heart Rate
Height (cm) was measured at the initial screening visit to the nearest 0.1 cm using a wall
mounted stadiometer and body weight was measured at every visit to the nearest 0.1 kg on a
digital weigh scale. Body mass index (BMI) was calculated as body weight (kg) divided by
height (m2). Waist circumference (WC) was measured to the nearest 0.1 cm using the World
Health Organization (WHO) method (mid-point between the palpated inferior border of the last
rib and upper border of the iliac crest in a horizontal plane at the end of normal expiration) (28).
Hip circumference (HC) was measured to the nearest 0.1 cm at the level of the major trochanter
(usually around the largest diameter of the buttocks) (28). Waist-to-hip ratio (WHR) was
calculated (waist (cm) divided by hip (cm)) from the measurement of the waist and hip
circumference. Body composition analysis (body fat percentage) was assessed by bioelectrical
impedance analysis as per manufacturer’s instructions (BioScan 916, Maltron International Lt,
Rayleigh, Essex, UK). Waist and hip circumference and body fat percentage were measured at
the start and end of the study.
Blood pressure (BP) and heart rate (HR) were measured at every visit in the sitting
position using an automatic blood pressure monitor (BpTRU®, VSM MedTech Ltd., Vancouver,
BC, Canada) following five minutes of seated rest.
4.4.5 Fasting Plasma Glucose and Lipids
Blood samples were collected from the antecubital vein following a 12 hour fast at the start
of the study. Screening blood tests included fasting glucose, total cholesterol, HDL cholesterol,
LDL cholesterol, and triglycerides. Plasma glucose and lipids were analyzed using standard
enzymatic procedures and LDL cholesterol was calculated using the Friedewald formula (32).
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4.4.6 Oral Glucose Tolerance Test
An oral glucose tolerance test (OGTT) was performed in the fasting participant (12 hours)
at the end of the study. An indwelling catheter was inserted in the forearm and three blood
samples for glucose and insulin were taken five minutes apart (-15, -10, -5 minutes). Participants
then ingested (0 minutes) a 75 gram solution of dextrose and venous blood samples were
obtained again at 30, 60, and 120 minutes for determination of plasma glucose and insulin.
Glucose was measured by a glucose oxidase method and serum insulin was measured with an
immunometric assay (Diagnostic Products Corporation, Los Angeles, CA). The glucose and
insulin data from the OGTT was used to assess insulin sensitivity (homeostatic model
assessment index, HOMA = fasting insulin (µU/ml) x fasting glucose (mmol/L) divided by 22.5
(29)) and insulin secretion (insulinogenic index (ISI) = ratio of change in insulin to change in
glucose from 0 to 30 minutes (Delta I30 divided by Delta G30) (30)). The HOMA index has been
validated with the gold standard euglycemic hyperinsulinemic clamp technique (31). During the
OGTT, fasting blood samples were also collected for of total, HDL and LDL cholesterol, free
fatty acids, and triglycerides. LDL was calculated using the Friedewald formula (32).
4.4.7 Magnetic Resonance Imaging
Intramyocellular lipid (IMCL) content of the mid-soleus muscle (predominately oxidative
muscle fibres) was assessed by proton magnetic resonance spectroscopy (1H-MRS) at the end of
the run-in period. MRS was performed on a 1.5 Tesla whole body MR system (Siemens
Symphony AG, Munich, Germany) using a body coil for radiofrequency transmission and
surface coil to receive signals. The 1H-MRS scans were performed at the Nuclear Medicine
Department at the McMaster University Medical Centre. Participants were advised to fast and
restrict physical activity for six hours prior to the procedure. Following screening for absence of
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MRI contraindications, the participant was placed in the supine position and the leg was
positioned and immobilized so that the calf was situated as close to the center of the magnet as
possible. The radio-frequency receive coil was fastened nearest to the region of interest to
collect the greatest signal. Participants remained in the supine position (feet first) within the MR
system. Three-plane spin-echo T1-weighted MR images were performed to guide placement of
the volume of interest for spectroscopy. Imaging parameters were chosen for suitable separation
of muscle, fascia, IMCL and extramyocellular lipid (EMCL) content (TR 3000 milliseconds
(ms), TE 30 ms, 128 averages, 1,024 data points over 1000 Hz spectral width, 1 cc voxel
volume, water signal suppressed using chemical selective saturation). Semi-automatic shimming
of the magnet with typical line widths of the water signal of 10 Hz was performed to optimize
magnetic field homogeneity. Several scout images were taken to determine the ideal position for
the voxel location. Volume of interest was centered over the mid-soleus muscle and vascular
structures and gross adipose tissue deposits were excluded as much as possible. The IMCL and
EMCL peak was integrated at 1.28 ppm and 1.48 ppm respectively. Since creatine content is
stable within the same muscle across a population (50), spectral intensities were referenced to the
methyl signal of creatine (Cr3) at 3.05 ppm serving as an internal reference. Spectra were
processed and the resonance curves for IMCL, EMCL, and creatine were measured using jMRUI
software v2.1 (51). Data is presented as arbitrary units.
After 3-plane localizer image acquisition, breath-hold axial T1-weighted image at the level
of mid-L4 (TR 400 ms, TE 13 ms) was acquired for the volume of visceral adipose tissue (VAT)
and subcutaneous adipose tissue (SAT). VAT and SAT was calculated using SliceOmatic 4.2
medical imaging software (SliceOmatic v.4.2, Tomovision, Montreal). VAT was defined as
adipose tissue within the inside edge of the abdominal wall and SAT was defined as adipose
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tissue on the outside edge of the abdominal wall. The intra-and-inter-observer coefficients of
variation for this method are 0.53% and 0.44% for SAT and 1.46% and 2.42% for VAT
respectively.
4.4.8 Statistical Analysis
Statistical analyses were performed using SPSS 10.1 for Windows (SPSS Inc., Chicago,
IL, USA). Pearson product moment correlation coefficient and Student’s t-tests were used to
determine correlations and differences of means between IMCL, GI, macronutrient composition
of the diet, anthropometric data, blood glucose, blood insulin and blood lipid parameters.
Statistical significance was set at p<0.05. All data are presented as means +SD unless otherwise
indicated.
4.5 Results
4.5.1 Subject Characteristics
Entering the 4 to 6 week study, the majority of the study population were female (73%)
and Caucasian (89%), with a mean age of 52 (+10) and the majority of the women were
menopausal (92%). According to the NCEP-ATP III definition for metabolic syndrome (1), all
participants had abdominal obesity (100%) (Waist Circumference (WC) >102 cm (males), >88
cm (females), 56% elevated triglycerides (>1.7mmol/L), 27% high blood pressure (>130/85),
23% low HDL cholesterol (<1.0mmol/L (males), <1.3mmol/L (females)) and 9% impaired
fasting glucose (>6.1mmol/L). The clinical characteristics of the study population had changed
very little by the end of the study (within 3%), however due to drop out rate, 6% more
participants had impaired fasting glucose, 10% lower HDL cholesterol, and 23% fewer women
were menopausal (Table 4.1).
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Table 4.1. Clinical Characteristics of the Study Population at Screening, Start and End of Study
Screening

Start

End

Variable

N = 171

N = 121

N = 95

Age

52 [+10]

52 [ +10]

53 [+9]

Male

47 (27)

33 (27)

28 (29)

Female

124 (73)

88 (73)

67 (71)

Menopause

115 (93)

81 (92)

62 (69)

Caucasian

152 (89)

108 (89)

86 (91)

Smoker

60 (35)

41 (34)

34 (36)

Calcium Channel Blocker medication

9 (6)

7 (6)

8 (9)

Beta Blocker medication

12 (7)

8 (7)

5 (6)

Anti-hypertensive medications (excluding ARB)

31 (18)

20 (17)

15 (16)

Diuretics

10 (6)

6 (5)

5 (5)

Aspirin

17(10)

12 (10)

8 (8)

Lipid Lowering Drugs

27 (16)

19 (16)

16 (17)

Abdominal Obesity

171 (100)

121 (100)

95 (100)

Triglycerides > 1.7 mmol/L

85 (50)

68 (56)

51 (54)

Blood Pressure > 130/85 mmHg

53 (31)

33 (27)

23 (24)

Fasting Glucose 6.1- 6.9 mmol/L

16 (9)

11 (9)

14 (15)

HDL-C < 1.0 mmol/L (M), < 1.3 mmol/L (F)

40 (23)

28 (23)

31 (33)

Numbers in round ( ) brackets represent percentage of the study population. Numbers in square
brackets [ ] represent + SD of the mean. M indicates males, F indicates females. ARB
designates angiotensin receptor blockers. C stands for cholesterol.
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4.5.2 Anthropometric Measurements, Blood Pressure and Heart Rate
At the start-and-end of the study, the participant’s mean BMI was 34.7+6.1 and 34.4+5.7
respectively, demonstrating that participants were classified as obese (BMI>30) during the study.
BMI, WC, HC, WHR, % body fat, systolic BP, diastolic BP and HR did not significantly change
(p>0.05) (Table 4.2).

Table 4.2. Anthropometric Characteristics, Blood Pressure and Heart Rate at Baseline and End
of Study
Start

End

Variable

N = 121

N = 95

p value

BMI (kg/m2)

34.7+6.1

34.4+5.7

0.34

Waist Circumference (cm)

111.0+14.5

110.5+12.6

0.69

Hip Circumference (cm)

121.4+12.4

121.1+11.6

0.43

Waist to Hip Ratio

0.92+0.09

0.91+0.08

0.44

% body fat

42.2+9.2

41.4+9.9

0.10

Systolic Blood Pressure (mmHg)

122.4+14.0

121.1+12.2

0.11

Diastolic Blood Pressure (mmHg)

78.5+7.9

77.7+7.7

0.32

Heart Rate (beats/minute)

75.4+12.8

72.9+11.2

0.07

Data are means +SD

4.5.3 Fasting Plasma Glucose and Lipids
After following dietary advice for a low fat, weight maintaining diet, fasting total serum
cholesterol, LDL cholesterol, and HDL cholesterol all significantly decreased (p<0.0001), while
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fasting plasma glucose significantly increased (p<0.05) (Table 4.3). There was a trend towards
a decrease in fasting triglycerides but it was not significant (p>0.05) (Table 4.3).

Table 4.3. Fasting Plasma Glucose and Lipids and Significance of Changes over the Dietary
Period
Start

End

%

Variable

N = 121

N = 95

Change p-value

Total Cholesterol (mmol/L)

5.6+1.2

5.1+1.0

-8.9

0.000 **

LDL Cholesterol (mmol/L)

3.3+1.0

3.0+0.9

-9.1

0.000 **

HDL Cholesterol (mmol/L)

1.4+0.4

1.3+0.3

-7.1

0.000 **

Triglycerides (mmol/L)

2.1+1.3

2.0+1.3

-4.8

0.186

Fasting Plasma Glucose (mmol/L)

5.4+0.6

5.5+0.8

+1.9

0.036 *

Data are means +SD, *p<0.05, ** p<0.0001

4.5.4 Dietary Intake and Physical Activity
There was a significant decrease in the percentage of energy (kilocalories (kcal)) from
total fat (p<0.0001) and saturated fat (p<0.01) and the MEDFICTS dietary assessment
questionnaire of fat intake (p<0.00001) (Table 4.4). The percentage of energy (kcal) from
carbohydrate and protein, as well as grams of fibre intake significantly increased (p<0.01) (Table
4.4). No significant differences were seen in energy intake (total kilocalories), GI, alcohol, or
physical activity level (p>0.05) (Table 4.4).
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Table 4.4. Dietary Intake and Physical Activity at the Start and End of the Study
Variable

Start (N = 121)

End (N = 95)

p value

Energy intake (kcal)

2077.4+625.1

2020.5+584.8

0.465

Total Fat (g)

79.1+32.8

70.7+32.8

0.025 *

Total Fat (% kcal)

33.0+7.1

29.6+7.5

0.0000 ****

Saturated Fat (g)

27.2+22.9

21.5+9.7

0.017 *

Saturated Fat (% kcal)

10.7+3.0

9.5+3.4

0.005**

Total Carbohydrate (g)

253.0+80.6

260.1+88.5

0.305

Total Carbohydrate (% kcal)

48.4+8.4

51.0+8.5

0.003**

Fibre (g)

20.7+9.8

23.8+11.3

0.008 **

Protein (g)

88.7+30.5

91.2+29.8

0.453

Protein (%)

17.0+3.4

18.0+3.4

0.010 **

Alcohol (%)

3.6+18.7

1.2+3.2

0.020*

Glycemic Index (%)

59.7+4.2

59.8+3.7

0.931

MEDFICTS score

64.4+25.8

46+18.6

0.0000****

Baecke Activity

2.4+0.6

2.5+0.5

0.417

Data are means +SD, *p<0.05, **p<0.01, ***p<0.0001, ****p<0.00001
% kcal;percentage of total energy, Baecke Activity;Baecke activity questionnaire
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4.5.5 Oral Glucose Tolerance Test
4.5.5.1 Insulin and Glucose
Upon completion of the study, there was a significant positive correlation with the
insulinogenic index (ISI) and percentage body fat and the MEDFICTS dietary fat questionnaire
(both, p<0.05), and a negative correlation between ISI and activity level (both, p<0.05). HOMA
was positively correlated with BMI, WC, and visceral adipose tissue (VAT) (all, p<0.0001), HC
and percentage of body fat (both, p<0.001), percentage of energy from dietary fat and grams of
saturated fat (both, p<0.05), and negatively correlated with HDL cholesterol (p<0.01).
Fasting insulin was positively correlated with BMI, VAT, WC and HC (all, p<0.001),
percentage of body fat (p<0.01), and grams of saturated fat, percentage of energy from dietary
fat, and GI (all, p<0.05), and negatively correlated with HDL cholesterol and activity level (both,
p<0.05). Thirty minute insulin was positively correlated with the MEDFICTS dietary fat
questionnaire (p<0.01), and BMI, VAT, percentage of body fat, and percentage of energy from
dietary fat and saturated fat (all, p<0.05), and negatively correlated with activity level, dietary
fibre (g) and percentage of energy from carbohydrate (all, p<0.05).
Fasting glucose was positively correlated with VAT (p<0.05). Thirty minute glucose was
positively correlated with VAT (p<0.05) and percentage of energy from saturated fat and total fat
(both, p<0.01), and negatively correlated with dietary fibre (g) and percentage of energy from
carbohydrate (both, p<0.05). Sixty minute glucose was positively correlated with VAT and WC
(both, p<0.01) and negatively correlated with HDL cholesterol (p<0.001). Glucose at 120
minutes was positively correlated with free fatty acids (FFA) (p<0.05) and negatively correlated
with carbohydrate (g) (p<0.05). Refer to Table 4.5 for insulin and glucose correlations.
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Table 4.5. Correlation Grid for Insulin and Glucose
GI

MED-

Total

Total

Sat

%

FICTS

Fat %

Fat (g) Fat %

ISI

0.22

0.26*

0.10

0.13

HOMA

0.19

0.14

0.23*

FastIns

0.21*

0.16

30mIns

0.18

30mPG
120mPG

Sat

Fibre

CHO

CHO

Fat (g) (g)

%

(g)

0.09

0.17

0.02

-0.07

0.10

0.21

0.19

0.22*

0.02

-0.07

0.10

0.22*

0.21

0.19

0.23*

-0.15

-0.14

-0.01

0.31**

0.25*

0.13

0.25*

0.22

-0.27*

-0.23*

-0.12

0.05

0.16

0.32**

0.16

0.31**

0.19

-0.25*

-0.25

-0.15

-0.07

-0.08

-0.02

-0.15

0.03

-0.15

-0.05

0.04

-0.21*

IMCL

VAT

Baecke

%BF

BMI

WC

HC

HDL

FFA

ISI

-0.02

0.02

-0.23*

0.23*

0.16

0.06

0.15

0.01

-0.18

HOMA

0.12

0.53$

-0.18

0.38#

0.51$

0.42$

0.40#

-0.30**

-0.17

FastIns

0.10

0.56$

-0.21*

0.35**

0.52$

0.43$

0.40$

-0.29*

-0.18

30mIns

-0.01

0.30*

-0.25*

0.26*

0.28*

0.21

0.19

-0.05

-0.12

FPG

0.11

0.26*

0.06

0.13

0.14

0.19

0.08

-0.16

-0.14

30mPG

0.09

0.23*

0.09

0.02

0.06

0.19

0.00

-0.17

-0.02

60mPG

0.15

0.33**

0.05

0.05

0.08

0.27**

0.08

-0.35#

0.17

120mPG

-0.01

0.16

-0.01

0.21

0.11

0.08

0.08

-0.14

0.26*

The data in the table represent correlation r values. *p<0.05, **p<0.01, #p<0.001, $p<0.0001,
GI;glycemic index, %;percentage of total energy, sat fat;saturated fat, CHO;carbohydrate, IMCL:
intramyocellular lipids (arbitrary units (AU)), VAT;visceral adipose tissue (AU), Baecke; Baecke activity
questionnaire, %BF;percentage body fat, BMI;body mass index, WC;waist circumference (cm), HC;hip
circumference (cm), HDL;high density lipoprotein cholesterol (mmol/L), FFA;free fatty acids (µmol/L),
ISI;insulinogenic index, HOMA;homeostasis model assessment, FastIns;fasting insulin, 30mIns;30
minute insulin, FPG;fasting plasma glucose, 30mPG;30 minute plasma glucose, 60mPG;60 minute
plasma glucose, 120mPG;120 minute plasma glucose: plasma glucose was measured in mmol/L, plasma
insulin was measured in pmol/L): insulin, glucose, FFA, HDL cholesterol were obtained during the oral
glucose tolerance test
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4.5.5.2 Blood lipids
At the end of the run-in period, fasting total cholesterol was negatively correlated with
dietary carbohydrate (p<0.05). LDL cholesterol was positively correlated with percentage of
energy from total fat and negatively correlated with percentage of energy from carbohydrate
(both p<0.05). Triglycerides were positively correlated with VAT (p<0.01). Free fatty acids
were positively correlated with percentage of body fat (p<0.01) and 120 minute plasma glucose
(p<0.05) and negatively correlated with WHR, dietary carbohydrate (g) and protein (g) (all,
p<0.05). HDL cholesterol was negatively correlated with WHR (p<0.0001), WC (p<0.001),
fasting insulin, 60 minute plasma glucose, VAT, HOMA, and dietary carbohydrate and protein
(g) (all, p<0.01), and fibre (p<0.05). Refer to Table 4.6 for blood lipid correlations.
4.5.6 Intramyocellular Lipids (IMCL), Subcutaneous Adipose Tissue (SAT), Visceral
Adipose Tissue (VAT)
At the end of the run-in period, IMCL was positively correlated with VAT (r=0.27,
p<0.05). IMCL was also positively correlated with WC (p<0.01), BMI, and HC (both, p<0.05),
and grams of dietary carbohydrate, fat and protein (all, p<0.05) (Table 4.7). IMCL was not
significantly correlated with HOMA, ISI, or any insulin, glucose or lipid measurements obtained
during the OGTT (p>0.05) (Table 4.5, 4.6). Subcutaneous adipose tissue (SAT) was positively
correlated with BMI, WC and HC (all, p<0.0001) and percentage of body fat (p<0.001) (Table
4.7). VAT was positively correlated with BMI, WHR, WC, fasting plasma insulin and HOMA
(all, p<0.0001), HC (p<0.001), triglycerides and 60 minute plasma glucose (both, p<0.01),
IMCL, 30 minute plasma insulin, MEDFICTS dietary fat questionnaire, fasting and 30 minute
plasma glucose, and grams of dietary protein and fat (all, p<0.05) (Tables 4.5, 4.6, 4.7). VAT
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was negatively correlated with HDL cholesterol (p<0.01) and activity level (p<0.05) (Tables 4.6,
4.7). The GI was positively correlated with VAT however it was not significant (p=0.06).

Table 4.6. Correlation Grid for Serum Lipids
CHO %

CHO (g)

Total Fat %

Protein (g)

Fibre (g) IMCL

Total-C

-0.25*

-0.21*

0.20

-0.01

-0.15

-0.17

LDL-C

-0.26*

-0.14

0.23*

0.07

-0.10

-0.11

HDL-C

-0.09

-0.29**

0.23

-0.32**

-0.26*

-0.20

FFA

0.04

-0.23*

-0.03

-0.22*

-0.18

-0.10

TG

0.01

-0.00

-0.04

0.13

0.07

-0.00

VAT

WC

WHR

%BF

FastIns

HOMA

60mPG

120mPG

HDL-C

-0.32**

-0.33#

-0.44$

0.07

-0.29**

-0.30**

-0.35**

-0.14

FFA

-0.11

-0.02

-0.23*

0.30**

-0.18

-0.17

0.17

0.26*

TG

0.31**

0.04

0.11

0.13

0.13

0.14

0.15

0.11

The data in the table represent correlation r values. *p<0.05, **p<0.01, #p<0.001, $p<0.0001,
%;percentage of total energy, CHO;carbohydrate, IMCL;intramyocellular lipids (arbitrary units
(AU)), VAT;visceral adipose tissue (AU), %BF;percentage body fat, WC;waist circumference
(cm), Total-C;total cholesterol (mmol/L), HDL;high density lipoprotein cholesterol (mmol/L),
LDL-C;low density lipoprotein cholesterol (mmol/L), FFA;free fatty acids (µmol/L),
TG;triglycerides (mmol/L), HOMA;homeostasis model assessment index, FastIns;fasting plasma
insulin (pmol/L), 60mPG;60 minute plasma glucose (mmol/L), 120mPG;120 minute plasma
glucose (mmol/L): FFA, insulin, glucose and cholesterol were obtained during the oral glucose
tolerance test
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Table 4.7. Correlation Grid for IMCL, SAT, VAT
BMI

WC

HC

%BF

WHR

Baecke

IMCL

0.22*

0.31**

0.23*

0.04

0.21

-0.04

SAT

0.68$

0.54$

0.81$

0.41#

-0.12

-0.21

VAT

0.48$

0.65$

0.37#

0.13

0.50$

-0.25*

MEDFICTS

Protein (g)

Total Fat (g)

CHO (g)

IMCL

0.05

0.24*

0.22*

0.28*

VAT

0.23*

0.25*

0.25*

0.05

The data in the table represent correlation r values. *p<0.05, **p<0.01, #p<0.001, $p<0.0001,
IMCL;intramyocellular lipid (arbitrary units (AU)), SAT;subcutaneous adipose tissue (AU),
VAT;visceral adipose tissue (AU), BMI;body mass index, WC;waist circumference (cm),
HC;hip circumference (cm), %BF;percentage body fat, WHR;waist to hip ratio, Baecke;Baecke
activity questionnaire, CHO;carbohydrate.

4.6 Discussion and Conclusions
This study demonstrated that individuals with abdominal obesity can significantly reduce
blood lipids by following dietary advice on consuming an ad-libitum low fat diet without any
strict dietary protocol to follow and without losing weight or increasing physical activity. At the
start-and-end of the study, the participant’s mean BMI was 34.7+6.1 and 34.4+5.7 respectively,
demonstrating that participants were classified as obese (BMI>30) during the study. Total energy
(kcal) intake, activity level, BMI, WC, hip circumference, WHR, and percentage body fat did not
significantly change (p>0.05) indicating that participants followed a weight maintaining diet.
There was a significant decrease in the percentage of total dietary fat (p<0.0001) and saturated
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fat (p<0.01) and the MEDFICTS score (dietary assessment questionnaire of fat intake)
(p<0.00001) demonstrating that the participant’s lowered their fat intake during the study.
The recommended NCEP-ATP III dietary interventions for obese individuals, specifically
to prevent coronary heart disease, include weight loss, physical activity and lowering the overall
fat, saturated fat, and cholesterol in the diet, with the primary goal of lowering LDL cholesterol
(1). This study provided dietary advice for following the NCEP-ATP III dietary
recommendations for lowering the overall fat and saturated fat. Participants reduced the
saturated fat and total fat in their diet while increasing the carbohydrate and protein in the diet.
The significant reductions (p<0.0001) in total cholesterol (-8.9% change) and LDL cholesterol
(-9.1% change) are consistent with other studies showing a reduction in serum lipids when
following a low fat diet (33, 37). A meta-analysis by Clarke et al (33) reported that replacing
saturated fat with complex carbohydrate can decrease total serum cholesterol by 0.52 (SE+0.03)
mmol/L and LDL cholesterol by 0.36 (SE+0.05) mmol/L. Other studies have shown an increase
in triglycerides and a decrease in HDL cholesterol when replacing saturated fat with
carbohydrate (34, 35), however, when fibre is increased along with carbohydrate intake, the
negative effects are reduced (35, 36). In this study, there were no significant changes in
triglycerides after following an ad-libitum low fat diet, however, HDL cholesterol decreased
significantly (p<0.0001) even though fibre intake increased throughout the study. An
explanation for the reduction in HDL cholesterol is that all serum lipids will be reduced when
restricting fat intake in the diet. Reductions in HDL cholesterol have been previously reported
when following a low fat diet (37) which prompted the NCEP-ATP III to include physical
activity and weight reduction along with following a low fat diet to reduce cardiovascular disease
risk (1). The focus of this study was to eliminate potential effects of variations in dietary fat
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intake which may influence IMCL content and not to lower serum lipids, therefore physical
activity and weight loss were not part of the protocol in this study. This study did demonstrate
that a weight maintaining, low fat, ad-libitum diet for 4 to 6 weeks can significantly reduce
serum lipids in obese individuals. Thus, a weight-maintaining, low fat diet may reduce an
individuals’ risk for developing cardiovascular disease if followed for a longer duration.
In animal (12, 13, 14, 15) and human studies (16, 17, 18), high fat diets have been shown
to increase IMCL and decrease insulin sensitivity. In this study, IMCL was positively correlated
with total dietary fat (p<0.05), which is consistent with studies showing a relationship with
dietary fat and IMCL however there were no significant correlations between IMCL and insulin
sensitivity. A possible explanation for not finding correlations with IMCL and insulin sensitivity
in this study is participants were given dietary advice regarding food choices for following a low
fat diet whereas other studies provided controlled high fat feedings and diets. Further, studies
demonstrating a relationship between insulin resistance and IMCL used the euglycemic
hyperinsulinemic clamp method (16, 17, 45). The current study did not find a correlation
between insulin resistance and IMCL possibly due to using the HOMA index to estimate insulin
sensitivity. The results of the current study are in agreement with previous studies using HOMA
that did not find a relationship between IMCL and insulin sensitivity (46, 47). Although HOMA
has been validated with the euglycemic hyperinsulinemic clamp technique (31), it is more a
measure of hepatic insulin resistance rather than an indicator of muscle insulin sensitivity. It
may be possible that the relationship between insulin resistance and IMCL may not be found
when using HOMA and a more accurate technique may have identified this relationship in the
current study. Further, no relationship was found between IMCL and two hour plasma glucose
(120mPG) after OGTT which is an indicator of muscle insulin sensitivity. The lack of
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relationship between IMCL and two hour plasma glucose may be due to the fact that the study
population was abdominally obese but otherwise healthy individuals with fasting and 120 minute
glucose and insulin within recommended ranges. The current results are consistent with other
studies that found no correlation between IMCL and insulin sensitivity in healthy, overweight
individuals (46, 48, 49). Further, a limitation of this run-in phase was that IMCL content was
measured only at the end of the study, therefore conclusions cannot be made on whether changes
occurred in IMCL and if there was any effect on insulin sensitivity after reducing fat in the diet.
On the other hand, IMCL was positively correlated with VAT (p<0.05) and VAT was positively
correlated with the OGTT fasting insulin (p<0.00001) and glucose (p<0.05), 30 minute insulin
and glucose (p<0.05), 60 minute glucose (p<0.01) and HOMA (p<0.0001). Findings are
consistent with a study by Koska et al (38) who found a positive correlation with fasting plasma
insulin and VAT (p<0.01) but no correlation with IMCL and insulin action on glucose uptake
and production in obese individuals. The results of this study showed that IMCL and VAT were
correlated with fat intake however VAT may independently have an effect on insulin sensitivity.
A third purpose of this study was to determine whether there was a relationship between
the glycemic index and metabolic profiles after following a low fat dietary advice phase for 4 to
6 weeks. Although participants were not given dietary advice on following a low GI diet, there
was a significant positive relationship between glycemic index (GI) and fasting insulin (p<0.05).
Wolever et al (41, 42) have previously shown that individual foods with different GI’s as well as
mixed meals varying in GI affect postprandial plasma insulin and glucose differently. Although
this study did not find a correlation between GI and plasma glucose, research has shown a
relationship between mean plasma insulin and glucose response areas under the curve with foods
varying in GI (41). Findings from this study are consistent with previous research demonstrating
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that insulin is positively correlated with the GI, indicating that lower GI foods can be less
demanding on the pancreas for insulin production (43, 44). Since abdominally obese individuals
are susceptible to developing insulin resistance, following a diet with lower GI foods may have
metabolic benefits such as improving insulin sensitivity and should be evaluated further.
In conclusion, this study has shown that a weight maintaining, low-fat, ad-libitum diet can
reduce total serum cholesterol and LDL serum cholesterol in abdominally obese individuals, a
population at risk for coronary heart disease, diabetes, and metabolic syndrome. These findings
may help to explain the importance of a low fat diet, especially for those individuals who do not
wish to reduce body weight or increase activity level. The participants in this study obtained
dietary advice on following a low fat diet for a short period of time. To confirm the present
findings, research is needed to determine whether individuals can follow dietary advice on
following a low fat diet for a longer duration. Further, participants in this study did not receive
dietary advice on following a low GI diet. Future research is needed to determine the long-term
effects of a non-prescribed, ad-libitum, low fat, low GI diet on metabolic profiles in free-living
individuals with abdominal obesity.
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CHAPTER 5
EFFECTS OF A EUCALORIC LOW GLYCEMIC INDEX DIET ON INSULIN
SENSITIVITY AND INTRAMYOCELLULAR LIPIDS IN ADULTS WITH
ABDOMINAL OBESITY
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5. Effects of a eucaloric low glycemic index diet on insulin sensitivity and intramyocellular
lipids in adults with abdominal obesity
5.1 Introductory Statement
Research has shown that insulin sensitivity is negatively correlated with intramyocellular
lipid (IMCL) content. It has been suggested that low glycemic index diets may improve insulin
sensitivity by suppressing non-esterified fatty acid release, which in turn may promote glucose
uptake and possibly lower IMCL content. This study was conducted to determine whether a long
term eucaloric low glycemic index diet can improve insulin sensitivity by reducing IMCL
content of skeletal muscle in abdominally obese individuals.

83

5.2 Abstract
Background: Abdominal obesity is associated with insulin resistance and increased IMCL
content of skeletal muscle. Low-glycemic-index (GI) diets may improve insulin sensitivity in
insulin resistant subjects but their effect on IMCL is unknown.
Objective: The purpose of this study was to determine the effect a low-GI diet (LGID) on
insulin sensitivity and IMCL content in weight-stable abdominally obese adults.
Design: Ninety-five men and non-pregnant, non-lactating women aged 53+10 years with
abdominal obesity were randomized to a 24-week intervention of either a weight-maintaining
low glycemic index diet (LGID, n=48) or control high-GI diet (HGID, n=47). 1H-MRS of the
soleus muscle and an oral glucose tolerance test were performed at the beginning and end of the
study to determine IMCL content and insulin sensitivity.
Results: On the LGID there were significant decreases from baseline in diet GI (p<0.0001),
intakes of total and saturated fat (p<0.001), and 60 minute postprandial glucose (p<0.05), while
intakes of carbohydrate and fibre increased (p<.0001). On the HGID there were significant
increases in diet GI (p<0.001), intakes of carbohydrate (p<0.001), total kcal intake (p<0.01),
insulinogenic index (p<0.01) and BMI (p<0.05), and a significant decrease in systolic blood
pressure (p<0.05). There were no significant changes in IMCL or other metabolic measures for
either group.
Conclusions: A LGID reduced the OGTT 60 minute plasma glucose but did not significantly
affect IMCL or insulin sensitivity in individuals with abdominal obesity.
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5.3 Introduction
Obesity is a complex disease characterized by an abnormal deposition of fat in adipose
tissue and is mainly the result of a positive energy balance where food intake is greater than the
body’s ability to utilize the food as energy (1). The excessive accumulation of adipose tissue
leads to an undesirable weight gain to the extent that health may be adversely affected (1).
Obesity, in particular abdominal obesity, has been shown to be a risk factor for developing
cardiovascular disease (2, 12), type 2 diabetes (3, 4, 5, 6, 12) and metabolic syndrome (7, 8).
Insulin resistance, a key feature of metabolic syndrome, is higher in individuals with overall
adiposity (9) and central abdominal obesity (10, 11). Although the mechanism of insulin
resistance is not fully understood, it has been suggested that individuals with abdominal obesity
cannot store lipids effectively in the subcutaneous adipose tissue which in turn leads to an
increase in storage of lipids in the visceral area and in organs other than adipose tissue such as
the liver, pancreas and skeletal muscle causing insulin resistance in these tissues (13, 14).
Research has shown that muscle fat is increased in individuals with insulin resistance (15) and
that insulin sensitivity is negatively correlated with intramyocellular lipid (IMCL) content as
assessed by examination from proton nuclear magnetic resonance spectroscopy (1H-MRS), a
non-invasive quantification of IMCL content in human muscle that can identify the relative
contributions of IMCL and whole body insulin sensitivity (16).
Evidence supports the role of carbohydrates in influencing insulin sensitivity by
improving insulin-stimulated glucose uptake by adipocytes when following a low glycemic
index diet (17). The glycemic index (GI) was developed as a classification of the blood glucoseraising potential of the available carbohydrate in foods (43) and is defined as the incremental
area under the blood glucose response curve after consuming a 50 gram available-carbohydrate

85

portion of a test food expressed as a percentage of the response after consuming 50 grams of oral
anhydrous glucose by the same subject (44, 45). Low glycemic index (GI) carbohydrates are
slowly digested and release glucose gradually into the blood stream and therefore may suppress
plasma concentrations of fatty acids (18, 19). The suppression of plasma fatty acids may
improve insulin sensitivity by promoting insulin-stimulated glucose uptake by skeletal muscle
and possibly reduce IMCL storage (19). A four week intervention study examining the effects of
a reduction in dietary GI on IMCL in healthy individuals showed improvements in insulin
sensitivity but no changes in IMCL storage levels (20). It still remains unclear whether a low GI
diet can improve IMCL stores in muscles of individuals who are at risk for developing insulin
resistance or type 2 diabetes.
The primary purpose of this 24 week intervention study was to determine whether a low
GI diet would reduce IMCL stores thereby improving insulin sensitivity in individuals with
abdominal obesity.
5.4 Subjects and Methods
This study was carried out on an outpatient basis at the Hamilton General Hospital,
Centre for Cardiovascular Obesity Research and Management, McMaster University, Faculty of
Health Sciences. The study protocol was approved by the Hamilton Health Sciences, McMaster
University human research ethics board and carried out in accordance with the Declaration of
Helsinki as revised in 2000. All participants were given a participant information sheet and gave
informed consent to participate in the study (Appendix 8.1). The trial is publicly registered with
ClinicalTrials.gov, number NCT00147264.
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5.4.1 Protocol
This thesis chapter consists of a 24 week low GI diet which is the randomization phase of a
parallel, 2x2 factorial design clinical trial that studied the effects of a low GI diet and telmisartan,
an angiotensin receptor blocker, on intramyocellular lipids (TRIM trial (Telmisartan-Induced
Reduction in Intra-Myocellular Lipids)).
5.4.2 Study Sample
A total of 2433 individuals from the general population responded through advertisement
in local media and underwent a telephone screening process. Of the 171 people who were
invited for an initial screening visit to assess eligibility, 32 did not meet the inclusion criteria and
18 refused to participate. Of the 121 enrolled participants, 95 completed the run-in phase of the
study resulting in a 21% drop out rate. Of the 95 men, and non-pregnant, non-lactating women
aged 30 to 70 years with abdominal obesity, with or without additional features of the metabolic
syndrome, who were eligible to participate in the randomization study, 48 participants were
randomized to the low GI diet (LGID) and 47 participants were randomized to the control, high
GI diet (HGID) (Figure 5.1). For the primary outcome (1H-MRS), 12 participants in the LGID
and 10 participants in the HGID had poor quality MRI scans and were excluded in the data
analysis (Figure 5.1). Abdominal obesity was defined as a waist circumference of >102 cm for
males and >88 cm for females (NCEP, ATP III) (21). Inclusion criteria included abdominal
obesity, ability to provide written informed consent, age between 30 and 70 years, and the ability
and willingness to complete dietary and activity diaries and questionnaires. Exclusion criteria
included diabetes or use of any anti-diabetic drug, uncontrolled hypertension, serum triglycerides
>10 mmol/L, active malignancy, chronic inflammatory disorders, endocrine, renal or hepatic
dysfunction, use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in
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the last 3 months, use of a lipid lowering medication-the dose of which had not been stable for at
least 3 months, body mass index of >45, intent to lose weight or use weight loss medications
during the study, contraindications to magnetic resonance imaging (MRI) such as claustrophobia
or metal prostheses, and any dietary restrictions that would prevent the participants from
following the study protocol.
5.4.3. Dietary Intervention
Participants were randomly assigned to either a low glycemic index diet (LGID, n=48) or
a control, high glycemic index diet (HGID, n=47) for 24 weeks by using an automated
randomization system. The aim of both diets was to be weight maintaining consisting of 55% of
energy from carbohydrate, 30% from fat, 15% from protein and 7% or less from saturated fats as
outlined by the American Heart Association (22). Forty percent of the total carbohydrate
consisted of either low glycemic index (GI) foods or high GI foods. Participants were provided
with low GI and high GI test foods on a monthly basis (Appendix 8.7) and were asked to keep
daily dietary records of the number of test foods they consumed each day (Appendix 8.7). The
number of test foods to be eaten each day was calculated based on the participant’s daily
estimated energy requirements according to the Lipid Research Clinic Requirement formula (23)
with an additional 300 kilocalories (kcal) per day added on for exercise and daily energy
expenditure (Appendix 8.2). One serving of test food contained approximately 15 grams of
available carbohydrate. Participants were asked to consume two servings of test foods with the
first meal of each day, with the remainder of the test foods to be consumed throughout the day.
Weekly compliance of test foods was calculated as the number of test foods consumed divided
by the number of test foods required multiplied by 100.
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N = 2261, Excluded
N = 860, Not meeting inclusion
criteria
N = 1313, Refused to participate
N = 89, Other reasons (desired
weight loss, no birth control,
diabetes, medications)

Participants Screened
N = 2433

Patients Consented to Participate in
Run-In Dietary Phase
N = 171

Excluded, N = 50
N = 32, Did not meet inclusion
criteria
N = 18, Refused to participate
N = 0, Other reasons
Participants Enrolled in Run-In Dietary Phase
N = 121

Withdrawals during Run-In Dietary Phase,
N = 26
Main Reasons for Exclusion:
N = 7, desired weight loss
N = 6, personal reasons
N = 5, time commitment
N = 5, adverse events
N = 3, unknown reasons

Participants Enrolled in Randomization Phase
N = 95

Low Glycemic Index Diet
N = 48
Lost to Follow Up N= 0

Primary Analysis (1H-MRS) N = 40
Excluded from analysis due to technical reasons
(poor quality MRI scans) N = 8

Figure 5.1. Participant Recruitment Flow Chart
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High Glycemic Index Diet
N = 47
Lost to Follow Up N = 0

Primary Analysis (1H-MRS) N = 40
Excluded from analysis due to technical
reasons (poor quality MRI scans) N = 7

Participants met seven times during the study for dietary advice, the collection and
dispensing of daily food records, analysis of diet compliance, dispensing of test foods, and
completing the MEDFICTS dietary assessment questionnaire (NCEP, ATP III) (Appendix 8.4)
(21). The 3-day food diaries were analyzed at baseline, and weeks 4, 12, and 24 (Appendix 8.5).
Micronutrients, macronutrients, and the GI of foods were calculated using the Food Processor
SQL Nutrition Analysis & Fitness software package version 9.5 (ESHA Research, Salem, OR,
USA) with missing values for GI added using the NutriPro diet analysis program (Glycemic
Index Laboratories Inc., University of Toronto). The GI was expressed with the GI of
glucose=100. Participants were instructed to maintain their habitual level of physical activity
throughout the study. The Baecke habitual physical activity questionnaire was administered at
the start-and-end of the study to determine activity levels (Appendix 8.6) (24).
5.4.4

Anthropometric Measurements, Blood Pressure and Heart Rate
Height (cm) was measured at the initial screening visit to the nearest 0.1 cm using a wall

mounted stadiometer and body weight was measured at every visit to the nearest 0.1 kg on a
digital weigh scale. Body mass index (BMI) was calculated as body weight (kg) divided by
height (m2). Waist circumference (WC) was measured to the nearest 0.1 cm using the World
Health Organization (WHO) method (mid-point between the palpated inferior border of the last
rib and upper border of the iliac crest in a horizontal plane at the end of normal expiration) (25).
Hip circumference (HC) was measured to the nearest 0.1 cm at the level of the major trochanter
(usually around the largest diameter of the buttocks) (25). Waist-to-hip ratio (WHR) was
calculated (waist (cm) divided by hip (cm)) from the measurement of the waist and hip
circumference. Body composition analysis (percentage of body fat) was assessed by bioelectrical
impedance analysis as per manufacturer’s instructions (BioScan 916, Maltron International Lt,
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Rayleigh, Essex, UK). Waist and hip circumference and body fat percentage were measured at
the start, middle and end of the study.
Blood pressure (BP) (mmHg) and heart rate (HR) (beats per minute) were measured at
every visit in the sitting position using an automatic blood pressure monitor (BpTRU®, VSM
MedTech Ltd., Vancouver, BC, Canada) following five minutes of seated rest.
5.4.5 Oral Glucose Tolerance Test
An oral glucose tolerance test (OGTT) was performed in the fasting participant (12 hours)
at the start, middle and end of the study. An indwelling catheter was inserted in the forearm and
three fasting blood samples for glucose and insulin were taken five minutes apart (-15, -10, -5
minutes). Participants then ingested (0 minutes) a 75 gram solution of dextrose and venous
blood samples were obtained again at 30, 60, and 120 minutes for determination of plasma
glucose and insulin. Glucose was measured by a glucose oxidase method and serum insulin was
measured with an immunometric assay (Diagnostic Products Corporation, Los Angeles, CA).
The glucose and insulin data from the OGTT was used to assess insulin sensitivity (homeostatic
model assessment index, HOMA = fasting insulin (µU/ml) x fasting glucose (mmol/L) divided
by 22.5 (26)) and insulin secretion (insulinogenic index (ISI) = ratio of change in insulin to
change in glucose from 0 to 30 minutes (Delta I30 divided by Delta G30) (27)). The HOMA
index has been validated with the gold standard euglycemic hyperinsulinemic clamp technique
(28). During the OGTT, fasting blood samples were also collected for serum total, HDL and
LDL cholesterol, free fatty acids, and triglycerides. LDL was calculated using the Friedewald
formula (29).
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5.4.6 Magnetic Resonance Imaging
Intramyocellular lipid (IMCL) content of the mid-soleus muscle (predominately oxidative
muscle fibres) was assessed by proton magnetic resonance spectroscopy (1H-MRS) at the end of
the run-in period. MRS was performed on a 1.5 Tesla whole body MR system (Siemens
Symphony AG, Munich, Germany) using a body coil for radiofrequency transmission and
surface coil to receive signals. The 1H-MRS scans were performed at the Nuclear Medicine
Department at the McMaster University Medical Centre. Participants were advised to fast and
restrict physical activity for six hours prior to the procedure. Following screening for absence of
MRI contraindications, the participant was placed in the supine position and the leg was
positioned and immobilized so that the calf was situated as close to the center of the magnet as
possible. The radio-frequency receive coil was fastened nearest to the region of interest to
collect the greatest signal. Participants remained in the supine position (feet first) within the MR
system. Three-plane spin-echo T1-weighted MR images were performed to guide placement of
the volume of interest for spectroscopy. Imaging parameters were chosen for suitable separation
of muscle, fascia, IMCL and extramyocellular lipid (EMCL) content (TR 3000 milliseconds
(ms), TE 30 ms, 128 averages, 1,024 data points over 1000 Hz spectral width, 1 cc voxel
volume, water signal suppressed using chemical selective saturation). Semi-automatic shimming
of the magnet with typical line widths of the water signal of 10 Hz was performed to optimize
magnetic field homogeneity. Several scout images were taken to determine the ideal position for
the voxel location. Volume of interest was centered over the mid-soleus muscle and vascular
structures and gross adipose tissue deposits were excluded as much as possible. The IMCL and
EMCL peak was integrated at 1.28 ppm and 1.48 ppm respectively. Since creatine content is
stable within the same muscle across a population (50), spectral intensities were referenced to the
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methyl signal of creatine (Cr3) at 3.05 ppm serving as an internal reference. Spectra were
processed and the resonance curves for IMCL, EMCL, and creatine were measured using jMRUI
software v2.1 (51). Data is presented as arbitrary units (AU).
After 3-plane localizer image acquisition, breath-hold axial T1-weighted image at the level
of mid-L4 (TR 400 ms, TE 13 ms) was acquired for the volume of visceral adipose tissue (VAT)
and subcutaneous adipose tissue (SAT). VAT and SAT was calculated using SliceOmatic 4.2
medical imaging software (SliceOmatic v.4.2, Tomovision, Montreal). VAT was defined as
adipose tissue within the inside edge of the abdominal wall and SAT was defined as adipose
tissue on the outside edge of the abdominal wall. The intra-and-inter-observer coefficients of
variation for this method are 0.53% and 0.44% for SAT and 1.46% and 2.42% for VAT
respectively.
5.4.7 Statistical Analysis
The statistical analyses were performed using SPSS 10.1 for Windows (SPSS Inc.,
Chicago, IL, USA). The primary analysis was an ANOVA of change in IMCL content in the
soleus muscle by treatment group covarying out baseline IMCL measurement, age, sex, change
in body weight, and body mass index. Pearson product moment correlation coefficient and
Student’s t-tests were used to determine correlations and differences of means between IMCL,
GI, macronutrient composition of the diet, anthropometric data, blood glucose, blood insulin and
blood lipid parameters. Statistical significance was set at p<0.05. All data are presented as
means + standard deviation (SD) unless otherwise indicated.
Assuming a two-sided alpha of 0.05 and a standard deviation of 5, the study sample was
powered at 90% to detect a minimum difference in change in IMCL content between treatment
groups of 3.7 (Arbitrary Units (AU)), based on a t-test with 40 participants per group.
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Additional participants were randomized to account for an anticipated drop-out rate of 30%. The
study sample was also powered at 90% to detect average changes between the start and end of
the 24 week study for insulin sensitivity of 0.96, free fatty acids of 26.6 µmol/L, triglycerides of
0.49 mmol/L, total cholesterol of 0.62 mmol/L, and LDL cholesterol of 0.56 mmol/L.
5.5 Results
5.5.1 Subject Characteristics
Entering the study, participants in the LGID and HGID group had abdominal obesity
(100%) and were similar in age (LGID 53.1+9.2 vs HGID 53.5+9.9) and sex (female, LGID
71% vs HGID 70%). The majority of the participants were Caucasian (LGID 88% vs HGID
94%) and the women were menopausal (LGID 97% vs HGID 91%). Clinical characteristics of
the study population at baseline and end-of-study are listed in Table 5.1.
5.5.2 Anthropometric Measurements
BMI significantly increased from the start-to-end of the study in the HGID group
(34.8+6.1 vs 35.0+6.2, p<0.05), but did not significantly change in the LGID group (34.0+5.2 vs
33.9+5.4, p>0.05). All participants in both groups maintained abdominal obesity throughout the
study for both the LGID group (start 109.5+14.0 vs end 110.0+14.4cm) and the HGID group
(start 111.6+11.1 vs end 112.0+12.1cm) but was not significant from start-to-end of study or
between groups (p>0.05). WC, HC, WHR, and percentage body fat did not significantly change
in either group, nor where there any significant differences between groups for any of the
variables after controlling for baseline (p>0.05). The participants’ anthropometric characteristics
at baseline and end of study are shown in Table 5.2.

94

Table 5.1. Clinical Characteristics of the Study Population at Baseline and End of Study
LGID

LGID

HGID

HGID

Baseline

End

Baseline

End

Variable

N = 48

N = 48

N = 47

N = 47

Age

53.1 [+9.2]

53.5 [+9.9]

Male

14 (29.2)

14 (29.8)

Female

34 (70.8)

33 (70.2)

Menopause

33 (97.1)

30 (90.9)

Caucasian

42 (87.5)

44 (93.6)

Smoker

18 (37.5)

16 (34.0)

Calcium Channel Blocker medication

4 (9.1)

2 (4.7)

4 (8.9)

3 (6.7)

Anti-hypertensive medications

10 (20.8)

9 (19.6)

5 (10.6)

4 (8.5)

Diuretics

3 (6.3)

2 (4.3)

2 (4.3)

2 (4.3)

Aspirin

3 (6.3)

5 (11.4)

5 (10.6)

4 (8.9)

Lipid Lowering Drugs

9 (18.8)

10 (20.8)

7 (14.9)

7 (14.9)

Abdominal Obesity

48 (100)

48 (100)

47 (100)

47 (100)

Triglycerides > 1.7 mmol/L

25 (52.1)

26 (60.5)

26 (55.3)

20 (45.5)

Blood Pressure > 130/85 mmHg

13 (27.1)

11 (22.9)

10 (21.3)

8 (17.0)

Fasting Glucose 6.1- 6.9 mmol/L

7 (14.9)

8 (18.6)

7 (14.9)

7 (14.9)

HDL Cholesterol

15 (31.3)

20 (41.7)

16 (34.0)

21 (44.7)

<1.0 mmol/L (M),<1.3 mmol/L (F)
Numbers in round brackets ( ) represent percentage of the study population. Numbers in square
brackets [ ] represent +SD of the mean. M indicates males, F indicates females.
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Table 5.2. Anthropometric and Body Composition Characteristics at Baseline and End of Study
LGID

LGID

HGID

HGID

Baseline

End

Baseline

End

Variable

N = 48

N = 48

P value

N = 47

N = 47

p value

BMI (kg/m2)

34.0+5.2

33.9+5.4

0.93

34.8+6.13

35.0+6.2

0.02*

WC (cm)

109.5+14.0

110.0+14.4

0.83

111.6+11.1

112.0+12.1

0.33

HC (cm)

120.2+10.7

119.4+11.7

0.61

122.1+12.6

121.9+11.4

0.68

WHR

0.91+0.08

0.92+0.07

0.37

0.92+0.07

0.92+0.07

0.62

% BF

41.2+10.9

41.4+7.3

0.99

41.7+9.0

41.9+8.8

0.41

Data are means + SD, *p < 0.05; BMI, body mass index; WC, waist circumference; HC, hip
circumference; WHR, waist-to-hip ratio; % BF, percentage body fat

5.5.3 Blood Pressure and Heart Rate
Systolic BP significantly decreased in the HGID group (start 122+14 vs end
117+15mmHg, p<0.05) but not in the LGID group (start 117+11 vs end 116+16mmHg, p>0.05),
nor were there any significant differences between groups after controlling for baseline (p>0.05).
Diastolic BP and HR did not significantly change in either group or between groups (p>0.05).
5.5.4

Dietary Intake and Physical Activity

5.5.4.1 Activity Level
Activity level, as assessed by the Baecke questionnaire, did not significantly change during
the randomization phase for either the LGID (p>0.05) (Table 5.3) or HGID (p>0.05) (Table 5.4)
and was not significantly different between groups (p>0.05) (Table 5.5).
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5.5.4.2 Compliance
Self-reported data from the test food diaries indicated an average compliance for the
consumption of test foods on the LGID was 87.7%+19.7 (range 30% to 138%) and 91.6%+15.9
(range 36% to 116%) on the HGID. Diet compliance was not significantly different between
groups (p>0.05). There was a significant positive relationship between average compliance and
average GI for the HGID (r=0.47, p=0.001) and a non-significant negative relationship between

Average Glycemic Index %

average compliance and average GI for the LGID (r=-0.27, p=0.07) (Figure 5.2).
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LGID: r = -0.27, p = 0.07
HGID: r = 0.47, p = 0.001
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Figure 5.2. Test Food Compliance and Glycemic Index
Average compliance (%) of test foods from weekly test food diaries and mean GI for the high
glycemic index diet, HGID □ (N = 47) and the low glycemic index diet, LGID ◆ (N = 48).
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There was a significant negative correlation between average compliance of test foods and
end of study IMCL for the LGID (r=-0.36, p=0.02) (Figure 5.3). No correlation was found
between average compliance of test foods and end of study IMCL for the HGID (r=0.05, p=0.73)
(Figure 5.3).
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HGID: r = 0.05, p = 0.73
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Figure 5.3. Test Food Compliance and IMCL
Average compliance (%) of test foods from weekly test food diaries (duration of study) and
intramyocellular lipid content (IMCL) (end of study) for the high glycemic index diet,
HGID □ (N = 40) and the low glycemic index diet, LGID ◆ (N = 40).
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There was a significant negative correlation between average test food compliance for
participants who were 70% or greater in compliance and change in IMCL from baseline to end of
study for the LGID (r=-0.44, p<0.007). For the HGID, there was a significant positive
correlation between average test food compliance (70% or greater) and change in IMCL from
baseline to end of study (r=0.35, p<0.04) (Figure 5.4)
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Figure 5.4. Test Food Compliance of 70% or greater and Change in IMCL
Average compliance (%) of test foods from weekly test food diaries for participants who were
70% or greater in compliance (duration of the study) and the change in intramyocellular lipid
content (IMCL) from baseline to end of study for the low glycemic index diet, LGID ◆
(N = 36), and the HGID □ (N = 37).
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5.5.4.3 Dietary Intake
The 3-day average GI and macronutrient data from the self-reported food diaries at
baseline and end-of-study for the LGID and HGID are listed in Table 5.3 and Table 5.4
respectively and comparisons between groups after controlling for baseline are listed in Table
5.5.
The participant’s achieved a significant reduction in the GI on the LGID (59.6+4.0 baseline
vs 55.4+2.7 end, p=0.0000) and a significant increase in the GI on the HGID (60.0+3.4 baseline
vs end 63.9+3.5, p=0.0000). There was also a significant difference in the GI between groups
after controlling for baseline (LGID 55.5+3.1 vs HGID 63.9+3.1, p<0.0001). The average GI
analyzed from the three-3 day food diaries on the LGID was 54.6+2.6 and 64.3+3.1 on the HGID
and was significantly different between groups (p<0.0000). The GI was not correlated with any
anthropometric measurements, fasting blood lipids, or blood glucose and insulin measurements
obtained from the OGTT (p>0.05).
Energy intake (kilocalories (kcal)) significantly increased on the HGID (1980+626 vs
2212+524kcal, p<0.05) but did not change on the LGID (2061+544 vs 2070+423kcal, p>0.05).
There were no significant differences in means between groups for energy intake after
controlling for baseline (HGID 2212+400 vs LGID 2065+400kcal, p>0.05).
Total carbohydrate intake significantly increased on both the LGID (baseline 261+92 vs
end 316+75g, p<0.0001) and the HGID (baseline 259+86 vs end 304+69g, p<0.01), but was not
significant between groups after controlling for baseline (LGID 316+62 vs 303+62g, p>0.05).
When expressed as a percentage of energy, carbohydrate significantly increased on the LGID
(LGID baseline 50+9 vs end 57+8% p<0.0001) but not on the HGID (baseline 52+8 vs end
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54+8%, p>0.05), and was significantly different between groups after controlling for baseline
(LGID 57+7 vs HGID 54+7%, p<0.05).
Total dietary fibre intake significantly increased on the LGID (baseline 23+11 vs end
42+14g, p<0.0000) but not on the HGID (baseline 25+12 vs end 24+7g, p>0.05), and was
significantly different between groups after controlling for baseline (LGID 43+10 vs HGID
23+10g p<0.0001).
Total fat intake significantly decreased on the LGID (baseline 75+39 vs end 58+18g,
p<0.05) but not on the HGID (baseline 66+31 vs end 70+30g, p>0.05) and was significantly
different between groups after controlling for baseline (LGID 58+23 vs HGID 70+23g, p<0.05).
When expressed as a percentage of energy, total fat intake significantly decreased on the LGID
(baseline 30+9 vs end 24+6, p<0.001) but not on the HGID (baseline 29+6 vs end 27+7, p>0.05)
and was significantly different between groups after controlling for baseline (LGID 24+6 vs
HGID 27+6, p<0.05).
Saturated fat intake significantly decreased on the LGID (baseline 23+11 vs end 17+6g,
p<0.01) but not on the HGID (baseline 20+9 vs end 21+11g, p>0.05), and was significantly
different between groups after controlling for baseline (LGID 17+9 vs HGID 21+9g, p<0.05).
When expressed as a percentage of energy, saturated fat intake significantly decreased on the
LGID (baseline 10+4. vs end 7+3%, p<0.001) and decreased on the HGID but it was not
significant (baseline 9+2 vs end 8+3%, p>0.05).
Protein intake expressed as grams or percentage of energy and alcohol intake as a
percentage of energy did not significantly change in either group or between groups after
controlling for baseline (p>0.05).
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Table 5.3. Dietary Intake and Physical Activity at Baseline and End-of-Study for the LGID
Low GI

Low GI

Baseline

End

Variable

N = 48

N = 48

p value

GI (%)

59.6+4.0

55.4+2.7

<0.0000

Energy (kcal)

2061+544

2070+423

0.253

CHO (g)

261.3+92.0

316.1+74.7

<0.0001

CHO (% energy)

49.7+9.4

57.3+7.6

<0.0001

Fibre (g)

22.9+11.0

42.0+13.9

<0.0000

Protein (g)

93.0+22.1

92.8+23.6

0.384

Protein (% energy)

18.0+3.4

17.1+3.1

0.121

Fat (g)

75.0+39.0

58.1+18.0

<0.05

Fat (% energy)

30.3+8.8

24.0+6.3

<0.001

Saturated Fat (g)

22.7+10.8

16.8+6.0

<0.01

Saturated Fat (% energy)

10.0+4.2

7.1+2.5

< 0.001

Alcohol (% energy)

1.6+4.0

1.3+2.6

0.756

MEDFICTS score

47.2+19.0

44.5+16.3

0.551

Activity Level (Baecke)

2.4+0.5

2.4+0.8

0.700

Data are means + SD; GI, glycemic index; CHO, carbohydrate
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Table 5.4. Dietary Intake and Physical Activity at Baseline and End-of-Study for the HGID
HGID

HGID

Baseline

End

Variable

N = 47

N = 47

p value

GI (%)

60.0+3.4

63.9+3.5

<0.0000

Energy (kcal)

1980+626

2212+524

<0.05

CHO (g)

258.9+85.9

303.7+69.3

<0.01

CHO (% energy)

52.3+7.5

54.2+7.6

0.105

Fibre (g)

24.6+11.7

23.8+7.0

0.553

Protein (g)

89.5+36.1

99.3+27.7

0.076

Protein (% energy)

18.0+3.5

17.7+3.1

0.202

Fat (g)

66.4+30.5

69.9+29.6

0.494

Fat (% energy)

28.9+6.0

27.2+6.8

0.208

Saturated Fat (g)

20.3+8.5

21.0+11.3

0.575

Saturated Fat (% energy)

9.0+2.2

8.2+2.9

0.141

Alcohol (% energy)

0.9+2.0

1.6+4.3

0.169

MEDFICTS score

44.7+18.2

44.3+14.4

0.970

Activity Level (Baecke)

2.6+0.5

2.4+0.8

0.118

Data are means + SD; GI, glycemic index; CHO, carbohydrate
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Table 5.5. Dietary Intake and Physical Activity for the LGID vs the HGID after Controlling for
Baseline
LGID

HGID

Variable

N = 48

N = 47

p value

Glycemic Index (%)

55.5+3.1

63.9+3.1

<0.0001

Energy (kcal)

2064.7+400.1

2211.8+400.1

0.107

Carbohydrate (g)

316.1+62.0

303.1+62.0

0.353

Carbohydrate (% energy)

57.5+7.1

54.0+7.1

<0.05

Fibre (g)

42.6+10.2

23.3+10.2

<0.0001

Protein (g)

93.3+22.1

98.9+22.1

0.267

Protein (% energy)

17.2+2.9

17.6+2.9

0.524

Fat (g)

57.8+23.0

70.2+23.0

<0.05

Fat (% energy)

23.9+6.4

27.3+6.4

<0.05

Saturated Fat (g)

16.7+8.7

21.2+8.7

<0.05

Saturated Fat (% energy)

7.1+2.6

8.3+2.6

0.058

Alcohol (% energy)

1.0+2.9

1.8+2.9

0.262

MEDFICTS score

44.3+14.6

44.6+14.6

0.920

Activity Level (Baecke)

2.4+0.7

2.4+0.7

0.620

Data are means + SD; data are differences in means controlling for baseline
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5.5.5

Oral Glucose Tolerance Test

5.5.5.1 Insulin and Glucose
HOMA index, fasting insulin, and insulin at 30, 60, and 120 minutes during the OGTT,
did not significantly change in either group or between groups after controlling for baseline
(p>0.05) (Figure 5.4, Table 5.6). The insulinogenic index (ISI) significantly increased in the
HGID group (baseline 15.2+9.7 vs end 19.2+15.0, p<0.01) and there was a non-significant trend
towards an increase in ISI in the LGID group (baseline 16.2+10.9 vs end 19.5+15.9, p=0.07)
(Table 5.6). The incremental area under the curve for insulin (iiAUC) significantly decreased in
the HGID (baseline 7047.0+4661.8 vs end 6718.2+4322.6, p<0.05) and a non-significant
decrease in the iiAUC in the LGID (baseline 6858.9+5500.1 vs end 6622.6+5658.2, p>0.05)
(Table 5.6). There was also a significant positive correlation between baseline and end-of-study
iiAUC for the LGID (r=0.77, p<0.0001) and the HGID (r=0.89, p<0.0001) but the slope of the
regression lines were not significantly different between groups (p>0.05) (Figure 5.5).
During the OGTT, 60 minute plasma glucose significantly decreased in the LGID
(baseline 10.7+2.2 vs end 10.2+2.1, p<0.05), but not in the HGID (baseline 10.7+2.9 vs end
10.4+3.2, p>0.05) and fasting, 30 minute and 120 minute plasma glucose did not significantly
change in either group (p>0.05) (Figure 5.4, Table 5.6). There was a significant positive
correlation between baseline and end-of-study 120 minute plasma glucose for the LGID (r=0.62,
p<0.0001) and the HGID (r=0.81, p<0.0001) and the regression slopes significantly differed
between the LGID and the HGID (p=0.04) (Figure 5.6). The incremental area under the curve
for glucose (igAUC) significantly decreased in the HGID (baseline 461.6+171.2 vs end
423.8+185.3, p<0.05) and decreased in the LGID but was not significant (baseline 440.3+153.6
vs end 399.9+138.1, p>0.05) (Figure 5.4, Table 5.6). There was a significant positive correlation
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between baseline and end-of-study igAUC for the LGID (r=0.56, p<0.001) and the HGID
(r=0.80, p<0.0001), and the slopes of the regression lines were significantly lower on the LGID
compared to the HGID (p=0.04) (Figure 5.5).

High GI

Low GI

Glucose (mmol/L)

*
12

8

4

Baseline
End

0

Insulin (pmol/L)

200

100

0

0

60
Time (min)

120 0

60
Time (min)

120

Figure 5.4. Mean Glucose and Insulin Values at Baseline (• ) and End-of-Study (ο) for the
HGID and LGID, obtained during the OGTT. Plasma glucose at 60 minutes significantly
decreased in the LGID group (*p<0.05).
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Table 5.6. Fasting Plasma Glucose and Insulin at Baseline and End of Study
LGID

LGID

HGID

HGID

Baseline

End

p

Baseline

End

p

Variable

N = 48

N = 48

value

N = 47

N = 47

value

HOMA

3.6+2.4

3.7+2.3

0.72

3.6+4.8

3.7+2.5

0.94

ISI

16.2+10.9

19.5+15.9

0.07

15.2+9.7

19.2+15.0

0.00**

Fasting

5.6+0.7

5.6+0.6

0.52

5.5+0.8

5.6+0.7

0.17

30 min

9.6+1.8

9.8+1.6

0.93

9.5+2.2

9.4+1.9

0.29

60 min

10.7+2.2

10.2+2.1

0.03*

10.7+2.9

10.4+3.2

0.07

120 min

8.3+2.7

8.2+0.172

0.17

8.8+2.8

8.6+2.6

0.89

igAUC

440.3+153.6

399.9+138.1

0.10

461.6+171.2

423.8+185.3

0.05*

Fasting

13.9+8.9

14.3+8.6

0.66

13.7+12.5

14.6+9.5

0.58

30 min

75.1+47.4

82.5+51.6

0.33

71.2+53.3

78.1+58.7

0.25

60 min

109.2+56.0

106.7+57.0

0.83

92.8+59.7

81.3+48.1

0.78

120 min

108.9+58.1

102.6+66.0

0.84

103.9+92.6

84.5+59.3

0.31

iiAUC

6858.9

6622.6

0.50

7047.0

6718.2

0.02*

+5500.1

+5658.2

+4661.8

+4322.6

Glucose

Insulin

Data are means + SD; ISI, insulinogenic index; plasma glucose is measured in mmol/L; plasma
insulin is measured in pmol/L; igAUC, incremental area under the curve for plasma glucose
obtained during the OGTT; iiAUC, incremental area under the curve for plasma insulin obtained
during the OGTT; *p < 0.05, **p < 0.01
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Figure 5.5. Relationship between Baseline and End-of-Study Incremental Area under the Plasma
Glucose Curve (Glucose AUC) and Incremental Area under the Plasma Insulin Curve (Insulin
AUC) Obtained During the OGTT for the HGID (•) and LGID (ο). For glucose AUC,
correlations were statistically significant for both HGID (r=0.795, p<0.0001) and LGID
(r=0.562, p<0.001), and the difference in the regression slopes was significantly different
(p=0.04). For insulin AUC, correlations were statistically significant for both HGID (r=0.886,
p<0.0001) and LGID (r=0.769, p<0.0001), but there was no significant difference in the
regression slopes between the two groups (p>0.05).
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Figure 5.6. Relationship between Baseline and End-of-Study 120 minute Plasma Glucose
obtained during the OGTT for the HGID (•) and LGID (ο). Correlations were statistically
significant for both HGID (r=0.81, p<0.0001) and LGID (r=0.62, p<0.0001) and the differences
in slopes between the two groups was significant (p=0.04).
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5.5.5.2 Blood Lipids
There were no significant changes in fasting total serum cholesterol, LDL cholesterol,
HDL cholesterol, triglycerides or free fatty acids in either group, nor were there any significant
differences between groups after controlling for baseline (p > 0.05). The participants’ fasting
serum lipids at baseline and end of study are shown in Table 5.7.

Table 5.7. Fasting Serum Lipids at Baseline and End of Study
LGID

LGID

HGID

HGID

Baseline

End

p

Baseline

End

p

Variable

N = 48

N = 48

value

N = 47

N = 47

Value

Total C (mmol/L)

5.3+1.1

5.2+1.1

0.31

4.9+0.9

4.9+0.8

0.78

LDL (mmol/L)

3.1+0.9

3.0+0.9

0.16

2.8+0.8

2.8+0.7

0.58

HDL (mmol/L)

1.3+0.4

1.3+0.4

0.28

1.2+0.3

1.2+0.4

0.24

TG (mmol/L)

1.9+0.8

2.1+0.9

0.15

2.2+1.7

2.1+1.4

0.63

FFA (µmol/L)

594.2

600.9

0.73

635.4

566.3

0.07

+231.9

+228.2

+235.6

+208.0

Data are means + SD; C, cholesterol; TG, triglycerides: FFA, free fatty acids

5.5.6. Intramyocellular Lipids (IMCL), Subcutaneous Adipose Tissue (SAT), Visceral
Adipose Tissue (VAT)
There were no significant changes in IMCL, in either group during the dietary intervention
or between groups after controlling for baseline. There were no significant changes in either
group during the dietary intervention or between groups for SAT or VAT after controlling for
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baseline (p>0.05). The participants IMCL, VAT and SAT at baseline and end of study are
shown in Table 5.8.
Post dietary intervention, there were significant positive correlations with IMCL and BMI
(r=0.21, p<0.5), WC (r=0.33, p<0.01), WHR (r=0.37, p<0.001), VAT (r=0.34, p<0.01), HOMA
(r=0.23, p<0.05), fasting plasma insulin (r=0.26, p < 0.05), diastolic BP (r=0.29, p<0.01),
percentage of energy from saturated fat (r=0.23, p<0.05) and total fat intake (g) (r=29, p<0.05).
IMCL was not significantly correlated with GI (p>0.05).

Table 5.8. IMCL, VAT and SAT at Baseline and End of Study
LGID

LGID

HGID

HGID

Baseline

End

p

Baseline

End

p

Variable

N = 40

N = 40

value

N = 40

N = 40

value

IMCL:Cr

6.1+1.3

6.1+1.2

0.52

5.7+1.2

5.9+1.6

0.42

LGID

LGID

HGID

HGID

Baseline

End

p

Baseline

End

p

Variable

N = 48

N = 48

value

N = 47

N = 47

value

VAT

211.4+73.6

226.7+86.5

0.16

195.8+63.4

201.9+75.0

0.53

SAT

365.0+125.4

373.7+125.4

0.24

405.0+148.9

388.0+148.5

0.82

Data are means + SD; muscle triglycerides are expressed as intramyocellular lipid:total creatine
ratio (IMCL/Cr) (Arbitrary Units (AU)); VAT, visceral adipose tissue (AU); SAT, subcutaneous
adipose tissue (AU).
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5.6 Discussion and Conclusions
Individuals who are obese or have abdominal obesity tend to consume excess kcal and/or
fat, which results in an accumulation of fat in organs other than adipose tissue such as muscle
causing insulin resistance in these tissues (13, 14). Research has demonstrated that dietary fat
intake is associated with IMCL content (30, 31). This study found significant positive
correlations with IMCL and total dietary fat (g) and percentage of energy from saturated fat
(p<0.05) which supports the role of IMCL being a storage site for fat when dietary fat is
increased. Further, IMCL was positively correlated with the HOMA index at end of study
(r=0.23, p<0.05) supporting the research demonstrating the positive relationship between IMCL
and insulin resistance (15, 16).
Insulin resistance is higher in individuals with abdominal obesity (10,11) and puts them at
risk for developing type 2 diabetes, coronary heart disease, and metabolic syndrome (2, 3, 4, 5, 6,
7, 8,12). de Koning et al (32) studied various ethnic groups in 5 different countries who were at
risk of developing type 2 diabetes and found that an increase in BMI, WC and WHR all had
positive associations with type 2 diabetes. This study showed significant positive correlations
with IMCL and BMI (p<0.05), WC (p<0.01) and WHR (p<0.001) which supports the beneficial
effects of reducing IMCL in a population at risk for developing type 2 diabetes. This study also
found positive linear correlations with GI and BMI, WC, and WHR but they were not significant
post intervention (r=0.21, p=0.06; r=0.20, p=0.07; r=0.17, p=0.13 respectively). Liese et al (33)
found similar results and suggested that the lack of relationship between GI and adiposity in their
study may have been due to an average GI of 58.0+4.0 which is similar to high GI diets in other
studies (18). In contrast to these findings, Ma et al (34) found the GI was independently and
positively associated with BMI (p=0.01), and the mean GI was also 58.0+3.9. This study had a
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slightly lower average GI of 55.4+2.7 for the LGID post-intervention. The difference in results
may be due to the difference in ranges for BMI. Ma et al (34) collected data on individuals with a
BMI varying from 18.5 to >30, whereas this study only looked at abdominally obese individuals
(BMI 34.4+5.7).
This study investigated whether a 24 week low glycemic index diet can improve insulin
sensitivity by reducing IMCL content of skeletal muscle in weight stable abdominally obese
individuals. Despite a significant reduction in GI on the LGID (59.6+4.0 baseline vs end
55.4+2.7, p=0.0000) and a significant increase in the GI on the HGID (60.0+3 baseline vs end
63.9+3.5, p=0.0000), as well as a significant difference in the GI between groups after
controlling for baseline (LGID 55.5+3.1 vs HGID 63.9+3.1, p<0.0001), neither IMCL or insulin
resistance (HOMA) significantly changed on the LGID (p>0.05). There was a trend towards an
improvement in insulin secretion (insulinogenic index (ISI)) on the LGID but it was not
significant (p=0.07), however the HGID did significantly improve ISI (p<0.01). The significant
improvement in ISI in the HGID is not consistent with other research, especially since the HGID
group significantly increased BMI (p<0.05) due to a significant increase in total daily energy
intake (p<0.05). Research generally favours weight loss for improvements in insulin sensitivity
without reductions in IMCL. Larson-Meyer et al (35) examined the effect of weight loss and
exercise on IMCL and insulin sensitivity and found no reductions in IMCL but improvements in
insulin sensitivity in all intervention groups (25% kcal restriction, 12.5% kcal reduction and
12.5% increase in energy expenditure, kcal restriction until a 15% reduction in body weight
followed by weight maintenance) (p<0.05), however there was no significant improvements in
insulin sensitivity between groups.
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This study does not support the hypothesis that a weight maintaining LGID will improve
insulin sensitivity by reducing IMCL content of skeletal muscle in abdominally obese
individuals. The lack of relationship may be due to the minimal change of -6.9% in GI for the
LGID. Goff et al (20) also investigated the effects of a 4 week low GI diet on IMCL and also
found no changes in storage levels of IMCL which may have been attributed to only a 15%
change in GI. Goff et al (20) did find significant changes in insulin sensitivity following the low
GI diet suggesting that insulin sensitivity may be independent of IMCL storage.
Another possible explanation for the lack of relationship between GI and IMCL could be
due to diet compliance. A limitation of the present study was the inability to control compliance
of the self-selected low or high GI test foods that the participants were required to consume each
day. Participants were free-living and choose a specific number of test foods from a list based on
their estimated energy intake and recorded the food choices on a daily food diary. The
compliance was calculated from self-reported data on the food diaries at the monthly visit. A
criticism of the low GI diet is that it is too complicated and difficult to follow (42). This study
does not support this criticism since average diet compliance for the LGID was high
(87.7+19.7%), however it is evident that not all individuals are willing to make changes to their
diet since compliance for the LGID ranged from 30% to 138%. Similar results were found for
the HGID; average diet compliance was 91.6+15.9% and ranged from 36% to 116%. These
results demonstrate that it is difficult to follow any type of diet if individuals are not motivated to
make changes to their usual dietary habits. Further, results showed a relationship between
average GI and average diet compliance for both the LGID and HGID. As diet compliance
increased on the LGID, the GI decreased (p=0.07), and as diet compliance increased on the
HGID, the GI increased (p<0.05). For example, the lowest compliance of 30% on the LGID
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resulted in an average GI of 59 which is similar to the average GI of 59.5 for the participant who
was 36% compliant on the HGID. For the participants who were highest in compliance (LGID
138% and HGID 116%), there was a greater difference in the GI of the diets (LGID 50.7 vs
HGID 63.3), which further demonstrates the importance of diet compliance. Results also
showed a significant (p<0.05) negative correlation between average diet compliance and IMCL
for the LGID, indicating that as diet compliance increases, IMCL decreases on the LGID. In
considering future long term studies, the compliance issue may need to be addressed to find
significant differences in outcome variables.
It is well documented that individuals with abdominal obesity are at risk for developing
diabetes (36), cardiovascular disease (36) and metabolic syndrome (7, 8). One characteristic of
metabolic syndrome is fasting blood glucose of >6.1 mmol/L (1). Fasting blood glucose values
of 6.1 to 6.9 is termed impaired fasting glucose (IFG) (37), or commonly called “prediabetes”,
which is also a risk factor for developing diabetes and cardiovascular disease (38). Maintaining
and/or improving glycemic control is therefore an important goal for abdominally obese
individuals, a population at risk for developing type 2 diabetes and cardiovascular disease.
Although only 14.6% of the participants entering this study had a fasting blood glucose of >6.1
mmol/L, the LGID did show significant improvements in 60 minute blood glucose obtained from
the OGTT (p<0.05) indicating that the responses to the different diets varied significantly post
intervention. Further, the slope of the regression line was significantly lower for the LGID
compared to the HGID for 120 minute glucose obtained from the OGTT (p = 0.04). This
suggests that the LGID lowers 120 minute glucose in abdominally obese individuals if their
blood glucose is high to begin with.
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Interventional studies examining the effects of dietary GI on serum lipids tend to favour
the role of the GI in improving triglycerides, LDL cholesterol and HDL cholesterol (39, 40, 41).
In the present study, despite the significant reductions in GI (p<0.0001), percentage of kcal from
total fat (p<0.001) and saturated fat in the diet (p<0.001), there were no significant changes in
fasting blood lipids post-intervention. A possible explanation may be that the participants
reduced their fasting blood lipids to normal levels after completion of the 4-to-6 week low fat
dietary advice run-in phase prior to entering this primary study. Participants in the run-in phase
did significantly decrease fasting serum total cholesterol, LDL cholesterol and triglycerides
(p<0.0001) due to a significant reduction in total dietary fat (p < 0.0001) and saturated fat
(p<0.01).
In conclusion, results from this study did not show improvements in insulin sensitivity or
reduce IMCL content of skeletal muscle in weight-stable abdominally obese individuals after
following a 24 week low glycemic index diet. Further research on the GI and IMCL is needed to
determine whether these findings would occur in different populations such as those with
impaired glucose tolerance or type 2 diabetes since these individuals would likely have insulin
resistance.
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CHAPTER 6
GLYCEMIC INDEX PREDICTS INDIVIDUAL GLUCOSE RESPONSES AFTER SELFSELECTED BREAKFASTS IN FREE-LIVING, ABDOMINALLY OBESE ADULTS
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Glycemic Index Predicts Individual Glucose Responses after Self-Selected Breakfasts in
Free-Living, Abdominally Obese Adults
6.1 Introductory Statement
Research has shown that the glycemic index (GI) predicts the postprandial glucose
responses elicited by mixed meals in various populations. The degree to which an individual’s
glycemic response to a meal is determined by the GI and other components of the meal remains
unclear, especially when meals are not consumed in a controlled setting. This study was
conducted to determine whether GI is a significant determinant of individual glycemic responses
elicited by self-selected breakfast meals in abdominally obese adults.
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6.2 Abstract
Background: Research has shown that the glycemic index (GI) predicts the postprandial glucose
responses elicited by mixed meals in various populations. The degree to which an individual’s
glycemic response to a meal is determined by the GI and other components of the meal remains
unclear, especially when meals are not consumed in a controlled setting.
Objective: The purpose of this study was to test whether the GI of self-selected breakfast meals
was a determinant of the individual glycemic responses in free-living adults with abdominal
obesity.
Design: Free-living non-diabetic adults (n=57) aged 53.9±9.8 with a BMI of 33.9±5.3 and waistcircumference (WC) 109±11cm underwent a 75g oral glucose tolerance test (OGTT) and, on a
separate day, wore a continuous glucose monitoring system (CGMS) for 24h during which time
they recorded all foods consumed. The protein, fat, available-carbohydrate (avCHO), and GI of
the breakfast meals were calculated from the food records and the incremental areas under the
glycemic response curves (iAUC) for 2h after breakfast (iAUCbreakfast) were calculated from
CGMS data. Values for iAUCbreakfast, avCHO, fat, fibre, and BMI were normalized by logtransformation. The ability of participant characteristics and breakfast composition to predict
individual iAUCbreakfast response was determined using a step-wise multiple linear regression
analysis.
Results: A total of 56% of the variation in iAUCbreakfast was explained by GI (30%, p<0.001),
iAUC after the OGTT (11%, p<0.001), avCHO (11%, p<0.001), and waist circumference (3%,
p<0.05). The effects fat, protein, dietary fibre, age, sex, and BMI were not significant (p>0.05).
Conclusions: In free-living abdominally obese adults, GI is a significant determinant of
individual glycemic responses elicited by self-selected breakfast meals.
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6.3 Introduction
The glycemic index (GI) was developed in 1981 as a classification of the blood
glucose-raising potential of carbohydrate containing foods (1) and is defined as the incremental
area under the blood glucose response curve after consuming a 50 gram available-carbohydrate
portion of a test food expressed as a percentage of the response after consuming 50 grams of oral
anhydrous glucose by the same subject (2, 3). Research has demonstrated that low-GI diets
improve glycemic control in diabetes (4, 5) and may decrease the risk of developing type 2
diabetes (6). Despite this evidence, there is controversy about the relevance of GI for free-living
individuals because of concerns that it is difficult to choose low-GI foods, that GI values are
imprecise, and that the GI does not predict the glycemic responses of individuals consuming
normal mixed meals due to the high day-to-day variation of glycemic responses and the
confounding effects of fat and protein (7, 8, 9, 10, 11). Previous studies showed that GI predicts
the postprandial glucose responses elicited by mixed meals in groups of normal individuals (12,
13), adults with type 2 diabetes (14), and youths with type 1 diabetes (15). These studies
examined the mean glycemic responses of groups of participants under controlled conditions.
The question about whether the GI can predict individual glycemic responses to self-selected
meals remains unclear. Variation in glycemic responses arises from at least four major sources:
diurnal variation (time of day), meal-related factors, participant-related factors (betweenindividual variation), and unexplained day-to-day variation (within individuals) (16). The
purpose of this study was to determine whether GI is a significant determinant of individual
glycemic responses elicited by self-selected breakfast meals in abdominally obese adults.
Only breakfast meals were included to remove the confounding effects of diurnal variation.
Abdominally obese adults were studied because they represent a population at risk for
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developing type 2 diabetes and may benefit from dietary approaches to reducing risk for
diabetes.
6.4 Subjects and Methods
This study was carried out on an outpatient basis at the Hamilton General Hospital,
Centre for Cardiovascular Obesity Research and Management, McMaster University, Faculty of
Health Sciences. The study protocol was approved by the Hamilton Health Sciences, McMaster
University human research ethics board. All participants were given a participant information
sheet and gave informed consent to participate in the study (Appendix 8.1). The trial is publicly
registered with ClinicalTrials.gov, number NCT00147264.
6.4.1 Protocol
This thesis chapter consists of results of an analysis of data collected at the end of the runin period of a randomized 2x2 factorial design clinical trial which studied the effects of a low GI
diet and telmisartan on intramyocellular lipids (TRIM trial (Telmisartan-Induced Reduction in
Intra-Myocellular Lipids).
6.4.2 Study Sample
A total of 2433 participants from the general population responded through advertisement
in local media and underwent a telephone screening process. Of the 171 participants who were
invited for an initial screening visit to assess eligibility, 121 participants met inclusion criteria
(refer to chapter 6 of this thesis) and were recruited for the main study. Participants were males
and non-pregnant, non-lactating females aged 30-70yrs with abdominal obesity and a fasting
plasma glucose <7.0 mmol/L. Abdominal obesity was defined as a waist circumference of >102
cm for males and >88 cm for females (17). Ninety-three of the 121 participants agreed to CGMS
monitoring and of these, 57 met inclusion criteria for this study which included: food intake
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including a breakfast meal, recorded for at least one day of the CGMS monitoring; valid and
complete CGMS data on the day food intake was recorded; the time between breakfast and the
next food intake being at least two hours; and a complete and valid OGTT. Reasons for
exclusion were: 11 participants did not meet CGMS criteria, 9 did not record a food diary, 7 had
an incomplete OGTT, one person did not eat breakfast, and 8 dropped out after the CGMS was
inserted.
6.4.3 Ad-Libitum Low Fat Diet
After recruitment, the study participants underwent a 6 week dietary advice run in period
during which time they followed a standardized low fat diet as outlined by the American Heart
Association (19) consisting of 55% energy from carbohydrate, 30% from fat, less than 7% from
saturated fat and 15% from protein. Daily energy requirements were estimated according to the
Lipid Research Clinic Requirement formula (18) with an additional 300 kcal per day added on
for exercise and daily energy expenditure (Appendix 8.2). Diets were prescribed on an adlibitum basis. The aim of the diet was to be weight maintaining and to eliminate potential effects
of variations in fat intake on IMCL content. Participants met with a nutrition counselor three
times during the run in period and were given an information sheet (Appendix 8.3) to provide
dietary advice on following a low fat diet. The participants completed three MEDFICTS dietary
assessment questionnaires to assess dietary fat (17) and the Baecke habitual physical activity
questionnaire was administered at the start-and-end of the study to determine activity levels
(Appendix 8.6) (20). Participants were instructed to maintain their habitual level of physical
activity throughout the study.
At the end of the run in period, participants completed a 3-day food diary (Appendix 8.5)
starting on the second day of the CGMS monitoring. The composition of the breakfast meal
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during one of the two days that included the CGMS monitoring was used for the purposes of this
study. A valid breakfast meal was defined as: first food intake before noon of greater than 99
kcal, recorded for at least one day of the CGMS monitoring; and, the time between breakfast and
the next food intake being at least two hours (because GI is a measure of glycemic response over
two hours). If valid data existed for more than one breakfast meal, one meal per participant was
chosen at random for analysis.
Macronutrients and GI of test foods were calculated using the Food Processor SQL
Nutrition Analysis & Fitness software package version 9.5 (ESHA Research, Salem, OR, USA)
for GI and macronutrient composition as a measure of the participant’s habitual dietary intake.
The GI values for the foods were expressed with the GI of glucose = 100 and derived from
published tables by using locally tested values where possible, as previously described by
Wolever et al (13). The GI of the breakfast meal was calculated as the sum of, for all foods in
the breakfast meal, the amount of available carbohydrate (avCHO) in the portion of food
consumed (gf) multiplied by (the GI of that food (GIf) divided by the amount of avCHO in the
breakfast meal) (gb)), (gf x GIf/gb) (13).
6.4.4 Continuous Glucose Monitoring System
One to two weeks before the end of the run in period, participants underwent 24 hour
continuous glucose monitoring for three days using a Medtronic MiniMed CGMS monitor
(Medtronic-MiniMed, Northridge, CA, USA). The CGMS monitor included a disposable
glucose indwelling sensor with an external electrical connector that was inserted using a sensor
inserter applicator into the subcutaneous tissue of the abdominal wall to measure interstitial fluid,
a glucose monitor that recorded a mean of 30 signals from the sensor every 5 minutes for a total
of 288 readings for a 24 hour period, and a communication device (Com-Station) enabling data
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stored in the monitor to be downloaded into a computer (21). The participants were instructed
on the use of the CGMS and a blood glucose meter (AscensiaTM ContourTM, Bayer HealthCare
LLC, Mishawaka, IN, USA) to enter four blood glucose values per day to calibrate the CGMS
monitor. A valid and complete CGMS data on the day food intake was recorded was defined as
288 sensor readings, at least three meter readings entered by the participant in the blood glucose
meter, and no sensor errors detected. The start of breakfast for the CGMS data analysis was
determined by examining the CGMS glucose values near the time the participant indicated that
breakfast was consumed to find when blood glucose started to increase, defined as when the
second of two successive glucose readings differed by > 0.2 mmol/L from the first. Fasting
blood glucose was taken to be the mean of the four values (0, 5, 10, and 15 minutes) before the
first increase in blood glucose. The glycemic response was measured for 120 minutes (24
readings) after the start of breakfast (iAUCbreakfast).
6.4.5 Oral Glucose Tolerance Test
At the end of the run in period, participants underwent a 75 gram oral glucose tolerance
test (OGTT) after a 12 hour fast. An indwelling catheter was inserted in the forearm and venous
blood samples were obtained for plasma glucose at 15, 10, and 5 minutes prior to ingestion of the
glucose load (75 gram solution of dextrose) and then again at 30, 60, and 120 minutes after
starting the glucose drink. Fasting plasma glucose was taken to be the mean of the three readings
following the fast. Glucose was measured by a glucose oxidase method and serum insulin was
measured with an immunometric assay (Diagnostic Products Corporation, Los Angeles, CA). A
complete and valid OGTT was defined as obtaining blood samples at 0, 30, 60 and 120 minutes
(iAUCOGTT).
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6.4.6 Anthropometric Measurements
Height (cm) was measured at the initial screening visit to the nearest 0.1 cm using a wall
mounted stadiometer and body weight was measured at every visit to the nearest 0.1 kg on a
digital weigh scale. Body mass index (BMI) was calculated as body weight (kg) divided by
height (m2). Waist circumference (WC) was measured to the nearest 0.1 cm at the beginning at
end of the run in period, using the World Health Organization (WHO) method (mid-point
between the palpated inferior border of the last rib and upper border of the iliac crest in a
horizontal plane at the end of normal expiration) (22).
6.4.7 Statistical Analysis
All data are presented as means +SD unless otherwise indicated. Calculations for
iAUCbreakfast and iAUCOGTT, ignoring area beneath the baseline were determined as previously
described (23). The values for iAUCbreakfast were divided into tertiles, and the mean values for
iAUCOGTT, protein, fat, avCHO, dietary fibre, and GI for participants within the iAUCbreakfast
tertiles were compared by ANOVA. The independent contributions of iAUCOGTT, BMI, WC,
protein, fat, avCHO, dietary fibre, and GI to predicting iAUCbreakfast was determined by step-wise
multiple linear regression (Lotus 123, Lotus Development) using the step-up procedure (24),
with age and sex included in all models (because some anthropometric and breakfast intake
variables were significantly related to age and sex). The variable with the most significant
correlation with iAUCbreakfast was added to the model first, all remaining variables were then
tested, and the most significant added sequentially to the model until no further significant
reduction in the residual variation was obtained. Prior to regression analysis, non-normally
distributed variables based on D’Agostino’s test (iAUCbreakfast, avCHO, BMI, fat, and fibre) were
normalized by log-transformation. Statistical significance was taken to be 2-tailed p<0.05, with

132

comparisons between individual means adjusted for multiple comparisons using Tukey’s
method.
6.5 Results
6.5.1 Subject Characteristics
Entering the study, participants mean age was 53.9+9.8 years and 68% were female. All
participants had abdominal obesity (109+11cm) (17) with a BMI of 33.9+5.3 (22). Age, BMI,
and WC were significantly correlated with total dietary fat (g) (r=0.28, p<0.05; r=0.27, p<0.05;
r=0.27, p<0.05, respectively). WC was also correlated with BMI (r=0.68, p<0.001) and avCHO
(g) (r=0.37, p<0.01). Clinical characteristics of the study population are listed in Table 6.1.

Table 6.1. Clinical Characteristics of the Study Population Divided by Tertile of iAUCbreakfast.
All Participants

Tertile 1

Tertile 2

Tertile 3

Variable

N = 57

N = 19

N = 19

N = 19

Sex (M:F), N

18:39

6:13

6:13

6:13

Age (years)

53.9±9.8 (37-69)

54.8±8.9

52.4±11.8

54.3±9.8

BMI (kg/m²)

33.9±5.3 (27-39)

32.3±2.9

36.1±5.8

33.1±6.1

Waist circumference (cm)

109±11 (93-122)

108±8

113±13

106±11

Data are means + SD; brackets ( ) are range; M, Males; F, Females

6.5.2 OGTT, CGMS and Dietary Intake
The OGTT showed 36 participants with normal fasting glucose (<5.6 mmol/L) of whom 19
had normal plasma glucose two hours after 75 grams oral glucose (2hPCG) (<7.8 mmol/L), 16
had impaired glucose tolerance (IGT) (2hPCG >7.8 to <11.1 mmol/L), and one had diabetes
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(2hPCG >11.1 mmol/L); 20 participants had impaired fasting glucose (IFG) (fasting glucose of
>5.6 to <7.0 mmol/L) of whom 8 had normal 2hPCG, 6 had IGT, and 6 had a diabetic 2hPCG;
one individual had diabetic values for both fasting and 2hPCG. Participants with diabetes based
on the OGTT had higher iAUCOGTT (405+41 vs 232+74 mmol/L x min/L) and iAUCbreakfast
(204+92 vs 114+83 mmol x min/L) compared to the participants without diabetes. The GI and
avCHO intake at breakfast did not significantly differ between the participants with and without
diabetes (p>0.05) (GI, 64+10 vs 60+9g; avCHO, 60+21 vs 68+40g, respectively).
Mean fasting glucose before breakfast was similar across the tertiles of iAUCbreakfast (Table
6.2). Participants in the highest tertile of iAUCbreakfast had significantly higher glycemic
responses after breakfast (Figure 6.1), higher fasting glucose before the OGTT, and a higher
iAUCOGTT than those in the lowest tertile of iAUCbreakfast (p<0.05) (Table 6.2). Despite large
ranges of intakes of avCHO, fat, protein, and fibre, only GI significantly differed between the
highest and lowest tertiles of iAUCbreakfast (p<0.05) (Table 6.2).
iAUCbreakfast was significantly correlated with GI (r=0.55, p<0.001), avCHO (r=0.35,
p<0.01), OGTT 2hPCG (r=0.40, p<0.01), and iAUCOGTT (r=0.38, p<0.01). Neither iAUCOGTT
nor iAUCbreakfast were significantly related to age, sex, BMI, WC, protein, fat, or fibre, and no
significant relationship was found between GI and avCHO (p>0.05).
When considered individually, the variable that explained most of the variation in
iAUCbreakfast was GI (r2=0.30) followed by 2hPCG (r2=0.16), iAUCOGTT (r2=0.14), and avCHO
(r2=0.12). Multiple regression analysis showed that, whereas age and sex were not significantly
related to iAUCbreakfast, GI, avCHO and iAUCOGTT had significant independent effects that
together explained 56% of the variation in iAUCbreakfast (GI, standardized β = 0.47+0.09,
p<0.001; avCHO, standardized β = 0.43+0.11, p<0.001; iAUCOGTT, standardized β = 0.36+0.09,
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p<0.001). WC, BMI, protein, fat, and fibre had no significant effects when added to the model
(p>0.05).
When the 8 participants with diabetes by OGTT or fasting glucose were excluded, the
results of the multiple regression analysis were similar to those for the total population, with age
(standardized β = -0.15+0.11, p=0.17), sex (standardized β = 0.16+0.14, p=0.24), GI
(standardized β = 0.51+0.11, p<0.001), avCHO (standardized β = 0.45+0.13, p<0.001), and

Glucose Increment (mmol/L)

iAUCOGTT (standardized β = 0.28+0.12, p<0.05) explaining 51% of the variation in iAUCbreakfast.

4
3
2
1
0
0

60
30
Time (min)

90

120

Figure 6.1. iAUCbreakfast for 57 free-living, abdominally obese adults by tertile of iAUCbreakfast.
Values are means±SEM, n = 19 per tertile group. Tertile 1 (), Tertile 2 (), Tertile 3 ().
iAUCbreakfast, incremental area under the glycemic response curve for 2 hours after breakfast.
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Table 6.2. CGMS, OGTT and Breakfast Meal Composition of Abdominally Obese Adults
Divided by Tertile of iAUCbreakfast.
All Participants

Tertile 1

Tertile 2

Tertile 3

Variable

N = 57

N = 19

N = 19

N = 19

iAUCbreakfast (mmol×min/L)

127+89

52.9+16.5a 104.6+15.6b

222.5+91.6c

(16-456)

(16-81)

(84-132)

(133-456)

256+93 (65-478)

214+85a

264+77ab

292+102b

Breakfast fasting glucose (mmol/L) 6.0+1.0 (3.2-8.9)

5.9+1.0

5.8+1.1

6.2+1.0

OGTT fasting glucose (mmol/L)

5.5+0.6 (4.4-7.6)

5.3+0.5a

5.5+0.8ab

5.7+0.6b

OGTT FG status (N:IFG:D)

36:20:1

15:4:0

12:6:1

9:10:0

OGTT 2hPCG status (N:IFG:D)

27:22:8

13:6:0

8:9:2

6:7:6

400+187

350+112

403+156

447+259

iAUCOGTT (mmol×min/L)

Composition of Breakfast Meal
Energy (kcal)

(124-1136)
Protein (g)

17+8 (3-43)

16+7

17+8

16+10

Fat (g)

7+5 (1-28)

8+5

7+7

8+4

Available carbohydrate (g)

67+38 (16-222)

55+24

67+28

79+53

Glycemic Index (%)

60+9 (37-85)

54+8a

62+8b

65+8b

Data are means + SD; brackets ( ) are range; means in a row with superscripts without a common
letterab differ, p<0.05. iAUCbreakfast, incremental area under the glycemic response curve for 2
hours after breakfast; iAUCOGTT, incremental area under the glycemic response curve for 2 hours
after 75 grams oral glucose; OGTT, oral glucose tolerance test; N, normal; IGT, impaired
glucose tolerance; D, diabetic; IFG, impaired fasting glucose; FG, fasting glucose; 2hPCG,
plasma glucose 2 hours after 75 grams oral glucose.
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6.6 Discussion and Conclusions
The results showed that in free-living participants with nondiabetic fasting glucose on
recruitment, a high WC, and a wide range of nutrient intakes, the GI of self-selected breakfast
meals varied over a considerable range and was a highly significant determinant of individual
glycemic responses. The 2.3-fold variation in meal GI (37-85) was a more important
determinant of iAUCbreakfast than the 13.8-fold variation in recorded avCHO intake (16-222 g).
The variation in recorded protein (3-43 g), fat (1-28 g), and fibre (0-56 g) intakes had a
negligible effect.
The present results are consistent with those of previous studies (13, 25) showing that GI
was a significant determinant of the glycemic response elicited by mixed breakfast meals
containing variable amounts of energy, avCHO, protein, fat, and fibre. In the present study
however, avCHO and GI together explained approximately 40% of the variation in iAUC
compared to approximately 90% in previous studies. There are two main reasons for this; one is
because each value of iAUC used in the regression analysis was the response of a single
individual on one occasion as opposed to the mean value for 8 to 12 individuals in previous
studies. The second reason is that in earlier studies, between-individual variation was reduced to
zero by having every participant test all of the test meals. In this study, every participant ate a
different test meal therefore the variation in iAUCbreakfast includes between-individual variation.
Further, this study used iAUCOGTT to control for between-individual variation, but iAUCOGTT is
an imprecise estimate of each person’s true response because of within-individual variation.
Upon enrollment, all participants met the eligibility criterion of a nondiabetic fasting
glucose of <7.0 mmol/L, however, during the OGTT, 8 participants had 2hPCG values in the
diabetic range of >11.1 mmol/L and one of these participants had a fasting glucose in the
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diabetic range of 7.6 mmol/L. The differences in classification based on 2hPCG compared to
fasting glucose were not unexpected because raised 2hPCG tends to occur earlier in the natural
history of type 2 diabetes than raised fasting glucose (26). Further, studies have shown that
when individuals not known to have diabetes are screened with an OGTT, 30-40% of those with
a 2hPCG in the diabetic range have nondiabetic fasting glucose (27, 28, 29). Day-to-day
variations in fasting glucose, occurring presumably due to variations in recent diet, activity,
sleep, stress, and illness, may account for differences in classification of diabetes on repeated
testing. In this study, participants who had diabetic 2hPCG were not excluded from the primary
analysis because they met inclusion criteria of a normal fasting glucose on screening. Although
the results with respect to the ability of GI to predict glycemic responses were not changed by
excluding participants with diabetic 2hPCG, the effect of iAUCOGTT was reduced because of the
reduced range of iAUCOGTT values after excluding those with diabetic 2hPCG values.
The results of this study showed that variation in the protein and fat content of self-selected
breakfast meals had a negligible effect on the glycemic responses they elicited. It is generally
considered that protein and fat reduce glycemic responses by delaying gastric emptying and
increasing insulin secretion (8, 30). The interquartile ranges (25th to 75th percentiles) for our
participants’ protein and fat intakes were 10-20g and 3-10g respectively, and the 10th and 90th
percentiles were 8-27g and 2-13g, which was within the range used in previous studies
examining whether adding 10-20g protein or 5-15g fat to avCHO reduces glycemic responses
(31, 32, 33, 34, 35). The results of these previous studies however are inconsistent; the effect of
10-20 g protein varies from 0 (31, 32) to modest (15% to 40%) (33, 34), to large (40% to 50%)
(35), and the effect of 5-15 g fat varied across a similar range (33, 34, 36, 37, 38, 39). The
results of this study do not challenge the concept that adding fat and protein to avCHO reduces
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glycemic responses but rather challenge the ability to extrapolate the results of this experimental
design to normal mixed meals. The experimental model of adding protein or fat to a fixed
amount of avCHO does not reflect normal eating patterns in which meals vary in the amounts of
all the nutrients they contain. To maintain energy balance, meals high in protein or fat would be
low in avCHO which would have more influence on the glycemic response. For example,
adding 15g fat to 50g avCHO from bread would reduce the glycemic response by approximately
20% (38), however, to make a meal isocaloric, the amount of avCHO would have to be reduced
to 16g, which would reduce the glycemic response by approximately 55% (40).
A perceived barrier to the clinical use of GI is a concern that it limits food choice (41),
however many commonly eaten foods have a low GI. In this study, 28% of self-selected
breakfast meals had a low GI (i.e.<55), thus the barrier may not be that the GI limits food choice
because they are uncommon but rather because it is difficult to know which specific foods have a
low GI. This difficulty arises because most foods are not labeled with their GI value, and the GI
values of foods reported in the International GI Tables (42) vary considerably. For example,
there are 100 GI values for various types of rice (42), which 34% are low GI (<56) and 33% are
high GI (>69). The present results do not address this issue directly, although they show it is
possible to select GI values for the foods recorded on a food record that predict the glycemic
response elicited by a mixed meal. It has been suggested that the variation in GI values for
similar foods is due to imprecise method of measuring GI (10), however when performed
correctly, the GI method is precise enough to distinguish between low GI and high GI foods with
95% certainty (43). This suggests that the variation of GI values for similar foods arises either
from use of incorrect methods or from real differences among foods due to differences in starch
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structure (44, 45, 46) related to genetic variety (47, 48), food processing, cooking, storage, and
serving methods (49, 50, 51).
A limitation of this study was that only the glycemic response elicited by breakfast was
considered, therefore the present results cannot necessarily be extrapolated to other meals of the
day. The glycemic response after lunch and dinner depends on many factors other than the
composition of the meal. These include the composition of the previous meal, the time interval
between meals, and the time of day (52, 53, 54, 55, 56, 57, 58). Another limitation of this study
is that only 57 of the 121 participants (47%) from the primary study were included. This number
is small in relation to the number of variables available for inclusion into the multiple regression
model, thus the results need to be interpreted with caution. In addition, the participants in this
study were all abdominally obese. The relative importance of the variables studied here in
determining glycemic responses may vary in different populations.
In conclusion, GI was a significant determinant of individual glycemic responses elicited
by self-selected breakfast meals in free-living, abdominally obese adults.
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7.1 General Discussion
Obesity has been on the rise in recent years and is now considered to be a worldwide
epidemic (1). Abdominal obesity, characterized by the accumulation of visceral fat, is now
recognized as an independent risk factor for cardiovascular disease and type 2 diabetes (2).
Abdominally obese individuals also have elevated stores of fat in skeletal muscle, specifically
intramyocellular lipids (IMCL), which appear to reduce insulin-stimulated glucose uptake and
cause insulin resistance (3, 4). Strategies for reducing risk factors for diseases in these
individuals include improving insulin sensitivity (5).
Studies examining the role of dietary fat and insulin sensitivity found that IMCL increased
with high-fat feeding and insulin sensitivity decreased (6, 7). The primary purpose of the first
study (run-in phase) in this thesis was to eliminate potential effects of variations in dietary fat
intake which may influence IMCL content in the main study. Participants in the run-in phase
significantly decreased dietary total fat (p<0.0001) and saturated fat (p<0.01) from advice on
following a low-fat diet and there was a significant relationship between IMCL and dietary fat
(p<0.05) but not with insulin sensitivity. A limitation of the run-in study was that IMCL content
was measured only at the end of the study, therefore conclusions cannot be made on whether
changes occurred in IMCL and if there was any effect on insulin sensitivity after reducing fat in
the diet. On the other hand, it was also hypothesized that following dietary advice on lowering
overall fat and saturated fat intake would improve metabolic profiles in adults with abdominal
obesity. The blood cholesterol data supported this hypothesis with an approximate 9% decrease
in total and LDL cholesterol. This is an important finding given that participants followed a
short-term (4 to 6 weeks), ad-libitum, weight-maintaining, low-fat dietary advice study. Since
abdominally obese individuals are at risk for developing cardiovascular disease due to elevated
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blood lipids, following a long-term low fat diet would not only help prevent cardiovascular risk,
but may also reduce the need for blood lipid lowering medication.
The role of the glycemic index (GI) in improving insulin sensitivity as well as reductions
in IMCL improving insulin resistance has been documented. However, it is uncertain whether
increased IMCL storage is a cause or consequence of insulin resistance. In the second study of
this thesis, the data did not support the hypothesis that a low glycemic index (GI) diet would
reduce IMCL stores, thereby improving insulin sensitivity in adults with abdominal obesity. The
lack of significant findings may be due to the minimal change of -6.9% in GI for the low GI diet,
as well as other issues associated with dietary studies such as accuracy in recording of 3-day
food diaries and weekly test food record diaries, and diet compliance. This study demonstrated
that the change in diet GI did not reduce fasting glucose but did reduce 60 minute postprandial
glucose and only reduced 120 minute postprandial glucose in individuals who already had high
glucose. Therefore the lack of effect on IMCL may be that the reduction in glucose was not
large enough or that it takes longer than 24 weeks to see an effect. A limitation of this study was
that the insulinogenic index and HOMA index was used to measure insulin sensitivity, whereas
the euglycemic hyperinsulinemic clamp technique is considered the reference standard to
measure insulin mediated glucose disposal and insulin sensitivity (8). Although the HOMA
index has been validated with the euglycemic hyperinsulinemic clamp technique (9), employing
the euglycemic hyperinsulinemic clamp technique in a long-term study may provide further
information on the role of the GI and IMCL in improving insulin sensitivity.
Research has demonstrated that the GI predicts postprandial glucose responses elicited by
mixed meals (10, 11, 12, 13) in participants under controlled conditions. The question about
whether the GI can predict individual glycemic responses to self-selected meals remains unclear.
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To address this issue, a continuous glucose monitoring system (CGMS) was used to assess
glycemic responses of a breakfast meal in the third study. It was hypothesized that the GI would
be a significant determinant of individual glycemic responses when individuals self-selected
their breakfast meals. The hypothesis was supported with the GI being the greatest determinant
of individual glycemic responses to a breakfast meal containing carbohydrate, fat and protein.
The results of our study in abdominally obese adults were in agreement with Fabricatore et al
(14) who also addressed this issue in overweight and obese, type 2 diabetics. These results
support the validity of the GI and that following a low GI diet can be beneficial in controlling
blood glucose in obese individuals with or without diabetes.
7.2 Future Directions
Both this study and research by Goff et al (15) have not shown changes in IMCL with a
low GI diet due to the minimal change in GI. Future long term studies are needed with a greater
change in GI to determine whether dietary GI will reduce IMCL thereby improving insulin
sensitivity. Future studies could also include different populations, especially individuals with
insulin resistance or type 2 diabetes, since they would generally have elevated IMCL at baseline.
7.3 Conclusions
The main hypothesis of this study was a low glycemic index (GI) diet will reduce
intramyocellular lipid (IMCL) stores, thereby improving insulin sensitivity in weight-stable
adults with abdominal obesity. The data presented in this dissertation do not support this
hypothesis. However, IMCL was positively correlated with the HOMA index concluding that
there is a positive relationship between IMCL and insulin resistance. It was also concluded that
a low GI diet improves 60 minute postprandial glucose and lowers 120 minute postprandial
glucose in abdominally obese individuals with high blood glucose.
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The hypothesis for the run-in phase of the main study was following dietary advice on
lowering overall fat and saturated fat intake will improve metabolic profiles in adults with
abdominal obesity. The data presented in this dissertation support this hypothesis with respect
to total cholesterol and LDL cholesterol. It was concluded that a low fat, weight maintaining
diet significantly reduces total cholesterol and LDL cholesterol.
The third hypothesis was the glycemic index (GI) is a significant determinant of individual
glycemic responses elicited by self-selected breakfast meals in free-living, abdominally obese
adults. The data presented in this dissertation support this hypothesis. It was also concluded that
GI is a more important determinant of glycemic response than available carbohydrate intake.
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PARTICIPANT INFORMATION SHEET
Title of Study: A randomized, 2X2 factorial design study to evaluate the effects of
telmisartan versus placebo, and of a low-glycemic index diet versus a low-fat diet, in
reducing intra-myocellular lipid content in people with the metabolic syndrome (TRIM
Study).
Investigator:

Dr. A. M. Sharma
Professor of Medicine
Center for Cardiovascular Obesity Research and Management
McMaster University, Faculty of Health Sciences.

Sponsor:

Canadian Institutes of Health Research (CIHR)
Boehringer Ingelheim Canada Ltd. /Ltee.
5180 South Service Road
Burlington, Ontario
L7L 5H4

INTRODUCTION
You are being invited to participate in a research study conducted by Dr. Arya M.
Sharma, because you may have signs of the “metabolic” syndrome”, which is
characterized by the presence of abdominal obesity, high blood pressure, glucose,
and/or lipid (fat) abnormalities.
In order to decide whether you want to be a part of this research study, you should
understand what is involved and the potential risks and benefits. This form gives
detailed information about the research study, which will be discussed with you. Once
you understand the study, you will be asked to sign this form if you wish to participate.
Please take your time to make your decision. Feel free to discuss it with your friends
and family, or your family physician.
McMaster University and the investigator Dr. Arya M. Sharma are under contract with
the Sponsors of this study and are receiving compensation to cover the costs of
conducting the study. Dr. Sharma has previously conducted research funded by
Boehringer Ingelheim, and has received honoraria from this company both as a
consultant and as a speaker on topics related to the use of telmisartan (Micardis®) at
scientific meetings sponsored by Boehringer Ingelheim.
WHY IS THIS RESEARCH BEING DONE?
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One out of two adults in Canada are currently overweight and therefore at increased
risk for a number of medical conditions including diabetes, heart attacks and stroke.
This increased risk is often due to the presence of the so-called “metabolic syndrome”,
which is characterized by the presence of high blood pressure, blood glucose and/or
lipid (fat) abnormalities. This research is being done to better understand the factors
underlying the metabolic syndrome and to determine whether this syndrome can be
improved by treatment with a drug (telmisartan- Micardis®) and/or a “low-glycemic” diet.

WHAT IS THE PURPOSE OF THIS STUDY?
People with the metabolic syndrome are at increased risk for diabetes and heart
disease because they do not respond well to insulin. This condition is called insulin
resistance. Insulin is a hormone that allows sugar to enter muscle cells. People with
the metabolic syndrome may be insulin resistant because they have increased muscle
fat, i.e. they store large amounts of fat in their muscle cells. Many factors like diet,
exercise, fat tissue, liver function, and genetics can affect muscle fat.
Some drugs can also influence muscle fat. Telmisartan belongs to a class of drugs
called “angiotensin receptor blockers” commonly used for the treatment of high blood
pressure. Laboratory experiments have shown that these drugs may also affect the
growth of fat cells and may therefore influence the storage of fat in other organs like
muscle or liver. These drugs may also reduce insulin resistance. This could be of
benefit to people with the metabolic syndrome. One aim of this study is therefore to
examine the effect of telmisartan on muscle fat, insulin sensitivity and fat tissue in
people with this syndrome.
Dietary factors can also influence muscle fat and how the human body responds to
insulin. Reducing the amount of easily digested carbohydrates in the diet (a “lowglycemic” diet) can improve how the body responds to insulin and may have positive
effects on blood sugar and fat levels. The mechanism of this effect is not known.
Therefore, a second purpose of this study is to examine whether a low-glycemic diet will
also affect muscle fat.
The effect of telmisartan and a low-glycemic diet on muscle fat will be tested in about
100 people with the metabolic syndrome. A research ethics board that ensures that
research studies do not violate an individual’s rights has reviewed and approved this
study protocol.
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WHO CAN PARTICIPATE IN THIS STUDY?
You may be eligible to participate in this study if you have at least three features of the
metabolic syndrome. These include increased waist circumference, elevated blood
glucose, abnormal blood fats, and/or elevated blood pressure. You must also be willing
to follow the dietary and treatment protocol required by the study and to complete the
various visits and investigations required by the protocol. As a number of medications
can interfere with the study, you cannot take part in this study if you are currently on
certain medications that can affect your blood pressure or blood sugar levels.
Because one of the main tests involved in the study will be performed by magnetic
resonance spectroscopy (MRS), you cannot participate in this study if you have any
contraindications to this technique, e.g. claustrophobia (fear of closed spaces), metallic
body parts, pacemakers, clipped blood vessels, or metallic fragments in your eye.
HOW LONG WILL THE STUDY LAST
The study will last about 32 weeks and requires at least 16 visits. In addition there will
be 6-8 visits for special examinations during the course of the study. The total time for
your participation in this study is estimated to be around 40 – 50 hours.
HOW WILL I BE ASSIGNED TO A TREATMENT GROUP IN THIS STUDY?
The participants in the study will be assigned at random, that is, by a method of chance
(like a flip of a coin), to one of four groups. You will have a 1 in 4 chance of being in
one of the following groups:
1)
2)
3)
4)

Telmisartan and low-glycemic diet.
Placebo and low-glycemic diet.
Telmisartan and control diet.
Placebo and control diet.

In this study you have a 50% chance of receiving telmisartan and a 50% chance of
receiving the placebo. A placebo is an inactive substance, like a sugar pill. The study
medication will be taken once per day in the morning, with or without food, for the
duration of the study. Neither you nor your study doctor will know which group you will
be in. In an emergency, the randomization code can be broken. You will also have a
50% chance or being in the group that receives the low-glycemic diet or the control diet.
The control diet consists of a low-fat diet, as recommended by the American Heart
Association for the treatment of individuals with high blood fat levels. Assignment to
either diet is open, so both you and your doctor will know whether you are on the lowglycemic or control diet. Despite being on telmisartan, placebo, or either diet, it is
possible that your metabolic syndrome may not improve or may worsen. Your condition
will be carefully monitored. If it does worsen, the study doctor will determine whether
additional treatment is necessary and whether it is safe or unsafe for you to continue in
the trial.
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WHAT TYPE OF A DIET WILL I NEED TO FOLLOW IF I TAKE PART IN THE STUDY?
If you participate in this study, at visit 2 you will be asked to follow a low fat diet. This
diet is recommended by the American Heart Association for people with high blood fat
levels. In addition to the low fat diet, at Visit 6 you will be assigned to either the lowglycemic diet or control diet, by chance (like flipping a coin). If you are assigned to the
low-glycemic diet you will be asked to eat a certain amount of carbohydrates that are
less easily digested (e.g. whole wheat bread, whole wheat pasta, and legumes). If you
are assigned to the control diet, you will be asked to eat a certain amount of
carbohydrates that are easily digested (e.g. white bread, rice, baked potato). Some key
foods, which will make it easier for you to follow these diets, will be provided to you in
the study. You will also be given instructions on how to choose other specific foods that
you need to eat.
At most visits the nutrition counsellor will meet with you to review your dietary habits,
give advice, and have you complete a MedFICTS questionnaire. The MedFICTS
questionnaire is a diet assessment tool that is used to assess your Calorie and fat
intake. Along with the key foods you will be given a daily food record to keep track of
their use and you will be asked to complete and return them prior to visits 7, 9, 10, 11,
12 and 14. These key food records will be reviewed at these visits. You will also
periodically be given a 3-day food diary to complete and return before future visits. In
these diaries, you will be asked to record your dietary intake and physical activity habits.
These diaries will be explained to you and you will be asked to return them before visits
2, 6, 7, 10 and 14. The diaries will be reviewed at these visits.
Potential Risks: There are no harmful effects with either diet.
Potential Benefits: You will receive dietary counselling and learn how to keep accurate
records of your food intake and activity habits. You will not be expected to lose weight
on either diet. However, reducing your fat intake may result in some weight loss (3 to 5
pounds) in some individuals.

WHAT WILL MY RESPONSIBILITIES BE IF I TAKE PART IN THE STUDY?
If you participate in this study, you will be asked to come to a screening visit (first
visit) after fasting for 12 hours (no alcohol for 24 hours). Fasting is when you do not
have anything to eat or drink except water. If you do not fast before visits that require a
fast, you will have to return at another time when you have fasted. At the screening visit
you will: a) be asked about previous medical problems, your current health and your
medications; b) have a brief examination including your weight, height, blood pressure,
heart rate, waist/hip circumference; c) have an electrocardiogram (a simple test that
measures the electrical activity of the heart and that can identify damage to the heart
muscle); d) have a bioelectrical impedance analysis (a simple test that estimates body
water content by passing a low-voltage current through the body); e) You will also have
blood drawn (3 tablespoons) to check your blood sugar levels, kidney and liver function,
and blood count and fat levels; f) supply a random urine sample to check kidney
function; and g) You will also be given a 3-day food diary to complete and return before
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the next visit. If you are a woman who is able to become pregnant the urine sample will
also be used to do a pregnancy test and you will be asked about your contraceptive
methods or childbearing potential. This visit should take between 2 and 3 hours.
At the second visit you will be seen by a physician or a nurse who will review the
screening blood test results, ECG, and your medication. Your weight, blood pressure,
and heart rate will be measured. The physician or nurse will determine whether you can
be enrolled in the study. If you meet the initial eligibility criteria, you will be given the
“run-in” study medication and be asked to take the first dose in the office. You will be
instructed on how to take your medication. You will also meet with the nutrition
counsellor to review your three-day food diary, and you will also complete a MedFICTS
questionnaire and be instructed on starting and maintaining the run-in diet. This visit
should take between 1 and 2 hours.
One week after the second visit, the nutrition counsellor will telephone you to assess
your compliance with the study diet and provide dietary advice.
The third visit you will have your weight, blood pressure and heart rate monitored. The
study nurse will review your compliance with the run-in medication, your medication,
monitor adverse events, and you will be given run-in medication. You will then meet with
the nutrition counsellor to complete a MedFICTS questionnaire, assess your compliance
with the diet, and be provided with dietary advice including any dietary adjustments or
changes that may be required. This visit should take 1-2 hours.
At the fourth visit the study nurse will review your compliance with the run-in
medication, your medication, monitor adverse events, measure weight, blood pressure,
and heart rate. You will then meet with the nutrition counsellor to complete a MedFICTS
questionnaire, assess your compliance with the diet, and be provided with dietary
advice including any dietary adjustments or changes that may be required (similar to
third visit). You will be given a 3-day food diary to complete and bring back with you at
the sixth visit. This visit should take around 1-2 hours.
The fifth visit includes a series of baseline tests that will be completed before you are
assigned to a treatment group. These tests will be scheduled over a 2 week period and
will not be completed on the same day. In order to minimize your number of visits, some
of these tests may be scheduled with Visit 4 and/or visit 6. Due to scheduling
availability, you will not have these tests in any particular order. The baseline tests
include: magnetic resonance spectroscopy (MRS), HOMA/OGTT/biomarkers/lipid profile
(fasting), bioelectrical impedance analysis (BIA), fat biopsy (fasting), muscle biopsy (4
hour fast), Doppler ultrasound of the brachial artery in forearm (fasting),
echocardiography, continuous subcutaneous glucose monitoring, and Actical physical
activity monitor. With the OGTT you will have blood drawn (9 tablespoons) and your
weight, blood pressure and heart rate will be measured. This visit will take a total of
about 9-10 hours (not consecutive hours).
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At the randomization (sixth) visit you will bring a completed 3-day food diary (given to
you at visit 4). The study nurse will review your compliance with the run-in medication,
monitor adverse events, review your medication, check biopsy and puncture sites and
review your eligibility for the study. You will then meet with the nutrition counsellor who
will assess your dietary compliance. If you are determined to be compliant with the runin medication and the run-in diet you will be randomized to one of four study groups.
Your weight, blood pressure, heart rate, and waist/hip circumference will be measured.
You will be asked to provide a random urine sample that will be stored until analysis
(kidney function test). If you are a pre-menopausal woman, a pregnancy test will be
performed on the urine sample. If you are on low-dose aspirin, an additional sample of
your urine will be stored for until analysis. You will be given the study medication and
will be asked to take the first dose at this visit. You will then meet with the nutrition
counsellor to complete the MedFICTS questionnaire, get dietary instructions, and be
given test foods. The nutrition counsellor will instruct you on how to maintain the weekly
test-food records. You will also be given a 3-day food diary to complete and return at
the seventh visit. This visit should take around 1-2 hours.
At the seventh visit, you will come in with a completed weekly test-food record and 3day food diary. The study nurse will review compliance with the study medication,
monitor adverse events, review your medications, measure your weight, blood pressure
and heart rate. At this visit, your dose of study medication (telmisartan or placebo as per
assigned study arm) will be increased from 80mg to 160mg (up-titrated). You will be
given the study medication and then asked to take the first uptitrated dose at this visit.
You will also meet with the nutrition counsellor to complete the MedFICTS
questionnaire, assess your compliance with the diet, be provided with dietary advice
including any dietary adjustments or changes that may be required, and be given test
foods. You will be given weekly test food records for you to complete and return at the
ninth visit. This visit should take around 1-2 hours.
At the eighth visit the study nurse will review compliance with the study medication,
review your medications, monitor adverse events, measure weight, blood pressure and
heart rate, and draw a blood sample (1 teaspoon) to assess your kidney function. If at
this visit your kidney function blood tests have increased by more than 30% since the
beginning of the study, you will be asked to lower the dose of study medication to 80mg
(telmisartan or placebo) and an unscheduled visit will be scheduled to repeat the kidney
function blood tests (1 teaspoon). If the repeated blood test results remain abnormal,
the study doctor will decide if it is unsafe for you to continue the study medication, even
at the lower dose. If so, the study medication will be discontinued but you can remain
enrolled in the dietary arm of the study. If the repeated blood tests are normal you will
continue the study medication, but at the lower dose. This visit should take between 12 hours.
At the ninth visit you will come in with a completed weekly test food record. The study
nurse will review compliance with study medication, review your medications, monitor
adverse events, measure your weight, blood pressure and heart rate, and give you
study medication. You will also meet with the nutrition counsellor to complete the
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MedFICTS questionnaire, assess your compliance with the diet, be provided with
dietary advice including any dietary adjustments or changes that may be required, and
be given test foods. You will be given weekly test food records and a 3-day food diary
for you to complete and return at the tenth visit. This visit should take around 1-2 hours.
At the tenth visit you will come in after an overnight (12hour) fast (no alcohol for 24
hours) and bring in a completed 3-day food diary and the weekly test-food records. The
study nurse will review compliance with study medication, review your medications,
monitor adverse events, measure your weight, blood pressure, heart rate, and waist/hip
circumference, and perform a bioelectrical impedance analysis. You will be asked to
provide a random urine sample that will be stored until analysis (kidney function test). If
you are a pre-menopausal woman, a pregnancy test will be performed on that urine
sample. You will have the OGTT at this visit with blood samples drawn (approximately 5
tablespoons) for analysis of blood sugar levels, insulin and biomarkers. The study nurse
will give you study medication. You will also meet with the nutrition counsellor to
complete the MedFICTS questionnaire, assess your compliance with the diet, be
provided with dietary advice including any dietary adjustments or changes that may be
required, and be given test foods. You will be given weekly test food records for you to
complete and return at the eleventh visit. This visit should take around 3 hours.
At the eleventh visit you will come in with a completed weekly test-food record. The
study nurse will review compliance with the study medication, review your medications,
monitor adverse events, measure your weight, blood pressure and heart rate, and give
you study medication. You will also meet with the nutrition counsellor to complete the
MedFICTS questionnaire, assess your compliance with the diet, be provided with
dietary advice including any dietary adjustments or changes that may be required, and
be given test foods. You will be given weekly test food records for you to complete and
return at the twelfth visit. This visit should take around 1-2 hours.
At the twelfth visit you will come in with a completed weekly test-food record. The
study nurse will review compliance with the study medication, review your medications,
monitor adverse events, measure your weight, blood pressure and heart rate, and give
you study medication. You will also meet with the nutrition counsellor to complete the
MedFICTS questionnaire, assess your compliance with the diet, be provided with
dietary advice including any dietary adjustments or changes that may be required, and
be given test foods. You will be given weekly test food records and a 3-day food diary
for you to complete and return at the fourteenth visit. You will then be scheduled for the
end of study tests (visit 13). This visit should take 1-2 hours.
The thirteenth visit includes a series of end of study tests that will be completed before
you discontinue study medication and study diet. These tests will be scheduled over a 2
week period and will not be completed on the same day. In order to minimize your
number of visits some of these tests may be scheduled with Visit 12 and/or visit 14. Due
to scheduling availability, you will not have these tests in any particular order. The end
of
study
tests
include:
magnetic
resonance
spectroscopy
(MRS),
HOMA/OGTT/biomarkers/lipid profile (fasting), bioelectrical impedance analysis (BIA),
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fat biopsy (fasting), muscle biopsy (4 hour fast), echocardiography, continuous
subcutaneous glucose monitoring, and Actical physical activity monitor. With the OGTT
you will have blood drawn (9 tablespoons) and your weight, blood pressure and heart
rate will be measured. This visit will take a total of about 9-10 hours (not consecutive
hours).
The fourteenth visit you will bring in a completed 3-day food diary and weekly test-food
records (given to you at visit 12). The study nurse will review compliance with the study
medication, review your medications, monitor adverse events, measure your weight,
blood pressure and heart rate, and you will have a physical examination. You will be
asked to provide a random urine sample that will be stored until analysis (kidney
function test). If you are a pre-menopausal woman, a pregnancy test will be performed
on the urine sample. If you are on low-dose aspirin, an additional sample of your urine
will be stored until analysis. You will be instructed to stop taking the study medication
(all remaining medication will be collected). You will also meet with the nutrition
counsellor to complete the MedFICTS questionnaire, review dietary compliance and
weekly test-food records. This visit should take around 1-2 hours.
The fifteenth visit you will be scheduled three days to one week following
discontinuation of study medication. You will have a Doppler ultra sound of the brachial
artery in the forearm (to assess your blood vessel functioning). This visit should take
around 1 hour.
The sixteenth visit will be a follow-up telephone call 2 weeks after stopping study
medication, to discuss with you any remaining issues regarding your participation in the
study. The study nurse will assess adverse events and schedule a clinic visit if
necessary.
WHAT TESTS WILL I HAVE AND WHAT ARE THE BENEFITS OR RISKS OF THESE
TESTS?
Blood Tests
Blood will be drawn at Visits 1, 5, 8, 10 and 13 to test your blood count, blood sugar,
blood fats, insulin and other hormones, markers of kidney and liver function, markers of
inflammation, obesity and heart problems. The amount of blood drawn at each visit will
range between 5 cc (1 teaspoon) to about 135 cc (9 tablespoons). The total amount of
blood taken over the course of the study will be around 400 cc, which is less than that
taken at a normal blood donation and should have no negative effects. Your blood
samples will be sent to and stored in the Research Laboratory at the Hamilton General
Hospital (HRLMP Clinical Trials and Clinical Research) and in Dr. Sharma’s lab at
McMaster University in line with approved procedures. Your blood samples will be used
for the purpose of this study and will allow us to explore new risk factors for obesity as
they emerge in the future.
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Potential risks: There is a possibility of a small bruise at the site where the needle stick
is administered. Some individuals may also experience a feeling of fainting on having
their blood drawn. Please inform the study nurse if you have previously experienced
such a reaction.
Potential benefits: These tests will provide information on your blood glucose and fat
levels, which, if elevated, are important risk factors for heart disease and stroke. These
tests will also provide information on kidney and liver function.
Should any
abnormalities be detected in these tests, they will be discussed with you by the study
doctor who will discuss the importance and treatment options for these findings.

Glucose Tolerance Test
An oral glucose tolerance test will be performed at Visits 5, 10 and 13. For this test we
will insert an intravenous needle (a small, 2 inches long, plastic needle as used for
infusions) into your vein for drawing blood samples. After taking 3 timed blood samples
(a total of 105 cc or 7 tablespoons), you will drink a bottle of sweet liquid containing 75 g
of glucose (sugar) and have 10 cc (2 teaspoons) of blood drawn after 30, 60, and 120
min. This test, commonly used for the diagnosis of impaired glucose tolerance and
diabetes, will be used to determine your glucose and insulin responses to a glucose
load. These variables will be used to calculate your sensitivity to insulin and the rate of
insulin release from your pancreas.
Potential Risks: Some individuals may feel nausea on drinking the sweet liquid. There
are no harmful effects.
Potential benefits: This will provide information on your risk for diabetes and heart
disease. Should any abnormalities be detected, they will be discussed with you by the
study doctor who will discuss the importance and treatment options for these findings.
Magnetic Resonance Spectroscopy
This test will be performed to examine your muscle, liver and visceral (internal organs)
fat at Visit 5 and Visit 13. The Magnetic Resonance Spectroscopy (MRS) is a new
method of scanning that examines structures in the body using magnetic fields and
harmless low energy radio waves. No x-rays are used. The scanning process is totally
painless and has no known harmful effects. However some people may not be suitable
for MRS scanning so you will be required to fill in a patient questionnaire before each
procedure.
The scan can take from 30 to 60 minutes. During the scan you will be asked to lie on a
special table, which moves into the tunnel of the machine. You need to keep still during
the examination and at times you will be asked to hold your breath. The technician will
talk to you through an intercom telling you what is happening, and when they are
starting each set of new scans. You will have verbal contact with the operator and the
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use of a button that will allow you to alert the operator if you need to be taken out of the
machine.
At times the machine makes loud knocking noises, which is part of the normal working
of this machine. You can wear earplugs or listen to music played in the background to
make this noise less obvious.
This test will be performed at McMaster University Medical Center. This test will be
done in the evening hours or during a weekend.
Potential Risks: The scanning process is totally painless and has no known harmful
effects. However, some people may find lying in the scanner difficult to tolerate, as the
tunnel is quite narrow. If this should occur, imaging will be stopped immediately, and
you will be removed from the scanner.
Potential Benefits: Currently, this test is mainly used for scientific investigations and the
results of this test are unlikely to be of direct benefit to you. However, if the scanning
does show an undiagnosed condition you will be informed and adequate therapy
recommended.
Fat Biopsy (mini liposuction)
From all participants of this study, a total two fat biopsies will be taken from the area
around the navel (one at Visit 5 and one at Visit 13). This procedure involves the
removal of small pieces of fat tissue using a sterile hollow needle, a technique also
referred to as mini liposuction. A medical doctor will clean an area located a few inches
around your navel and inject a small amount of local anaesthetic ("freezing") into and
under the skin. He/she will then make a small incision (~4-5 mm) in the skin in order to
create an opening through which to put the biopsy needle into the fat tissue located
under your skin. There is a small amount of bleeding from the incision, but this is
minimal. The doctor will then loosen and collect small pieces of fat through the biopsy
needle. This procedure will be repeated several times to ensure that enough fat is
collected (~2-5 grams; about 1-2 teaspoons). During the time that the samples are
being taken (~2-3 minutes), you may feel the pressure of the needle and on some
occasions this may be moderately painful. However, the discomfort passes very
quickly. This test will be performed at the Hamilton General Hospital. The total time for
each biopsy is around 20-30 minutes.
Following the biopsies, the incisions will be closed with a sterile strip (paper tape) and
covered with a sterile dressing. In order to allow the incisions to heal properly and
minimize any risk of infection, you should avoid prolonged submersion in water for 2-3
days. Daily showers are acceptable, but baths, swimming, saunas, etc. should be
avoided for at least 4 days following the biopsy procedure.
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Potential Risks. The biopsy technique is routinely used in physiological research, and
complications are rare provided that proper precautions are taken. However, there may
be some internal bleeding at the site of the biopsy, which can result in bruising and
temporary discoloration of the skin. On occasion, a small lump may form under the site
of the incision, but this normally disappears within 2-3 months or within a few days to a
week if massaged. As with any incision, there is also a slight risk of infection, however
this risk is virtually eliminated through proper cleansing of the area and daily changing
of wound coverings. If the incision does not heal within a few days or you are in any
way concerned about inflammation or infection, please contact us immediately.
Dr. Sharma, a medical doctor who is trained in this procedure, will perform this biopsy.
In past experience with similar subjects, almost all subjects experienced bruising and
discoloration of the skin at the site of the biopsy (which lasted about 1-2 weeks);
approximately 1 in 400 have experienced a local skin infection; 1 in 20 have
experienced a small lump at the site of the biopsy (in all cases this disappeared within
about 1-2 weeks using local massage); and 1 in 400 have experienced a temporary loss
of sensation in the skin at the site of incision (an area of numbness about the size of a
Loonie which lasted up to 4 months). There is also an extremely remote chance (1 in
1,000,000) that you will be allergic to the local anaesthetic.
Potential Benefits: This test is currently only used for scientific investigations and the
results of this test are unlikely to be of direct benefit to you. However, this test can help
us better understand the effects of telmisartan and the low-glycemic diet on fat tissue
biology.
Muscle Biopsy
From some participants of this study, a total of two muscle biopsies will be taken from
the outer thigh (one at Visit 5 and one at Visit 13). This procedure involves the removal
of a small piece of muscle tissue using a sterile hollow needle. A medical doctor will
clean an area over your quadriceps muscle (Vastus Lateralis) and inject a small amount
of local anaesthetic ("freezing") into and under the skin. He/she will then make a small
incision (~4-5 mm) in the skin in order to create an opening through which to put the
biopsy needle into your thigh. There is a small amount of bleeding from the incision, but
this is minimal. The doctor will then quickly cut off a very small piece of muscle (~250
mg; about the size of the eraser on the end of a pencil) and remove the needle from
your leg. A small sample of fat tissue will also be collected from this site at the same
time. During the time that the sample is being taken (~5 sec), you may feel the
sensation of deep pressure in your thigh and on some occasions this is moderately
painful. However, the discomfort very quickly passes and you will be quite capable of
performing exercise and daily activities.
Following the biopsies, the incisions will be closed with sterile suture (stitch), and
wrapped with a tensor bandage. You should refrain from excessive muscle use for the
remainder of the day. Once the anaesthetic wears off, your leg may feel tight and often
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there is the sensation of a deep bruise or "Charlie Horse". Analgesics (pain killers) such
as Tylenol ® or Ibuprofen (such as Advil ® or
Motrin ®) are acceptable if you experience significant pain associated with the biopsy.
It is also beneficial to periodically apply an ice pack to the biopsy site the following day,
as this will help to reduce any swelling and any residual soreness. The following day
your leg may feel uncomfortable when going downstairs. The tightness in the muscle
usually disappears within 2 days and subjects routinely begin exercising at normal
capacity within a day. In order to allow the incision to heal properly and minimize any
risk of infection, you should avoid prolonged submersion in water for 2-3 days. Daily
showers are acceptable, but baths, swimming, saunas, etc. should be avoided for at
least 4 days following the biopsy procedure.
This test will be performed at McMaster University Medical Center. The total time for
each biopsy is around 30-60 minutes.
Potential Risks. The biopsy technique is routinely used in research, and complications
are rare provided that proper precautions are taken. However, there is a risk of internal
bleeding at the site of the biopsy, which can result in bruising and temporary
discoloration of the skin. On occasion, a small lump may form under the site of the
incision, but this normally disappears within 2-3 months or within a few days to a week if
massaged. As with any incision, there is also a slight risk of infection, however this risk
is virtually eliminated through proper cleansing of the area and daily changing of wound
coverings. If the incision does not heal within a few days or you are in any way
concerned about inflammation or infection, please contact us immediately.
This biopsy will be performed by Dr. Tarnopolsky, who has performed over 10,000 of
these in patients and healthy people ranging in age from 1 week to 90 years. In past
experience with healthy young subjects, approximately 1 in 2,000 have experienced a
local skin infection; 1 in 500 have experienced a small lump at the site of the biopsy (in
all cases this disappeared within ~1-2 weeks using local massage); 1 in 1,500 have
experienced a temporary loss of sensation in the skin at the site of incision (an area of
numbness about the size of a Loonie which lasted up to 4 months), and 1 in 100 have
experienced bruising around the site of incision which lasted for ~4-5 days. While there
is also a theoretical risk of damage to a small motor nerve (that is used to allow your
muscle to move) branch of the outer leg muscle, this has never been seen in over
10,000 biopsies performed by Dr. Tarnopolsky. The risk of damaging a small motor
nerve branch is impossible to truly estimate, but in the extremely unlikely chance that it
did occur, only about 20% of the lower part of one of four large muscles that moves the
knee would be affected (hence, it would not impact on function in daily activities) and
even this small area of muscle would likely recover in 6 – 9 months. There is also an
extremely remote chance (1 in 1,000,000) that you will be allergic to the local
anaesthetic.
Potential Benefits: This test is currently only used for scientific investigations and the
results of this test are unlikely to be of direct benefit to you. However, this test can help
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us better understand the effects of telmisartan and the low-glycemic diet on muscle
tissue biology.
You will not be eligible for muscle or fat biopsies if you are taking certain medications
such as anti-coagulants (blood thinners), e.g. warfarin, or antiplatelet medication
(medication to prevent clumping of certain cells in you blood), e.g. Plavix®. You will be
asked about these types of medications at the beginning of the study and before the
biopsies are scheduled.

Continuous Glucose Monitoring
A 3-day blood sugar (glucose) record will be obtained at Visits 5 and 13. For this test a
small plastic needle will be inserted under the skin and taped securely. You will feel a
small prick when the needle is inserted (most patients find it virtually painless). The
needle will then be hooked to a monitor, the size of a mobile phone, which could easily
be worn on your belt or placed in your pocket. The monitor will record blood sugars
every 5 minutes. You will not feel this.
In order to set the monitor you will need to do finger prick glucose testing 4 times a day
using a glucose tester that we will provide. These measurements will then be entered
into the monitor.
You can continue all normal activities except water immersion sports like swimming,
sitting in a hot tub or bathing in a bathtub.
Potential Risks: Besides the mild discomfort that you may experience when the needle
is placed under the skin or when you do the finger-prick blood sugar measurements,
there is really no other risk to you. Although infection at the insertion site may occur,
this is usually not a concern.
Potential Benefits: The 3 day continuous glucose measurements will help us gauge how
well you are responding to the diet or medication. This test will also provide more
accurate measurements of how your blood sugars vary with activity and meals. If any
abnormalities are discovered, the study doctor will discuss these with you.
Activity Monitoring
In order to monitor your physical activity, you will be asked to wear an electronic activity
monitor (Actical™). This monitor is about the size of a matchbox and is worn around
your waist on a belt for 72 hours at the same time as the continuous glucose-monitoring
device at visits 5 and 13.
Potential Risks: none.
Potential Benefits: This device will let us calculate the amount of calories consumed by
physical activity during the measurement period.
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Heart Ultrasound
An ultrasound study of your heart will be performed between visits 4 and 6.
Measurements will be taken at rest by a trained ultrasound technician. This test uses
high frequency waves to create a picture of the heart. The test is painless and will take
around 60 minutes.
Potential Risks: none.
Potential Benefits: This test will provide information on the structure and function of your
heart. Should we discover any abnormality that may be important to your health; you
will be informed and advised to take the appropriate steps for further diagnostics or
treatment.
Ultrasound of the Blood Vessels of the Arm
In this test, we will measure the diameter of your artery that supplies blood to your arm.
This will be done with ultrasound. Measurements are taken at rest, after blocking the
circulation in your upper arm with a blood pressure cuff for 5 minutes and after taking
one tablet of nitro-glycerine (0.15mg or 0.3mg) under your tongue.
Potential Risks: During this test, a blood pressure cuff will be inflated to high pressures
for a continuous 5-minute period. At this time, the blood pressure cuff may cause mild
discomfort or aching around your arm. You may feel increasing numbness or tingling
(pins and needles) in your hand, which will rapidly stop when the cuff pressure is
released. No harmful consequence is expected from this test. The ultrasound should not
cause any discomfort. Nitro-glycerine may cause a brief headache or dizziness.
Potential Benefits: This test is currently only used for scientific investigations and the
results of this test are unlikely to be of direct benefit to you. However, this test can help
us better understand the effects of telmisartan and the low-glycemic diet on blood
vessel function.
Body Composition Analysis (Bioelectrical impedance)
This test will be performed at Visits 1, 5, 10 and 13. This test examines the water and
fat content of your body by passing weak electrical current through your body via
electrodes attached to your hands and feet. This test is totally painless, has no known
harmful effects and takes less than 10 minutes.
Electrocardiogram (ECG)
An ECG will be performed at Visit 1 or 2. This test measures the electrical activity in the
heart through 12 leads connected to your chest and limbs to an electrocardiograph. It is
a non-invasive and safe procedure taking less than 15 minutes.
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WHAT WILL HAPPEN WITH MY BLOOD, URINE, AND TISSUE SAMPLES?
All samples will be used for the purpose of this study. All samples will be stored under
appropriate conditions either at the Research Laboratory at the Hamilton General
Hospital (HRLMP Clinical Trials and Clinical Research) or in the research laboratory of
Dr. Sharma. They may also be shared with colleagues at other laboratories for
measurements relevant to the study. All samples will be stored and analyzed in a
manner that will not allow direct identification of you (the participant). Only Dr. Sharma
will maintain a list linking the samples to an individual participant.
Because these tests will be performed for research purposes only and will allow us to
explore new risk factors for obesity as they emerge in the future, these tests will not be
useful for the diagnosis or management of any medical condition. Therefore you will not
be provided with the results of these tests.
Any samples remaining after the completion of the above measurements will be stored
for a maximum duration of 10 years, after which they will be adequately discarded or
destroyed. During this time the samples can also be used for the measurements of new
tests that may arise and be deemed relevant for this project.
The samples will be used for research and such use may result in inventions or
discoveries that create new products or diagnostic or therapeutic agents. In some
instances, these inventions and discoveries may be of potential commercial value and
may be patented and licensed by the researchers/sponsor. You will not receive any
money or other benefits derived from any commercial or other products that may be
developed from use of the samples.
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?
This study will study the effects of telmisartan in people with metabolic syndrome.
Telmisartan (MiCARDIS ®) is a commonly used drug for the control of high blood
pressure. The major side effects of telmisartan are headache, dizziness, fatigue
(tiredness), back pain, diarrhea, and upper respiratory tract infections and sinusitis. In
rare cases, a potentially life threatening condition called angioedema may occur. The
symptoms of angioedema may include swelling of the face, lips, tongue and throat. If
you have any of these symptoms at any time during the study, immediately discontinue
study medications and contact your physician or study doctor. As the dose of
telmisartan used in this study is higher than the dose approved for the treatment of high
blood pressure, the side effects may be more common. This study will also test the
effect of a “low-glycemic” or a “low-fat” diet. This requires your cooperation and may be
considered inconvenient. There is a reasonable likelihood (1 in 50) that changes to
your diet may result in indigestion, constipation, bloating, or other symptoms. In such
cases, you should report these problems to the nutrition counsellor, who will
recommend appropriate adjustments to your diet.
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The potential risks and discomforts of the various tests have been described above.
When blood samples and biopsies are taken, you may have some discomfort and/or
develop some bruising or very rarely, a minor infection. You may also have some
nausea during the oral glucose tolerance tests. You will be asked about side effects of
the diet and treatment at each visit.
Because the safety of telmisartan for an unborn fetus or newborn is unknown, you
cannot participate in this study if you intend to become pregnant, are pregnant or are
breastfeeding. If you are a woman who is able to have children, you must agree not to
become pregnant while you are in this study. You will need to use an acceptable
method of birth control to avoid pregnancy. Acceptable methods of birth control for this
study include: intra-uterine device (IUD), oral, implantable/injectable contraceptives, or
epidermal patch. Using barrier methods such as condoms, vaginal diaphragm,
spermicidal jelly or sponge is not acceptable. If you become pregnant despite these
precautions OR if your method of birth control is discontinued or changes, you agree to
immediately notify the study team.
If you choose to take part in this study, you will be told about any new information,
which might affect your willingness to continue to participate in this research.

HOW MANY PEOPLE WILL BE IN THIS STUDY?
There will be at least 100 people with the metabolic syndrome taking part in this study.
WHAT ARE THE POSSIBLE BENEFITS FOR ME AND/OR FOR SOCIETY?
The information obtained from participating in this study may show that telmisartan
and/or a low-glycemic diet are effective in the reduction of muscle fat and improve
insulin sensitivity and other health problems related to the metabolic syndrome.
Observations made in this study may also help us better understand some of the
biological abnormalities related to this syndrome. No other benefit of participation can
be guaranteed.
You will receive some counselling regarding healthy lifestyles and will receive all of your
study medication and some foods free of charge. You will also receive information
regarding your body composition, blood pressure, blood glucose and lipid values and
heart function during the course of the study.
IF I DO NOT WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER
CHOICES?
It is important for you to know that you can choose not to take part in the study. There
are other choices such as improving your diet and increasing your level of exercise or
taking other medications, for the treatment of the metabolic syndrome. Your study
doctor will discuss these with you.
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Choosing not to participate in this study will in no way affect your care or treatment.
WHAT INFORMATION WILL BE KEPT CONFIDENTIAL?
The study staff will contact your family doctor regarding your selection and participation
in this study. This is important for your safety and well being.
Personal records relating to this study will be kept confidential at all times except where
required by law. Only the study doctor will keep a record of your name, address, phone
number, health card number and family doctor’s name. On documents, your initials and
assigned participant number will identify you.
Information obtained during this study, including your medical records, will be available
to the sponsor of this study, the Hamilton Health Sciences/McMaster University
research ethics board that reviewed the ethical aspects of this study, and the
government regulatory agencies (such as Health Canada) to check the accuracy and
completeness of the information. This is to ensure that the study has been conducted
according to GCP (Good Clinical Practice) quality standards. However, no records,
which identify you by name or initials, will be allowed to leave the hospital. By signing
this consent form, you or your legally acceptable representative authorizes such access.
It is important to note that this original signed consent form and the data, which follows,
may be included in your health record.
The results of this study may be published in a professional journal or presented at
scientific meetings or to government regulatory authorities; however, your identity will
NOT be disclosed in those journals or presentations.
Blood, urine and tissue samples will be identified only by your participant number. The
individual results of any analyses, except for the screening and safety tests (blood
sugar, blood lipids, blood count, kidney and liver function), body composition and blood
pressure will not be made known to you or to any other party and will only be used to
identify differences between treatment groups in the study.
Your study records will be stored for the period of time required by applicable law. Until
those records and samples are destroyed, you have the right to request that the
samples and data collected be destroyed. Confirmation that the samples have been
discarded will be made to you in writing.

CAN PARTICIPATION IN THE STUDY END EARLY?
If you volunteer to be in this study, you may withdraw at any time and this will in no way
affect the quality of care you receive. You may also refuse to answer any questions you
do not want to answer and still remain in the study. The investigator may withdraw you
from this study if circumstances arise which warrant doing so.
WILL I BE PAID TO PARTICIPATE IN THIS STUDY?
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A small amount of compensation, will be offered to those patients who qualify for and
undergo the muscle and fat biopsies ($50.00/ biopsy), otherwise, no compensation will
be paid for your participation. However, we will reimburse you for parking and meals
during your visits.
WILL THERE BE ANY COSTS?
Participation in this study will be at no cost to you. The medication, study foods and
clinic visits will be provided free of charge. Your participation in this research project will
not involve any additional costs to you or your health care insurer.
WHAT HAPPENS IF I HAVE A RESEARCH-RELATED INJURY?
Side effects or harm are possible in any research despite high standards of care, and
could occur through no fault of your own or the investigators. Known side effects have
been described in this consent form, however unforeseeable harm may also occur. If
you are injured as a direct result of taking part in this study, you should immediately
contact the study doctor. Reasonable and necessary medical expenses will be made
available to you by the sponsor (Boehringer Ingelheim), provided such expenses are not
covered by your medical or hospital insurance and are in no way attributable to the
negligence or misconduct of any agent or employee of McMaster University or Hamilton
Health Sciences. Financial compensation for such things as lost wages, disability or
discomfort due to this type of injury is not routinely available. However, if you sign this
consent form it does not mean that you waive any legal rights you may have under the
law, nor does it mean that you are releasing the investigator(s), institution(s) and/or
sponsor(s) from their legal and professional responsibilities.
IF I HAVE ANY QUESTIONS OR PROBLEMS, WHOM CAN I CALL?
If you have any questions about the study now or later, please phone Sue Damjanovic
(TRIM Coordinator) at 905-527-4322 ext. 44710, or if you think you have a researchrelated injury, please phone Dr. A. Sharma at 905-527-4322 ext 46806 or the Research
Nurse at 905-521-5030 (pager).
If you have any questions regarding your rights as a research participant, you may
contact: Hamilton Health Sciences Patient Relations Specialist at 905-521-2100, ext.
75240.
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CONSENT STATEMENT

SIGNATURE OF RESEARCH PARTICIPANT/LEGALLY-AUTHORIZED
REPRESENTATIVE
I have read the preceding information thoroughly. I have had the opportunity to ask
questions, and all of my questions have been answered to my satisfaction. I agree to
participate in this study. I understand that I will receive a signed copy of this form.

______________________________________
Printed Name of Participant

______________________________________
Signature of Participant

__________________
Date / Time

Consent form administered and explained in person by:
_____________________________________
Name and title

_____________________________________
Signature

_____________________
Date / Time

SIGNATURE OF INVESTIGATOR:
In my judgement, the participant is voluntarily and knowingly giving informed consent
and possesses the legal capacity to give informed consent to participate in this research
study.

______________________________________
Signature of Investigator
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_______________
Date

APPENDIX 8.2
NUTRITION SOURCE DOCUMENT:
ESTIMATED ENERGY REQUIREMENTS
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Nutrition Source Document: Estimated Energy Requirements
Date: ______/______/________
day

month

Completed by: ________________________

year

Participant initials: ___________ Participant ID number: ___________ (4 digits)
1.) Weight (from Visit 1 source document) _______ kg
2.) Height (from Visit 1 source document) _______ cm
3.) Age (from Visit 1 source document)

_______ years

4.) What are the participant’s daily Estimated Energy Requirements?______kcal
EER (kcal) = ( number based on age and gender x body wt in kg) + 300kcal
= ( ___________ x __________kg ) + 300kcal
= ____________________ (Rounded to nearest 100kcal)
5.) Number of daily test food servings to be consumed during randomization: ________
Table 1 - Calculation for daily EER

Age
0–5
6–9
10 – 14
15 – 19
20 – 24
25 – 29
30 – 34
35 – 39
40 – 44
45 – 49
50 – 54
55 – 59
60 – 64
65 – 69
70 +

Column 1
Males
103.4
78.5
61.3
50.8
45.7
39.6
38.2
34.3
33.0
32.3
31.7
29.9
30.3
28.3
26.2

Table 2 – Daily Test Food Requirements for Randomization

Column 2
Females
102.7
72.5
53.3
36.7
35.7
33.8
31.6
29.4
27.3
27.9
26.7
26.1
27.3
26.3
25.8

Calculation for Energy Expenditure Requirements
(EER) based on a diet of 55% of total energy
derived from carbohydrates (CHO) with 40% of
available CHO provided from the test foods.
Total kcal/day x 0.55 = kcal from CHO
kcal of CHO divided by 4 kcal/g = total g CHO
total g CHO x 0.40 = grams CHO
grams CHO divided by 15 grams of CHO per test
food serving = # test food servings
# test food servings are rounded to the nearest 0.5
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EER

# Of Daily Test
Food Servings*

EER

# Of Daily Test
Food Servings*

1500

6

3100

12

1600

6

3200

12

1700

6.5

3300

12.5

1800

7

3400

13

1900

7

3500

13.5

2000

7.5

3600

14

2100

8

3700

14

2200

8.5

3800

14.5

2300

9

3900

15

2400

9

4000

15

2500

9.5

4100

15.5

2600

10

4200

16

2700

10.5

4300

16.5

2800

10.5

4400

17

2900

11

4500

17

3000

11.5

APPENDIX 8.3
FACTS ON FAT INFORMATION SHEET
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It is important to include fat in our daily diet but a diet that is too high in fat, especially bad fats,
can lead to health problems. There is a lot to learn about fat and its role in health.

SATURATED FAT
These are the BAD fats. Saturated fats are
found in meats, whole milk dairy products,
coconut and palm oil, chocolate, processed
foods, and fast foods. Saturated fat can
increase risk for heart disease, so it is
important that you keep your saturated fats
to less than 10 % of your daily diet. By
reducing the total amount of fat in your diet,
you will usually decrease the saturated fats
as well. The important thing to remember is
that saturated fats are the bad fats.

WHAT IS FAT?
Fat is one of the three main components of
food; the others are protein and
carbohydrate. Fat has 9 Calories per gram
compared to protein and carbohydrate at
4 Calories per gram. Individuals who eat a
high fat diet regularly may be eating too
many Calories and gain weight.

UNSATURATED FAT
If you are going to ingest fat, then these are
the types of fats that you should have
because they are “good fats”. Unsaturated
fats are usually listed on product labels as
monounsaturated or polyunsaturated fats.
Any type of fat that is liquid at room
temperature is an unsaturated fat. Some
unsaturated fats must be supplied by the diet
because our body cannot make them. These
important good fats are the omega-3 fats.
They can be found in liquid oils, nuts and
seeds, soybeans, flaxseed, fish and omega-3
products such as eggs. The omega-3 fats
may help reduce your risk for developing
heart disease.

HYDROGENATION
Beware of hydrogenated fats because they
are bad fats. Hydrogenation is a process that
changes the good polyunsaturated fat to a
bad saturated fat or “trans fat”. Trans fats
are found in margarines, bakery products,
snack foods, and fast foods. Foods that list
hydrogenation or partially hydrogenated oils
in the first 3 ingredients usually contain
trans fats and saturated (bad) fats. Trans fats
are linked to heart disease and should be
avoided.
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The recommended daily fat intake should be less than 30% of your total caloric intake. Here are
some suggestions to help reduce the total amount of fat in your daily diet.

Try to avoid
the bad fats

Saturated

“Trans fats”

Have more of
the good fats
Polyunsaturated
and
monounsaturated

Ways to reduce the fat in your diet:
 Drink skim or 1% milk
 Use less or try reduced-fat sauces,
gravies, mayonnaise, cheeses and
sour cream
 Use non-hydrogenated margarine
rather than butter or regular
margarine
 Cut extra fat off meat and remove
skin and visible fat from poultry
 Broil, bake, boil or barbeque rather
than frying foods
 Try salsa, mustard, chutneys, or
spices to flavour foods rather than
butter or margarine
 Have lettuce salads with oil or lowfat dressing instead of potato and
macaroni salads
 Limit snack foods, baked goods, and
deep-fried foods

Food Sources
whole milk, butter,
poultry skin, fatty
cuts of meat,
coconut oil and
palm oil, creamy
salad dressings
shortening,
hydrogenated
margarine, crackers,
cookies, cakes, pies,
chips and other
snack foods,
processed foods

Food Sources
Any liquid
vegetable oil, fish,
flax seed and flax
oil, nuts and seeds,
oil salad dressings

HEALTHY FAST FOOD CHOICES

Choose foods from all 4 food groups in
Canada’s Food Guide to Healthy Eating.
Food Group
# of
Food Ideas
Servings (one serving)

Milk
Products
Vegetables
and Fruits
Grain
Products
Meat and
Alternatives

2-4
(for
adults)

1 cup low fat
milk or non-fat
yogurt

5-10

½ cup of
vegetables,
1 fruit

5-12

1 slice of bread,
½ cup of pasta

2-3

1/3 cup tofu,
½ cup beans,
3 ½ oz of meat,
fish or poultry

Wendys: small chili, milk, salad with
low fat dressing, (omit the fries)
Tim Hortons: juice, soup (water
based), low fat muffin, coffee with
milk
McDonalds: choose from the healthy
choice menu, juice, milk (omit the
fries)
Subway: choose from the 7 grams of
fat or less menu, water, juice, milk,
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APPENDIX 8.4
MEDFICTS DIETARY ASSESSMENT QUESTIONNAIRE
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APPENDIX 8.5
3-DAY FOOD DIARIES

186

3 DAY FOOD DIARY: PARTICIPANT INSTRUCTIONS
Participant initials: ____________ Participant ID#: ____________
•
•
•
•

•
•

•
•
•

Please maintain your usual eating habits.
Complete the food record the week before your next appointment.
Use a new diet record form for each day. It may be helpful for dietary input if the
participant attaches labels from the products eaten to the 3-day food diary. The
labels can be attached to page 2 of each day.
Write down everything you eat and drink for 2 weekdays and 1 weekend day
(whenever possible). Try and record the food and beverage items immediately
after you have consumed them. Remember to include the time at which the food
was eaten.
Use measuring cups, tablespoons, teaspoons to measure or a scale to weigh out
the quantities of food. The more accurate the better!!
Describe the food in as much detail as possible. Specify item, brand, and
amount.
- ½ cup Delmonte fruit cocktail canned in light syrup
- 2 tsp Becel regular margarine
- 45 g (1 large slice) of Dempsters 7 grain bread
Write down the percent fat in milk products (i.e. %MF, or %BF).
- 8 oz 1% milk
- 175 g 1% Astro fruit bottom peach yogurt
Include items added to food and drinks.
- i.e. sugar, cream, ketchup, dressings, sauces, toppings, spreads, etc.
Include on your food record the fat used when preparing foods.

- i.e. Butter, canola oil, etc.
•
•

Write down the name of the restaurant if you are eating out.
Describe the method of cooking.
- Steaming, broiling, pan-fried, deep-fried.

Examples
Correct
1 medium bagel
1 teaspoon regular Becel Margarine
2 ounces of lean ham
1-ounce medium cheddar cheese (33% MF)
1 tsp mustard
1 lettuce leaf (Romaine lettuce)

Incorrect
1 ham and cheese sandwich

Correct
1 ½ cup cooked white rice (Uncle Ben’s)
2 cups stir fried vegetables
½ zucchini
¼ red pepper
3 mushrooms
½ cup cooked broccoli
2-ounce boneless, skinless chicken breast
1 tsp cornstarch
1 Tbsp soy sauce
1 Tbsp teriyaki sauce
1 Tbsp canola oil

Incorrect
rice with chicken and stir-fried vegetables
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3-DAY FOOD DIARY Dispensed Visit # ___ Returned Visit #____
Participant initials: ____________

Day 1

Date: ______/______/________
day

Amount
of Food

month

Participant ID#: ____________
Is this a usual day? ____no ____yes

year

Description of Foods and Beverages
(please, enter one item per line)
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Time of Day

3-DAY FOOD DIARY Dispensed Visit # ___ Returned Visit #____

Participant initials: ____________
Day 2

Date: ______/______/________
day

Amount
of Food

month

Participant ID#: ____________
Is this a usual day? ____no ____yes

year

Description of Foods and Beverages
(please, enter one item per line)
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Time of Day

3-DAY FOOD DIARY Dispensed Visit # ___ Returned Visit #____

Participant initials: ____________
Day 3

Date: ______/______/________
day

Amount
of Food

month

Participant ID#: ____________
Is this a usual day? ____no ____yes

year

Description of Foods and Beverages
(please, enter one item per line)

190

Time of Day

APPENDIX 8.6
BAECKE PHYSICAL ACTIVITY QUESTIONNAIRE
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APPENDIX 8.7
LOW GLYCEMIC INDEX AND HIGH GLYCEMIC INDEX WEEKLY
TEST FOOD DIARIES
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Weekly Test Food Diary
Low GI diet

Initials: ________________

ID#: __________________________

Dispensed Visit #: ______________

Returned Visit #: _______________

Start Date: _____________________

Finish Date: __________________

Please have ____________ servings of the test foods every day.
= _______________ for ____________ days

Compliance % = # of test foods consumed _________________
divided by # of test foods required __________ X 100 = _____________

•

Record the intake of the test foods as soon as possible after consumption.

•

Ensure that at least two servings are with the first meal of the day.

•

Measure all of the foods as precisely as possible (use measuring cups and
measuring spoons provided)

•

Indicate the number of servings of each test food consumed.
(one “x” will equal one serving for each food)
Each measurement is one serving unless otherwise specified.
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ID#: _______________________
Week #: ________

Initials: _______________________

Week starting: __________/__________/__________
Day
Month
Year

Low Glycemic Index Diet

Serving
Total

G with
di Psyllium
Bran Buds
(1/3 cup)
Raisin Bran (dry)
(1\2 cup)
Oatmeal (non-instant)
(1\2 cup cooked, 1/3 cup dry)
Red River Cereal
(1/2 cup cooked, 1/6 cup dry)
Pumpernickel bread Dimpflmeier
1 slice = 1 ½ servings
Pumpernickel bread Holtzheuser
1 slice = 1 ½ servings
Linseed bread Dimpflmeier
1 slice = 1 ½ servings
100% Rye bread Vollkornbrot
1 slice = 1 ½ servings
Barley (¼ cup dry or ½ cup cooked
= 2 servings)
Pasta (al dente) (3/4 cup cooked or
1/3 cup dry = 2 servings)
Parboiled Rice
(1/3 cup cooked)
Bulgar
(1/2 cup cooked)
Beans: canned, kidney, navy, white,
cooked (1/2 cup)
Beans, canned Brown, baked, plain
(1/2 cup)
Beans, Chickpeas, canned
(3/4 cup = 2 servings)
Lentils: red, brown, green,
(1/2 cup cooked)
PC Instant Black Bean Soup
(dry) (½ portion or 34g)
PC Instant Vegetable Barley soup
(dry) ( ½ portion or 23g)
PC Instant Lentil Soup
(dry) (1/2 portion or 33g)
Habitant Split Pea Soup, canned
(2/3 cup)
SERVING TOTAL
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Weekly Test Food Diary
Control diet

Initials: _______________________

ID#: ________________________

Dispensed Visit #: ______________

Returned Visit #: ___________

Start Date: _____________________

Finish Date: _______________

Please have __________ servings of the test foods every day.
= _______________ for ____________ days

Compliance % = # of test foods consumed _________________
divided by # of test foods required __________ X 100 = _____________

•

Record the intake of the test foods as soon as possible after
consumption.

•

Ensure that at least two servings are with the first meal of the day.

•

Measure all of the foods as precisely as possible (use measuring cups
and measuring spoons provided)

•

Indicate the number of servings of food consumed. (put an “x” for each
serving of food in the appropriate box)

Each measurement is one serving unless otherwise specified.
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Initials: ___________________________
Week #: __________

ID#: _________________

Week of: __________/__________/__________
Day
Month
Year

Control Diet (High
Glycemic Index Diet)

Serving
Total

President’s Choice
Cornflakes (2/3 cup)
Crispex Cereal
(2/3 cup)
Corn Bran Cereal
(2/3 cup)
Cheerios cereal
General Mills (2/3 cup)
Shredded Wheat
(1 large or ½ cup)
Cream Of Wheat
(1/2 cup cooked)
Melba Toast
(4 each)
White Bread
(1 slice)
Whole Wheat Bread
60% (1 slice)
Whole Wheat Bread
100% (1 slice)
Light Rye Bread
(1 slice)
Soda Crackers
(7 each)
Graham Crackers
(3 each)
Stoned Wheat Thins
(3 each)
White Polished Rice
Cooked (1/3 cup)
Brown Rice
Cooked (1/3 cup)
Instant Potatoes
Cooked (1/2 cup)
Home-made mashed
potatoes, cooked
(1/2 cup)
Idaho Baked Potato
(½ medium or ½ cup)
Instant Potato and Leek Soup
(1/2 package or 17 g)
SERVING
TOTAL

197

